INDEX

The locators in the index include both chapter and page numbers, e.g., 30:1.5 indicates that the reference is to chapter 30, pages 1 and 5. Numbers, such as 2-hour, are alphabetized as if spelled out. Because extensive racial/ethnic variation data are presented with many conditions discussed, the index entries for race/ethnicity reflect only where specific data are presented, e.g., A1c variations. Where there is race/ethnicity information pertinent to a particular group, e.g., American Indian/Alaska Native, it will be found under the index entry for that ethnic group. Tables, figures, and appendices are not indexed.

A

A1c. See Glycated hemoglobin (A1c)
Abacavir sensitivity, 12:4
Abatacept
in prevention of type 1 diabetes, 37:6–7
tepilizumab efficacy, 37:12
ABCC8 gene
gliclazide response, 14:10
neonatal diabetes mellitus, 7:10
p.Ser1369Ala polymorphism, 14:10
sulfonfonylurea receptor encoding, 7:5
Abdominal circumference (AC). See Fetal abdominal circumference
Abdominal obesity. See also Obesity
adiponectin levels with, 13:18–19
association with smoking, 33:23
with binge eating disorder, 33:21
with breastfeeding after gestational diabetes, 15:13
with Cushing syndrome, 6:15
by diabetes status, treatment, age, 9:14
diagnosis of metabolic syndrome, 18:9
enhanced cytokine production with, 25:20
with general obesity, 9:14
with metabolic syndrome, 13:21
in metabolic syndrome diagnosis, 19:10
in normal weight individuals, 13:12
obstructive sleep apnea association, 25:29
in schizophrenia, 33:22
stroke risk factors, 19:10
waist circumference measurement of, 9:14
Abdominal pain, 27:9
ABO/9q34 variants, 12:12
Absolute insulin deficiency, 1:6; 2:3
Acanthus nigricans
congenital generalized lipodystrophy, 7:14,16
diagnosis of type 2 diabetes in youth, 15:2
familial partial lipodystrophy, 7:17,18,19
insulin resistance syndrome type A, 7:12
Acarbose
diabetes development after, 38:11
lowering of postprandial hyperglycemia, 38:8
prevention study, 38:12
Acarbose Cardiovascular Evaluation (ACE). See 38:11
Accelerator hypothesis, 11:13; 15:11
ACCORD studies
A1c levels and cardiovascular risk, 1:24
blood pressure control and mortality, 36:10
blood pressure control effects, 16:14; 18:17; 21:24
glycemic control and dementia, 16:15
intensive control and cardiovascular disease, 22:47
intensive glycemic control effects, 16:13; 18:14–15
intensive vs. conventional insulin therapy in, 19:13
lipid control effects, 16:14; 18:16; 21:25
macrovascular effects of glucose control, 18:14–15
metabolic memory with prolonged hyperglycemia, 21:23
neuropathy evaluation and outcomes, 23:5–7,11
retinopathy outcomes, 21:23–24
statin therapy benefits, 16:14
therapeutic strategies and cognitive decline, 24:10–12
ACR (albumin:creatinine ratio)
albuminuria, 22:2
elevated albuminuria classification, 22:3
for indication of albumin excretion, 22:12
with peripheral arterial disease, 20:9–10
predictive value with glomerular filtration rate, 22:22
renal disease in youth with diabetes, 15:20
stroke risk prediction with, 19:3,10
Acromegaly, 6:15
Actigraphy, 25:6,9,21,29–30
Action for Health in Diabetes (Look AHEAD) cohort. See Look AHEAD
Action in Diabetes and Vascular Disease (ADVANCE) trial. See ADVANCE trial
Action to Control Cardiovascular Risk in Diabetes (ACCORD). See ACCORD studies
Activities of daily living (ADL). See also Instrumental activities of daily living (IADL)
definition of, 34:2
diabetes and morbidity status, 34:8
diabetes association with, 34:3
diabetes and body mass index, 34:3
diabetes and heart disease mortality, 34:4
diabetes and neurodegeneration association, 34:5
diabetes association with, 34:3
family history of diabetes, 34:4
home health care needs with, 34:4
hypercoagulability, 34:5
hypertension, 34:5
insomnia in, 34:5
lowered LDL cholesterol, 34:5
measured by, 34:5
mortality from cardiovascular disease, 34:5
prevalence by demographic factors, 34:4–5
trends in national estimates, 34:9–11
Actos (pioglitazone) ACT NOW study, 38:10
Actos Now for the Prevention of Diabetes (ACT NOW), 38:10
Acute insulin response (AIR)
insulin secretion capacity measure, 13:17
measurement for first-phase response, 13:17
with sleep restriction, 25:2
Acute metabolic complications
DKA, 17:1–5
hyperglycemic hyperosmolar state, 17:6–8
hypoglycemia, 17:9–13
lactic acidosis, 17:8–9
Acute painful small fiber neuropathy, 23:3
Acute renal failure
chronic hypertension/gestational diabetes risks, 5:33
with contrast-induced nephropathy, 22:39
with diabetes and pyelonephritis, 30:10
pregestational diabetes vs. controls, 5:25
AD dementia
amnestic cognitive impairment progression to, 24:3
association with diabetes, 24:4–5
cerebrovascular mechanisms for, 24:4
diabetes link, 24:3
genetic causes of, 24:3
hyperinsulinemia as risk factor, 24:4,13
manifestation of Alzheimer’s disease, 24:1
memory effects in, 24:1–2
mixed pathology in, 24:2
non-cerebrovascular diabetes links, 24:4–5
prevalence and projections for, 24:2–3
risk factors for, 24:3
treatment or prevention recommendations for, 24:3
vascular comorbidity with diabetes, 24:8
ADCY5 gene, 14:8
Adipocytes
adiponectin production, 13:18
CAV1 mutation in, 7:16
defective differentiation with PPARγ mutation, 7:19
effects of sleep restriction, 25:11
factors from, 25:20
perilipin 1 in, 7:19
premature apoptosis in, 7:19
reduced differentiation in lipodystrophy, 7:20
seipin in, 7:15–16
thiazolidinediones and development of, 32:12
Adipocytokines/adipokines
in Bardet-Biedel and Alstrom syndromes, 6:16
in congenital generalized lipodystrophy, 7:15
impaired adipose tissue secretion of, 13:18
with obstructive sleep apnea, 25:20
sleep and circadian disturbances, 25:20
systemic inflammatory response and, 25:10

Adiponectin
in abdominal obesity, 13:18–19
in congenital generalized lipodystrophy, 7:15
effects of, 13:18
gene polymorphisms, 38:11
relative hypoinsulinemic state and, 6:17
sleep apnea-related glucose metabolism abnormalities, 25:20
type 2 diabetes risk and, 13:19

Adipose gene expression regulator, 14:11

Adipose tissue
AGPAT2 expression in, 7:15
circadian regulation of, 25:24
congenital generalized lipodystrophy, 7:13
familial partial lipodystrophy, 7:17,19,20–21
hyperleptinemia association with, 22:38
inflammatory markers from, 23:7
inflammatory pathways in, 13:18–19
PPARG expression in, 7:19
reactive oxygen species effects on, 25:20
in type 2 diabetes, 13:18; 15:2

Adipose tissue-derived inflammatory markers, 23:7

Adipose-infiltrating macrophages, 13:19

Adiposity. See also Abdominal obesity;
BMI (body mass index); Obesity; Waist circumference
fetal overgrowth, 5:56
generalized and central with diabetes, 20:11
insulin resistance in older adults, 16:1
neonatal, 5:50; 13:12
of offspring, 4:13; 5:74; 13:12–13
prevalence in youth, 15:34
reproducibility of measurements, 18:10–11

Adult diabetic physical/metabolic characteristics
A1c, 9:3–4
blood pressure status, 9:17–18
BMI and waist circumference, 9:14–16
C-reactive protein, 9:23
data sources and limitations, 9:1–2
family history of diabetes, 9:13
fasting insulin levels, 9:11–12
fasting plasma glucose, 9:4–6
fibrinogen, 9:23
glycemia in untreated diagnosed diabetes, 9:7–10
glycosylated hemoglobin, 9:3–4
high-density lipoprotein cholesterol, 9:19–20
inflammation markers, 9:23
laboratory evaluation techniques, 9:2
low-density lipoprotein cholesterol, 9:20–21
parity, 9:23
self-reported health, 9:24
testing methods, 9:2
total cholesterol, 9:18–19
triglycerides, 9:21–22
2-hour plasma glucose, 9:6–7
untreated diagnosed diabetes, 9:7
Adult Treatment Panel criteria, 1:19
Adult-onset diabetes mellitus, 1:12; 15:1
Adult-onset type 1 diabetes, 2:4

Adults
adverse consequences of tooth loss, 31:34–35
diagnosed diabetes incidence, 3:16
duration of diabetes, 8:8–9
dysglycemia prevalence, 3:14
overall prediabetes incidence, 3:13
prevalence and incidence of type 1 diabetes, 2:10–13
type 1 diabetes onset, 2:4–5
type 1 diabetes prevalence in U.S., 1:10–11
visual impairment with diabetes, 21:2

ADVANCE trial
A1c levels and cardiovascular risk, 1:24
blood pressure control effects on retinopathy, 21:25
cardiovascular disease prevention, 16:13
in geriatric population, 16:13
high ACR/low eGFR, 22:22
intensive glycemic control effects, 16:13
micro-/macrovascular association with blood pressure, 19:12
risk factor control in stroke, 19:13

Advanced glycation endproducts (AGEs). See also Receptor for AGEs
accumulation in articular cartilage, 32:16–17
accumulation in kidney disease, 22:31
autofluorescence measurement, 1:16
bone fragility in type 2 diabetes, 32:12
contribution to bone fragility, 32:3
diabetes complications and, 1:16;
19:10–11
dietary source for, 22:35
formation of, 1:15
in kidney disease, 22:54
links to glycemia, 24:4
markers for, 21:22
with periodontal disease, 31:24
and receptors in dementia, 24:4
relation to dementia, 22:9; 24:4
sRAGE in neuropahty pathogenesis, 23:7
stroke risk predictors, 19:10–11
Aerobic organisms, 30:14

Affected sibpair (ASP) families
genetics of type 1 diabetes study design, 12:2
major histocompatibility complex linkage demonstration, 12:6–7

Affymetrix GeneChip 500K Mapping Array Set, 12:6

Africa, chronic HBV and HCV infection in, 26:10

African descent
African-specific alleles, 12:3–4
founder (AGPAT2) mutation, 7:15
risk of albuminuria, 22:14

type 1 diabetes in, 15:2

Afro-Caribbean, lower extremity amputation risk in, 20:25

Age. See also Children and adolescents;
Diabetes in youth
cataract association with, 21:33–35
changes in A1c with, 1:11
chronic hypertension with pregestational diabetes and, 5:33
diabetes prevalence age <20 years, 2:5
diagnosed, undiagnosed, and total prevalence, 3:9
diagnosed diabetes incidence, 3:16
diagnosed diabetes prevalence by, 3:4–5
ESRD incidence rate by age groups, 22:27
glaucoma association with, 21:36
maternal mortality and, 5:21–22
measure of initiation of type 1 diabetes, 12:12
prediabetes prevalence, 3:13
racial/ethnic differences in age at onset of
type 2 diabetes, 22:27
retinopathy improvement with, 21:26
sexual dysfunction in men, 28:8
type 1 diabetes incidence, 2:6
type 2 diabetes incidence in youth, 3:16

Age-related macular degeneration (AMD), 21:38

Age-related macular edema, 21:38

Aging, Demographics, and Memory Study, 24:3

AGPAT2 gene
in congenital generalized lipodystrophy

A1c, type 1 diabetes, 7:15
mutations with congenital generalized lipodystrophy, 7:1,15

AHSC (nonmyeloablative autologous hematopoietic stem cell therapy), 37:14

AKT2 gene
familial partial lipodystrophy, 7:19–20
mutation in familial partial lipodystrophy, 7:1,19

Alanine aminotransferase (ALT). See ALT (alanine aminotransferase)

Alanine risk variants in HLA genes, 12:5

Alaska Natives. See American Indian/Alaska Native

Albumin excretion rate (AER), 15:20; 22:12

Albumin:creatinine ratio (ACR). See ACR (albumin:creatinine ratio)

Albuminuria. See also Macroalbuminuria; Microalbuminuria

albumin-to-creatinine ratio, 22:2
as biomarker of ESRD progression, 22:9
classification of, 22:3
death rates with albuminuria elevation, 22:20
elevation in diabetic kidney disease, 22:5–6,12–19
major causes of death with, 22:20
as marker for nephropathy, 22:3
mechanisms for, 22:10
in MODY, 7:4
morbidity/mortality thresholds for disease associations, 22:19
mortality risk with type 1 diabetes, 22:20
normalization with glycemic control, 22:12
podocyte changes and, 22:8–9
prevalence in type 2 diabetes by duration, 22:14
prevalence of persistent, 22:12
relationship with hyperfiltration, 22:6
spontaneous regression in diabetes, 22:17
in staging of chronic kidney disease, 22:3
Albuminuria, moderate. See Microalbuminuria
Albuminuria, severe. See Macroalbuminuria
Alcohol consumption
cancer and diabetes risk factors, 29:6
congenital malformation prediction by, 5:10
diabetes and prediabetes, 10:9–10
in diabetes care, 33:23
liver and gallbladder disease, 26:13
relation to distal symmetrical polyneuropathy, 23:12
relationship to retinopathy, 21:27
risk of hypoglycemia, 17:11
in shift workers, 25:26
type 2 diabetes risk and, 13:9
Alefacept, 37:13
Alefacept, 37:13
Alefacept, 37:13
Alefacept
Aliskiren, 22:50
Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE), 22:50–51
Allegheny County Type 1 Diabetes Registry (ACR)
childhood-onset mortality in type 1 diabetes, 35:12
incidence of type 1 diabetes, 15:6
life expectancy and mortality trend, 35:5–6,7
mortality classification used in, 35:8
mortality in diabetes of youth, 15:38
tooth loss with type 1 diabetes, 31:33
type 1 diabetes mortality, 35:3–4
Alleles, associative testing for over-representation, 14:2
Alpha cells, pancreatic effects of, 6:7
Alpha-1 antitrypsin (AAT) study, 37:13
Alpha-glucosidase inhibitors
acarbose in prevention study, 38:8,9,11
glucose intolerance progression to diabetes effects, 1:19
oral glycemic control, 39:2
in postprandial hyperglycemia, 38:8
prediabetes-diabetes progression effects, 38:13
use in geriatric population, 16:14
voglibose study, 38:9
Alpha-linolenic acid (ALA)
cardiac autonomic neuropathy therapy, 23:8,9
intake/FADS1 and FADS2 interactions, 11:16
in Western diet, 11:12
Alpha-tocopherol
Alpha-tocopherol, Beta-Carotene Cancer Prevention study, 29:8
Alstom syndrome
genetic syndromes with diabetes risk
function of cilia in, 7:12
ALT (alanine aminotransferase)
association with fetuin-A, 13:20
diabetes association, 26:5
diabetes mortality association, 26:7
liver injury estimates, 26:3–4
nonalcoholic steatohepatitis and diabetes status, 13:20
prediction of incident diabetes, 26:5
Alzheimer’s disease (AD)
Alzheimer’s disease (AD)
American Academy of Family Physicians, 1:23
American Academy of Pediatrics
diabetes management recommendations, 41:12
hyperbilirubinemia guidelines, 5:71
neonatal hyperglycemia management, 5:69
American Academy of Periodontology (AAP), joint survey with Centers for Disease Control and Prevention, 31:4–5,8–9,15,17,23
American Association of Clinical Endocrinologists, 18:15
American College of Cardiology Foundation (ACCF), 19:14
American College of Obstetricians and Gynecologists (ACOG)
gestational diabetes screening recommendations, 1:28–29
hypertensive disorders of pregnancy, 5:30
maternal mortality coding, 5:21
pregestational diabetes blood glucose recommendations, 5:72
American Diabetes Association (ADA)
A1c cutpoint for screening, 1:26
A1c endorsement of, 1:13
adiposity measurement recommendations, 18:10
blood pressure goals, 18:17
clinical practice guidelines, 41:3
community screening recommendations, 1:23,26
comparisons of A1c and other glycemic measures, 1:14
criteria for DKA, 17:1
diabetes definition, 2:3
diagnostic criteria for diabetes, 36:1,2
etiologic classification of diabetes, 15:3
forms of diabetes, 1:3
gestational screening recommendations, 1:28–29
4:2
glycemia cutoffs and definitions, 13:16
hypoglycemic episode categories, 17:9
impaired glucose tolerance cutoffs acceptance by, 1:13
neuropathy classification for clinical use, 23:2
optimal first trimester A1c levels, 5:10
peripheral arterial disease screening recommendations, 20:3
physiologic framework for classification of, 15:1–2
Provider Recognition Program, 41:2
recommended screening tests, 1:6
revision of classification, 1:13
revision of glycemic control guidelines, 18:15
risk classification for diabetes, 20:21
risk scores from clinical factors, 1:23
screening for diabetic kidney disease, 22:4
screening for type 1 diabetes, 1:27
screening time recommendations, 4:4
Standards of Medical Care for gestational diabetes, 5:72
stroke risk control recommendations, 19:12,14
undiagnosed and prediabetes criteria, 9:2
American Heart Association (AHA)
clinical practice guidelines, 41:3
eexercise guidelines, 19:11
stroke risk control recommendations, 19:12,14
American Indian
See American Indian/Alaska Native
American Indian reservations
U.S. centers for SEARCH, 15:4
U.S. vs. non-U.S. countries diabetes prevalence, 2:2
American Indian/Alaska Native. See also Pima Indian studies
A1c for screening, 1:26
albuminuria with type 2 diabetes, 22:18,30
cardiovascular risks with diabetes, 22:21
childhood and adolescent incidence, 2:6
degree of heritage and kidney disease, 22:29,34
diabetes as risk for stroke, 19:1
fetal overnutrition with maternal diabetes, 15:12–13
foot ulcers, 20:17
Gila River Indian Community periodontitis study, 31:9,15,17,20
GWAS for, 14:9
impaired glucose tolerance in, 1:18
Indian Health Service records for, 2:5
lower extremity amputation risk in, 20:24
metabolic syndrome prevalence, 13:23
neuropathy prevalence, 23:10
obesity prevalence in youth, 15:12
obesity trends in, 15:12
Ojibwa-Cree community, 15:12
Oklahoma Indians, 13:23; 21:29;
22:18,30; 23:10
pregestational diabetes prevalence during pregnancy, 5:17–18
prevalence by county, 3:8
prevalence of diagnosed diabetes, 3:4
progression of kidney disease in, 22:18–19
retinopathy prevalence in, 21:29
screening in youth, 1:14; 15:4
type 2 diabetes common variants in, 14:8
type 2 diabetes incidence in youth, 3:16;
15:9
type 2 diabetes prevalence, 3:5–6
type 2 diabetes prevalence in youth, 1:14;
15:9
American Medical Association Diabetes Measures Group, 41:2
American Stroke Association, 19:14
Amino acid residues
foreign peptide binding effects, 12:4
in HLA genes, 12:4–5
Amino acid sequence
association-function relation, 14:10
nonsynonymous single nucleotide polymorphisms, 12:6
Amnestic mild cognitive impairment, 24:2
Amniotic fluid insulin concentration, obesity in childhood, 15:13
Amputation. See Lower extremity amputation
Amyloid
Alzheimer’s disease characteristic, 24:1
cascade effects of insulin, 24:3
cerebrospinal fluid levels as marker, 24:4
clearance and insulin in brain, 24:4,13
glucose metabolism derangement and brain pathology, 24:5
islet toxicity in type 2 diabetes, 1:6
Anaerobic organisms, 30:13,14; 31:23
Androgen deprivation therapy (ADT), 29:13
Anencephaly, 5:65
Angiotensin II receptor blocker (ARB)
blood pressure management with stroke and diabetes, 19:12
with diabetes in youth, 15:20
in kidney disease, 22:49
modification of ESRD risk with, 22:32
retinopathy effects of, 21:25
vascular NAVIGATOR study, 38:9
Angiotensin-converting enzyme (ACE) inhibitor
albuminuria improvement with, 22:18
blood pressure management with stroke and diabetes, 19:12
cardiovascular event reduction with, 38:12
with diabetes in youth, 15:20
DREAM study with, 38:9
effect on retinopathy progression, 21:24
renoprotective effect in type 2 diabetes, 22:49
Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen
Detected Diabetes in Primary Care (ADDITION)
health behaviors changes in, 1:27
screening benefits, 1:24–25
Ankle-brachial index (ABI)
hematostatic factors with low, 20:8
in peripheral arterial disease, 20:3
Annular pancreas, 7:11
Anorectal atresia, 5:60
Anorexia nervosa
characteristics of, 33:19
type 1 diabetes mortality with, 35:4
Anorexigenic neuropeptides, 25:20
Antepartum hemorrhage, 5:24–25
Anti-CD3 monoclonal antibody intervention studies
otelixizumab, 37:11,12
tepilizumab, 37:11
secondary prevention trials, 37:11–12
Anti-CD20 monoclonal antibody, 37:12–13
Antigen-presenting cells (APCs), 12:2–3
Antihyperglycemic medications (non-insulin). See also Glucose-lowering agents
biguanide drugs, 5:36
blood pressure and diabetic status, 9:17
diabetes treatment, 39:2–3
expenditures for, 40:59,62,65,70–71
gene encoding for drug target, 14:2
General Practice Research Database data, 5:36
genes encoding targets for, 14:2
Guidelines for use, 18:15
healthcare expenditure data for, 40:61,65,72,77
lactic acidosis incidence with, 17:8
in lipodystrophy management, 7:1
patterns of use by age, 39:2–3
preconception use of, 5:11,36
for prevention of dementia, 24:13
trends in use of, 39:3
use in older patients, 41:7
use in pregnancy, 5:11
use with pancreatitis-related diabetes, 6:7
Antihypertensive medications
hypertension prevalence and use of, 5:29
patient expenditure for, 40:62–63,65
use in early pregnancy, 5:11
Anti-IL-1β monoclonal antibody, 37:13
Anti-inflammatory factors/mechanisms
adiponectin, 13:18–19
alpha-1 antitrypsin, 37:13
in Bardet-Biedel syndrome, 6:16
with cardiovascular disease, 18:12
docosahexaenoic acid, 37:5
fibrinogen, 18:12
genes related to fatty acid metabolism, 11:16
in type 1 diabetes intervention studies, 37:14
Anti-insulin receptor antibodies, 6:15
Anti-islet autoantibodies. See Glutamic acid decarboxylase autoantibodies (GADA);
Insulinoma associated-2 autoantibodies (IA-2A)
Antithromocyte globulin (thymoglobulin) ATG, 37:13
Anxiety disorders/symptoms
causal issues and mechanisms linking diabetes to, 33:18–19
generalized anxiety disorder and diabetes complications, 33:18
generalized anxiety disorder symptoms, 33:16
lifetime anxiety diagnosis with diabetes, 33:18
measurement issues, 33:18
panic disorder, 33:16
patient factors related to prevalence, 33:18
posttraumatic stress disorder symptoms, 33:16
prevalence, 33:16–19
prevalence in youth, 33:18
social phobia, 33:16
treatment and intervention, 33:19
Apgar scores
with maternal diabetes, 5:48–49
with newborn macrosomia, 5:56
Apynea-hypopnea index (AHI), 25:14
APOE-ε4 gene
dementia risk with and without diabetes, 24:8
diabetic neuropathy association, 21:29
genetic susceptibility for dementia, 24:3
polymorphism, 21:25
retinal hard exudates with diabetes, 21:25
retinopathy association, 21:29
Apolipoprotein E allele
with newborn macrosomia, 5:56
Apolipoprotein E gene
with maternal diabetes, 5:48–49
with newborn macrosomia, 5:56
ApoE-ε4 allele. See also APOE-ε4 gene
Apolipoproteins
glycemic control associations, 15:28
HDL formation, 22:35
in late-onset dementia, 24:3
retinopathy association, 21:25
role in vascular risk, 18:8–9
Apoptosis
in benign prostatic hyperplasia, 28:4
in diabetes of youth, 15:10
gene regulation of, 7:10
glucotoxicity effect on beta cells, 11:13
in hemochromatosis, 6:10
in lipodystrophies, 7:19
mitochondrial gene mutation and, 7:9
during nephrogenesis, 22:42,43
in steatohepatitis, 26:5
zinc finger gene regulation of, 9:16

Appetite regulation
hormones in, 25:10
leptin in, 22:37–38
melanocortin receptor in, 7:11
sleep restriction effects on, 25:11

Appropriate Blood Pressure Control in Diabetes trial, 19:11

Appropriate-for-gestational age infants (AGA)
birth trauma in, 5:58–59
birth trauma with vaginal delivery, 5:59
hyperbilirubinemia in, 5:71
neonatal encephalopathy incidence, 5:49
neonatal hypoglycemia rates, 5:70
neonatal morbidities in, 5:56

Area under the receiver-operator-characteristic curve
A1c cutpoint analysis, 1:9
prediction of fatty liver disease, 26:2
prediction of type 1 diabetes risk, 12:10
type 2 diabetes risk prediction, 13:24

Arginine risk variant in HLA genes, 12:5

ARIC study
A1c levels and cancer risk, 24:8
A1c vs. fasting plasma glucose for diagnosis of diabetes, 36:2–3
ankle/brachial index and stroke risk, 20:14–15
biomarkers for cardiovascular disease prediction, 18:12
diabetes prediction of cognitive decline, 24:8
glycemic measures in, 1:21
L1:18 levels and type 2 diabetes, 13:19
metabolic syndrome prevalence, 13:22
metabolic syndrome traits and diabetes risk, 13:24–25
periodontitis and central retinal vein diameter with type 2 diabetes, 31:15
physical activity and retinopathy, 21:27
race/ethnicity in stroke risk in diabetes, 19:7
racial/ethnic differences in retinopathy, 21:27–28
type 2 diabetes and SRY gene association,
19:10–11

Arizona. See also Pima Indian studies
age-adjusted total preexisting diabetes during pregnancy, 5:13–14
albuminuria with type 2 diabetes, 22:18,30
diabetes/glaucoma association, 21:37
metabolic syndrome in, 13:23
offspring risks with gestational diabetes, 4:13
prevalence of diagnosed diabetes, 3:4
trends in type 2 diabetes in youth, 15:15

Asparagine acid risk variant in HLA genes, 12:5

Aspergillosis, 30:16

Aspirin prophylaxis study
dose-dependent effects on A1c, 1:12
effect on cardiovascular events, 18:17
preeclampsia prevention, 5:33
preterm delivery in diabetic women with, 5:45
stillbirth rate with low-dose, 5:37
use with diabetes, 39:6–7

Association testing for type 2 diabetes links, 14:2

AST (aspartate aminotransferase)
liver injury measurement, 26:3–4
prediction of incident diabetes, 26:5

Asthma
comorbidity with diabetes, 5:6
maturation impairment of immune system, 15:11
prevalence in children and adolescents, 2:2
Th2 overactivation and, 11:11

Asymptomatic diabetes. See Prediabetes

Atenolol, 19:12

Atherosclerosis pathophysiology
insulin-like growth factor-1 association, 19:11
in stroke mechanisms, 19:3
subclinical, 18:13

Atherosclerosis Risk in Communities (ARIC) study. See ARIC study

Atorvastatin, 36:10

ATP3 metabolic syndrome. See Metabolic syndrome

ATP-regulated potassium channel (KATP), 7:4–5

Attention deficit/hyperactivity disorder, 2:2

Atypical antipsychotic medications
diabetes induced by, 6:11
type 2 diabetes risk with, 33:1,22,24

Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS), 4:10–11,13

Australian studies/population
cardiovascular autonomic neuropathy, 15:27
change in type 1 diabetes genotype, 11:3
diabetes registries, 2:5
diabetic retinopathy prevalence in youth, 15:18–20
disability with diabetes, 34:3
gestational hypertension prevalence in, 5:34
GI symptom turnover in, 27:5
Intranasal Insulin Trial (INIT 1), 37:6
major malformations with type 2 diabetes, 5:62
major maternal morbidity and mortality measures, 5:24
microalbuminuria prevalence in diabetic youth, 15:24
preeclampsia rates in, 5:34
prevalence of DKA at diagnosis, 17:2

Austria
glycemic control trends, 15:28
pediatric type 2 diabetes prevalence, 15:9
prevalence of DKA at onset, 15:17; 17:2
Autism spectrum disorders
in children and adolescents, 2:2
risks in offspring with maternal diabetes, 5:76
Autoantibodies measurement standardization, 15:2
Autoantibody-negative type 2 diabetes, 1:5
Autoantibody-positive type 2 diabetes, 1:5
Autoimmune diabetes
autoantibody presence with, 2:3
autoimmune polyendocrine syndromes, 6:14
BCG vaccine for, 11:9
criteria for diabetes in youth, 15:3
diagnosis and screening for, 1:6
every life diet in, 15:11
environmental factors, 6:13–14
foreign peptide binding in, 12:4–5
immune response initiation, 37:2
immunodysregulation polyendocrinopathy
enteropathy X-linked, 6:14–15
initiation of, 37:2
latent autoimmune diabetes of adults, 27:9
in neonates, 7:9
onset in obese persons, 2:3–4
rubella and, 6:4
sleep quality associated with, 25:9
viral infections and, 11:4
in youth, 15:3
Autoimmune disease
foreign peptide binding in, 12:4–5
functional candidates for, 12:6
initiation of, 12:4
KIAA0350 gene for susceptibility to, 12:6
MHC region in, 12:2
other diseases with type 1 diabetes, 1:3;
11:10; 39:6
self and non-self, 12:2
susceptibility gene mapping for, 12:8–9
Autoimmune gastritis, 27:15–16
Autoimmune polyendocrine syndromes (APS), 6:14
Autoimmune response. See Type 1 diabetes
immune response
Autoimmune thyroid disease, 6:15; 12:12
Autoimmune type 1 diabetes (type 1a), 1:3
Autoimmunity criteria for diabetes in youth, 15:3
Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (AbATE) Trial, 37:12
Automation to Simulate Pancreatic Insulin REsponse (ASPIRE) study, 17:13
Autonomic neuropathy. See also Cardiovascular autonomic neuropathy
diabetic cystopathy and, 28:4
risk factors for diabetic kidney disease, 22:39–40
role in infections in diabetic patients, 30:4
Autosomal dominant lipodystrophies, 7:17–20
Autosomal recessive lipodystrophies, 7:13–17
Avon Longitudinal Study (England), 5:75
B
B-2 microglobulin, 22:2, 9
BABYDIAB study
BCG vaccine and beta cell function, 11:9
cesarean section interaction with immune response genes, 11:16
diabetes exposure and type 1 diabetes risks, 11:13
islet autoimmunity risk with, 11:10
respiratory infection predictive of islet autoimmunity, 11:7
seroconversion as marker for type 1 diabetes, 37:2
type 1 diabetes and enterovirus infection, 11:5–6
in type 1 diabetes in youth predicted by weight gain, 15:11
BABYDIET study
delayed gluten exposure, 37:5
enterovirus infections, 11:5
gluten triggering autoimmunity, 27:14
respiratory infections and autoimmunity, 11:7
Bacillus Calmette-Guérin (BCG)
in prevention of type 1 diabetes, 11:9;
37:11
risk of type 1 diabetes with, 11:9
Bacterial infections. See also Infections associated with diabetes
of skin and soft tissue, 30:11–12
Bacteriuria, asymptomatic, 22:55–56;
28:20; 30:9
Bacteroides infections, 30:13
Baltimore Eye Survey, 21:7
Baltimore Longitudinal Study of Aging (BLSA)
all-cause mortality association of tooth loss, 31:41
fasting glucose and prostate size, 28:5
glucose metabolism derangement and brain pathology, 24:5
progressive development of type 2 diabetes, 13:16
Baltimore-Washington Cooperative Young Stroke Study, 19:8
Baltimore-Washington Infant case-control study, 5:68
Bardet-Biedel (BB) syndrome, 6:16
Bariatric surgery to treat diabetes, 39:10
Beaver Dam Eye Study (BDES)
age-related macular edema, 21:38
 cortical (lens) opacities, 21:34
 in diabetic vs. nondiabetic persons, 21:36
dry eye association with diabetes, 21:37
duration of type 2 diabetes and impairment, 21:4
lens opacity with diabetes, 21:34
microaneurysms in, 1:16
visual impairment with type 2 diabetes, 21:4
Becaplermin, 20:22
Behavioral intervention
hypoglycemia management, 17:13
modifiable risk factors for type 2 diabetes, 13:1
type 2 diabetes risk factors, 13:6–12
Behavioral Risk Factor Surveillance System (BRFSS). See BRFSS data
Belarus, breastfeeding promotion in, 13:13
Belgian Diabetes Registry, 37:6
Berardinelli-Seip Congenital Lipodystrophy 2 (BSCL2), 7:15
Beta blockers, 6:11–12
Beta cell dysfunction/function
abatacept effects, 37:6–7, 12
accelerated growth in early life, 15:11
acute insulin response and proinsulin levels, 13:17
apoptosis in diabetes in youth, 15:10
autoantibody appearance with injury, 37:2
autoimmune destruction in youth, 15:2
circadian disruption effects, 25:26
in combined types 1 and 2 diabetes, 1:5
cortisol effects on, 25:19
delay of function in, 1:3
dysfunction in type 2 diabetes, 13:17
type 1 diabetes risk factors, 11:4
type 2 diabetes risk factors, 11:4
etiology of dysfucntion in pregnancy, 4:3
genetic variants affecting, 14:7–8
glucose sensitivity changes, 37:3
glucose toxicity effects on, 7:19
IL-1β effects on, 37:13–14
markers for, 13:17
melatonin receptors in, 25:28
meta-analysis for, 14:9
mitochondrial gene mutation and apoptosis, 7:9
in monogenic diabetes, 1:4
nonimmune causes of dysfunction, 1:3
pathophysiology of injury, 6:5
PAV4 and development, 7:7
plasmid-encoded proinsulin effects, 37:14
postprandial hyperglycemia effects on, 38:8
proinsulin elevation as failure marker, 18:11
proinsulin measurement and ratio, 13:17
proinsulin peptide effects, 37:14
regulation of apoptosis, 7:10
rotavirus infections of, 11:8
secretory capacity measurement, 13:17
smoking effects on, 13:16
teilzumab and abatacept for, 37:5
in type 1 diabetes, 11:3, 5
in type 1 diabetes, 11:3
in type 2 diabetes patients, 1:5
in type 2 diabetes transition, 13:16–17
Beta-hemolytic streptococci, 30:12–13
Birth trauma association with, 5.58–59
birth trauma risk association, 5.56
category criteria, 13.13
excess fetal size, 5.49
of liveborn infants in maternal diabetes, 5.55–56
in MODY3, 7.5
with preexisting diabetes, 5.50
proportionate/disproportionate LGA, 5.59
relation to adult obesity, 15.12
shoulder dystocia and trauma, 5.57–58
type 2 diabetes risk association, 13.13

Black Women's Health Study. 13.14; 25.24
Black/African American. See also Sea Island Gullah African Americans
African-specific HLA haplotypes, 12.3–4
albuminuria in, 22.18
arterial stiffness in, 15.34
brachial plexus palsy risks in, 5.58
complication-specific mortality with type 1 diabetes, 35.8–9
dementia prevalence in, 24.3
excess mortality with type 1 diabetes, 35.5–6
familial partial lipodystrophy in, 7.18
glycated albumin levels in, 3.15
HbA1c prevalence with diabetes, 26.10
hypertension and heart disease risk, 18.9
lung cancer incidence, 29.8
progression of kidney disease in, 22.18
proinflammatory cytokines in, 13.19
race as risk factor for prostate cancer, 29.9
region of U.S. residence, 8.9–10
retinopathy screening disparities, 15.18
risk factors for peripheral arterial disease, 20.7
self-reported diabetes, 15.8
sleep and glycemic control in, 25.9
sociodemographic characteristics, 8.6
stillbirth rates, 5.37
telephone access, 8.14
thyroid cancer in, 29.10
type 1 diabetes early mortality in, 35.7
type 1b diabetes in, 6.18
with undiagnosed diabetes, 8.20
world region of residence, 8.10

Bladder cancer
meta-analysis for medication association, 29.13
pioglitazone and thiazolidinedione studies, 29.11

Blindness. See Visual impairment
Blood pressure control. See also
Hypertensive disorders of pregnancy albuminuria progress with, 22.48–49
care of diabetes patients, 41.4–5
clinical trials on control of risk factors, 18.17
by diabetes status, 9.17
diastolic vs. systolic in pregnancy outcomes, 5.33
geriatric diabetes, 16.14

BMI (body mass index)
brachial plexus palsy risk with maternal, 5.58
calculation of, 9.2
cancer association with, 29.6
cardiovascular disease association with, 18.11
clinical risk categories for type 2 diabetes, 13.11
criteria for screening in youth, 1.14
diabetes status, treatment, age, 9.11–13
dentomental cancer risk and, 29.9
evening chronotype association, 25.27
factors in increased prevalence of diabetes, 3.19–20
general obesity measurement, 9.14
gestational diabetes association, 4.5
GTT level interaction with, 13.20
and incidence of type 1 diabetes, 11.13
and increased diabetes prevalence, 3.19–20
leptin/ghrelin levels with sleep duration, 25.11
myocardial infarction risk association, 18.10
nonpregnant women, 5.6
osteoarthritis and diabetes risk factors, 32.16–17
in pediatric patients with type 2 diabetes, 15.2
prenatal detection of malformations, 5.67
with previous gestational diabetes, 4.12
relation to retinopathy, 21.26
for risk assessment in Asian subgroups, 26.6
risk for progression to diabetes, 1.18
rosiglitazone prevention and, 38.9
subclinical cardiovascular disease relation to, 18.10
thyroid cancer association, 29.10
total diabetes prevalence, 3.19
in type 1b diabetes, 15.2
waist circumference measures with, 13.12

Bogalusa Heart Study
increase in overweight in childhood, 15.12

Bone complications
alendronate for bone loss, 32.14
bone density with diabetes, 32.3, 7–10
bone fragility in, 32.2
bone mineral density, 32.9
bone structure with diabetes, 32.12
diabetes duration and fracture risk, 32.14
diabetic complications as risk factor, 32.12
economic cost of fractures, 32.1–2
fall frequency with diabetes, 32.10–11

Blot hemorrhages (retinal). 21.12
Bmal-1 gene, 25.24, 27
Bovine insulin exposure, 37:3
Brachial plexus palsy (BPP)
with shoulder dystocia, 5:58–59
transient vs. permanent with maternal diabetes, 5:59
with vaginal delivery, 5:59
Bradford-Hill cause-effect criteria, 6:10
Breastfeeding
after gestational diabetes, 15:13
for infants of diabetic mothers, 5:73–74
obesity in offspring in maternal diabetes, 4:13
obesity protective effect, 13:13, 15:13
type 2 diabetes protective effect, 15:13
BRFSS data
cost of diabetes model, 40:59
dental care utilization, 31:39
depressive disorders and symptoms, 33:4
diabetic foot ulcers, 20:20, 23:14
diagnosed diabetes prevalence plateau in, 3:17
foot and eye care, 41:8
health insurance coverage, 42:11
healthcare utilization and insurance coverage, 42:11
intended pregnancy and health-related behaviors, 5:12
medication use and self-care practices, 39:1–14
oral health, 31:32
periodontitis prevalence, 31:6
physical activity, 10:12
prevalence of diabetes, 36:3
prevalence of diabetes in women of child-bearing age, 5:4, 5
prevalence of heart disease with/without diabetes, 18:4
race/ethnicity variations in depression, 33:9
retinopathy care and insurance, 21:11
screening in heart disease patients, 1:24
survey for diabetes surveillance, 2:5
tooth loss/missing teeth with diabetes, 31:32
type 2 diabetes/prediabetes county level prevalence, 3:8–9
BSCL2 gene
congenital generalized lipodystrophy, 7:15–16
mutations with congenital generalized lipodystrophy, 7:1
Bulimia nervosa, 33:19
Bupropion therapy, 33:22
Burning mouth syndrome, 31:38
C
C10orf159, type 1 diabetes risk, 12:8
Cadmium levels in blood, 20:9
Calcineurin inhibitors, 6:11
California. See also Kaiser Permanente Northern California; Kaiser Permanente Southern California; Rancho Bernardo Study
age-adjusted total preexisting diabetes during pregnancy, 5:13–14
brachial plexus palsy risk factors, 5:58
chronic hypertension with pregestational diabetes, 5:33
deliveries with pregestational diabetes, 5:15,16–17
early induction for birth trauma prevention, 5:59
gestational diabetes prevalence, 4:7
gestational diabetes prevalence trends, 4:7
Hispanic/Latino population, 3:7
maternal morbidity with acute myocardial infarction, 5:23
metabolic syndrome in, 13:23
Multi-Ethnic Study of Atherosclerosis, 31:6
nephropathy prevalence data, 5:29
permanent brachial plexus palsy estimates, 5:59
preconception planning/counseling, 5:8
preclampsia rates with chronic hypertension, 5:34
preclampsia rates with pregestational diabetes, 5:34
preclampsia/eclampsia with gestational diabetes, 5:34–35
pregestational diabetes prevalence during pregnancy, 5:17–18
severe maternal morbidity with postpartum abruption, 5:25
shoulder dystocia with vaginal delivery, 5:56–57
stillbirth/weight gain relation, 5:43
surveillance system for pregestational diabetes and pregnancy, 5:13
total diabetes percentages, 8:9
U.S. centers for SEARCH, 15:4
U.S. vs. non-U.S. countries diabetes prevalence, 2:2
California Health Discharge Database, 5:24
California Health Interview Survey (CHIS), 3:8
California Men’s Health Study, 28:6
Canadian Cerebral Palsy Registry, 5:49
Canadian Diabetes Association, 4:4, 5:72
Canadian Hospital Morbidity database, 5:23
Canadian Normoglycemia Outcomes Evaluation (CANOE), 38:9–10,13
Canadian studies
cesarean delivery in diabetic women, 5:46
chronic hypertension rates >10%, 5:33
classification of diabetes in children/adolescents, 2:4
deliveries with pregestational diabetes, 5:15
independent diabetes association with, 5:37
major malformations with type 2 diabetes, 5:62
nephropathy prevalence data, 5:29
nephropathy prevalence in youth, 15:20,23
preclampsia in type 1 vs. 2 diabetes, 5:35
pregestational diabetes in pregnancy trends, 5:15
pregnancy planning and glycemic control, 5:8
prevalence of retinopathy in diabetes of youth, 15:18
shoulder dystocia with vaginal delivery, 5:56
surveillance system for pregestational diabetes and pregnancy, 5:13
type 2 diabetes in Aboriginal youth, 15:10
undifferentiated diabetes in pregnancy trends, 5:15
Canadian Task Force on Preventative Health Care
A1c cutpoint for screening, 1:26
diabetes screening recommendations, 1:23
Canagliflozin, cardiovascular benefits of, 18:15
Canagliflozin Cardiovascular Assessment (CANVAS) trial, 18:15
Canakinumab, 37:13
Cancer and diabetes, 29:1–21
in adults with and without diabetes, 29:2–4
alcohol consumption, 29:6
androgen deprivation therapy, 29:13
bladder cancer, 29:9
breast cancer, 29:8
breast cancer chemotherapy, 29:13
cancer incidence, 29:4
cancer mortality, 29:4–7
cancer recurrence and second cancer, 29:14
Candidate causal genes

- adiponectin gene polymorphisms, 38:11 for diabetic kidney disease, 22:43
- diabetic kidney disease relationship, 22:43
- HLA class II alleles in type 1 diabetes, 11:3 polymorphism, 38:9 related to dietary exposures, 11:16 for retinopathy, 21:29
- for type 1 diabetes risk, 12:8
- type 2 diabetes associations, 14:6

Candida albicans, 30:5,9,11; 31:38

Candidate causal genes

- adiponectin gene polymorphisms, 38:11 for diabetic kidney disease, 22:43
- diabetic kidney disease relationship, 22:43
- HLA class II alleles in type 1 diabetes, 11:3 polymorphism, 38:9 related to dietary exposures, 11:16 for retinopathy, 21:29
- for type 1 diabetes risk, 12:8
- type 2 diabetes associations, 14:6

CANRISK calculator, 1:23

Capillary blood glucose (CBG), 1:26

Captopril, 22:48–49

Capture-recapture analyses, 2:5

Carotid endarterectomy (CEA), 19:6

Caries

Cardiovascular autonomic neuropathy

- See Cardiovascular autonomic neuropathy

Cardiovascular autonomic neuropathy

- See also Cardiovascular autonomic neuropathy

Cardiovascular derangement

death certificate limitations for determining, 36:3
effect of sexual chronotype, 25:27
lifestyle intervention effects on, 38:15
markers in offspring of mothers with diabetes, 5:74
pathways for impact of sleep duration on, 25:12
REM-related sleep apnea and, 25:17

Cardioangiopathy

in Alstrom syndrome, 7:12
BSCL2 mutations, 7:15
in congenital generalized lipodystrophy, 7:14
LMNA mutations, 7:19,20
maternal mortality from, 5:22
maternally inherited diabetes and, 7:9
neonatal morbidity with hypertrophic, 5:68

Cardiovascular autonomic neuropathy (CAN)

with diabetes in youth, 15:26–27
esophageal dysmotility and, 27:8
hyperglycemia in diabetes, 23:13
glycemia association with, 15:27
glycemic control in type 2 diabetes, 23:13
heart rate and hyperglycemia association, 23:13–14
incidence and prevalence, 23:12
metabolic memory in, 23:13
onset and course of, 23:13
risk factors, 23:13
symptoms of, 23:6
tests for, 15:27, 23:6–7
treatment of, 23:9

Cardiovascular autonomic reflex tests (CARTs), 23:6–7

Cardiovascular congenital abnormalities, 5:65

Cardiovascular disease (CVD)

See also Heart disease and diabetes

aspirin prophylactic use with diabetes, 39:6–7
diabetes in older adults, 16:6–7
diabetic kidney disease as risk factor for, 22:19
glycemic risk factors for complications, 1:24
high-sensitivity C-reactive protein in, 19:10
mortality in diabetic persons, 36:8
mortality with macroalbuminuria, 22:20
with previous gestational diabetes, 4:12
subclinical markers for, 15:34, 18:13
type 1 diabetes mortality with duration >20 years, 35:9

Cardiovascular disease risk factors

acarbose effects on, 38:12
ADDITION study, 1:27
arterial stiffness in youth, 15:34
blood glucose in screening for, 1:22–23
coronary artery calcification association with, 15:37
diabetes in youth
dyslipidemia, 15:33
elevated blood pressure, 15:29,33
glycemic control, 15:29
diabetic kidney disease as, 22:19–24
in geriatric diabetes, 16:5–6
glycemic measures for prediction of, 1:18
hyperglycemia, 18:7–8
hypertension, 18:9
insulin resistance, 18:11–12
lipids and lipoproteins, 18:8–9
metabolic syndrome, 18:9–10
mortality with cardiac autonomic neuropathy, 15:27
obesity, 18:9–11
obesity and insulin resistance in youth, 15:33–34
presence of diabetes, 36:1
with previous gestational diabetes, 4:12
pulse-wave velocity association with, 15:34
type 1 diabetes mortality and, 35:11

Cardiovascular Health Study

intermittent claudication, 20:7–8
racial/ethnic differences in retinopathy, 21:27
type 2 diabetes risk and adiponectin levels, 13:19

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease (VERTIS CV) trial, 18:15

Cardiovascular system malformation, 5:62

Caries, 31:36–38

Carotid artery

- intimal-medial wall thickness and peri-odontitis, 31:15
- RAGE association with atherosclerosis, 19:11
- stenting, 19:16
- stroke risk and bruits, 19:9

Carotid endarterectomy (CEA), 19:16

Carotid intima media thickness (cIMT)

acarbose effects on, 38:12
cardiovascular risk stratification, 18:13
in diabetes of youth, 15:34–37
periodontal disease as risk for, 31:15
Carpenter-Coustan gestational diabetes criteria, 4:7,10
CARS (cysteiny1-tRNA synthetase) gene, 22:43

Case-control studies. See also DPP study; SEARCH for Diabetes in Youth study
allelie spectrum for type 2 diabetes expansion, 14:6
anti-HCV antibody association with subsequent diabetes, 26:8
Baltimore-Washington Infant Study, 5:68
benign prostatic hyperplasia and dysglycemia, 28:5
biases in medication-cancer risk studies, 29:10–11
breastfeeding and type 1 diabetes risk association, 11:9
cataract prevalence, 21:34
contraception exposure risks, 5:13
coneal epithelial fragility values in type 2 diabetes, 21:37
corticosteroid treatment and hyperglycemia risk, 27:15
cow’s milk exposure meta-analysis, 11:9–10
diabetes and gallstone disease association, 26:15,18
diabetes as tuberculosis risk factor, 30:17
diabetes-cancer risk associations, 29:7,9,10
eating disorders and type 1 diabetes in adolescents, 33:19
enteroviral infections at diagnosis of type 1 diabetes, 11:4
ever vs. never breastfeeding, 5:74
foot ulcer and vibratory insensitivity association, 23:14
genetic risk score calculation, 13:5
genetic risk studies for type 1 diabetes, 12:2
genotype associated with type 1 diabetes, 12:6–7
gestational diabetes and periodontitis association, 31:22
glycemic control and dyslipidemia, 15:33
growth in children with type 1 diabetes vs. without diabetes, 11:13
low birth weight association with chronic kidney disease risk, 22:42
major malformations with maternal diabetes, 5:60,65,67
melatonin secretion and type 2 diabetes development, 25:28
MTNR1B and abnormal glucose metabolism, 25:28
National Birth Defects Prevention Study, 5:11
neonatal seizures with maternal type 1 diabetes, 5:49
nitrosamine consumption and type 1 diabetes risk, 11:14
obesity as independent risk factor for diabetes, 5:10
periodontitis and gestational diabetes risk, 31:14
periodontitis severity and erectile dysfunction, 31:16
periodontitis severity and other disease associations, 31:16
plaque and periodontal health in children with type 1 diabetes, 31:21
pneumococcal bacteremia with diabetes, 30:8
preterm birth and type 1 diabetes association, 11:15
serum α-tocopherol and diabetes risk, 11:13
Stillbirth Collaborative Research Group, 5:37,43
transient vs. permanent brachial plexus palsy, 5:59
type 1 diabetes risk and psychological stress, 11:15
type 1 diabetes-associated single nucleotide polymorphisms, 12:10
vitamin D exposure in infancy, 11:11–12
waist-to-hip ratio association with myocardial infarction, 18:10–11
Cataracts
with diabetes, 21:33–34
extraction of, 21:35–36
vs. lens opacities, 21:34
prevalence of, 21:34
risk factors with type 1 diabetes, 21:34–35
risk with diabetes types, 21:1
risk with diuretic use, 21:34
Catecholamines. See also Sympathetic nervous system activity
effects on insulin sensitivity, 25:19
impaired release in diabetes, 17:9
Causitive Classification of Stroke System, 19:2
Cox-effect relationship criteria, 13:10
CAV1 (caveolin-1) gene
mutations with congenital generalized lipodystrophy, 7:1,15–16
PTRF regulation of expression of, 7:16
CDC Maternal Mortality Study Group, 5:21
CDC Pregnancy Mortality Surveillance System, 5:21
CEL (carboxyl-ester lipase) gene in MODY7, 7:7
Celiac disease (CD)
detection by IgA antibodies, 27:13
diagnosis of, 27:12–13
epidemiology of, 27:10–12
genetic predisposition to, 27:9
gluten as trigger for diabetes, 27:14
 gluten-free diet effects on A1c, 27:14
 glucose-free diet for management, 27:13–14
histologic changes in small intestine, 27:9–10
immune response to gluten, 27:9
latent autoimmune diabetes of adults with, 27:9
prevention of, 27:12
symptoms of, 27:12–13
tissue transglutaminase autoantigen in, 27:9–10
type 1 diabetes association, 27:11–12
Cell adhesion molecules
endothelial dysfunction markers, 13:20
levels in obstructive sleep apnea, 25:20
in proinflammatory and insulin resistance pathways, 13:19
Cellular memory. See Metabolic memory
Centers for Disease Control and Prevention (CDC). See also BRFSS data; NHANES data; NHIS data
American Academy of Periodontology joint surveys for diabetes surveillance, 31:4–5,8–9,15,17,23
diabetes risk factor control trends, 41:3
Division of Diabetes Translation, 2:2–3
maternal mortality studies, 5:21
maternal mortality surveillance, 5:21
sociodemographic data from, 8:2
surveys for diabetes surveillance, 2:5
Central macular edema. See Macular edema
Central nervous system malformations, 5:62
Central obesity. See Abdominal obesity
Central/South Americans. See also Hispanic ethnicity
cyclophosphamide and thymoglobin, 37:14
diagnosed diabetes prevalence, 3:6–7
fasting and impaired glucose predictive power, 1:20
prediabetes prevalence, 3:14
total glycemic prevalence, 3:14–15
undiagnosed diabetes prevalence, 3:12–13
Cerebral amyloid angiopathy, 24:4
Cerebral edema
with DKA in youth, 17:3,5
with lactic acidosis, 17:8–9
Cerebral palsy, 5:49
Cerebrovascular disease/events
albuminuria and stroke risk, 19:10
cognitive impairment with, 24:1–2
comorbidity with diabetes, 16:5,11
hormonal contraception and risks for, 5:13
hypercoagulability link with, 19:11
hyperglycemic hyperosmolar state precipitation risk, 17:6
mortality trends with diabetes in pregnancy, 5:22
in nursing home residents, 40:47
pathophysiology of stroke, 19:3
pregestational diabetes and hypertension in, 5:33
premature mortality with diabetes, 40:68
risk management for, 19:12–14
risk with peripheral arterial disease, 20:13
subclinical cerebrovascular disease, 24:3
tooth loss association, 31:16
vascular cognitive impairment, 24.3

Cesarean delivery
birth size and, 5.59
confounding of stroke data, 5.22
in diabetic women, 5.46
interaction with PIH gene, 11.16–17
maternal complications of diabetes, 5.25
postpartum wound infection, 5.24
for prevention of birth injury, 5.59
pulmonary embolism association, 5.24
rates with diabetes, 5.46,58
shoulder dystocia rates with, 5.57
sleep disturbance relation to, 25.21
venous plasma glucose levels and, 4.8

Charcot neuroarthropathy
complication of diabetic neuropathy, 23.14
etiology of, 20.18
foot deformity with, 23.5
sensory abnormality with, 32.18

Chicago Childhood Diabetes Registry
diabetes in children and adolescents, 2.6–7
mortality in diabetes of youth, 15.38
type 1 diabetes surveillance, 2.5

Children and adolescents. See also Diabetes in youth
age for testing, 1.14
birth month and seasonal patterns for type 1 diabetes, 2.7
chronic diseases in, 2.2
classification of diabetes in, 2.3; 15.1–4
comparison with international rates, 2.7
complications of diabetes in, 15.13–38
criteria for screening, 1.14
diabetes-pancreatitis interactive effects, 31.18–21
DKA treatment recommendations for, 17.5
eye mortality with type 1 diabetes, 15.38–39; 35.9
eating disorder prevalence, 33.19
glycemic tests comparisons, 1.14
hyperglycemic hyperosmolar state incidence in, 17.6
incidence of DKA in established diabetes, 17.2
incidence of type 1 diabetes in U.S., 2.6–7;
15.5–6
ketosis with types 1 and 2 diabetes, 15.2–3
life expectancy predictions for, 36.8
maternal diabetes consequences for, 4.12–13
metabolic syndrome prevalence, 13.23–24
new-onset diabetes in youth, 15.2
prevalence of overweight in youth, 15.12
prevalence of type 1 diabetes in U.S., 2.5;
15.4–5
race/ethnicity projections for type 1 diabetes, 2.10
SEARCH study, 2.2.5; 15.4
seasonality of type 1 diabetes, 2.7–9
temporal trend in, 2.9–10; 15.6.9–10
tooth eruption rate with diabetes, 31.36
type 1 diabetes prevalence, 2.5; 15.4–5
type 2 diabetes prevalence and incidence, 3.17; 15.8–9
U.S. population incidence, 2.6
U.S. population prevalence, 2.5
Children’s Hospital of Pittsburgh (CHP)-based type 1 diabetes registry, 35.3–4
Chinese Americans. See also Asian/Pacific Islander
dental visits with insurance, 31.39
metabolic syndrome prevalence, 13.22
periodontal disease prevalence, 31.6
retinopathy prevalence, 21.29
sleep quality and insulin resistance association, 25.9

Chinese/Taiwanese studies. See also Asian/Pacific Islander
A1c for screening, 1.26
Da Qing study, 1.25; 38.5
diabetes and gallstone disease, 26.15
diagnosed diabetes prevalence, 3.7–8
gestational diabetes regression, 1.29
glucose measures and diabetes risk, 1.20
glycated albumin and fasting glucose correlation, 1.15
immunotherapy trials, 37.14
lifestyle intervention trial, 1.19
lung cancer-diabetes association, 29.8
new-onset diabetes risk with HCV infection, 26.10
sleep quality and glycemic control association, 25.9

Cholesterol measures/control
for cardiovascular risk associated with diabetes, 36.10
heart disease association with, 18.8–9
levels with claudication, 20.8

Cholesterol-lowering medications
expenditures for, 40.66
treatment in diabetes, 39.5–6

Chorionicomnionitis, 5.24

Chromosomes
6q24, 7.9–10
11p15.5 regulation of INS gene transcription, 7.5
12q13 and type 1 diabetes susceptibility, 12.6
12q24 and type 1 diabetes susceptibility, 12.6
16p13 region and type 1 diabetes susceptibility, 12.6
INS gene mutations in 11p15.5, 7.10–11

Chronic bilirubin encephalopathy, 5.71

Chronic distal symmetric polyneuropathy.
See Distal symmetrical polyneuropathy

Chronic hypertension with pregestational diabetes
diagnostic criteria in pregnancy, 5.33
maternal deaths with, 5.22
maternal stroke/cerebrovascular complications, 5.33
prepregnancy rates of, 5.33
prevalence of, 5.33
rates of poor pregnancy outcomes with, 5.33
stillbirth rates, 5.37
treatment in pregnancy, 5.33
types 1 and 2 diabetes, 5.33

Chronic inflammatory demyelinating polyneuropathy (CIDP), 23.3

Chronic kidney disease (CKD). See also Diabetic kidney disease; Kidney disease associated with diabetes
associated with diabetes, 22.56–57
defined, 22.3
diagnosis of diabetic kidney disease, 22.4
equations for GFR estimation, 22.3
estimated prevalence by type of diabetes, 22.12
management with diabetes, 22.54
prognosis of infections with, 22.22
staging developments in, 22.2

Chronic Kidney Disease Epidemiology Collaboration, 22.3

Chronic pancreatitis (CP)
diagnosis and treatment of, 6.7–8
hereditary/genetic pancreatitis, 6.8
prevalence of diabetes with, 6.7

Chronotype, 25.27–28

CfDEC (cell death-inducing DNA fragmentation factor a-like effector c) gene, 7.17

Ciliopathy, heterogeneous, 6.16; 7.12

Circadian disturbances. See Sleep and circadian disturbances

Circadian system
CRY2 gene, 14.8
genes and regulation of, 25.24
mitochondria metabolism, 25.20–21,24–30
melatonin regulation of, 25.28
misalignment, 25.24,27
morning/evening chronotype, 25.27–28
MTNR1B gene, 14.8

Cirrhosis (end-stage liver disease)
correlation with prevalence of diabetes, 6.10
diabetes prevalence and liver function, 26.11
fatty liver disease progression to, 26.2.6
with hemochromatosis, 6.9
late development with lipodystrophy, 7.14
liver transplantation, 26.11–13
new-onset diabetes incidence with, 26.11
portal hypertension and diabetes risk, 26.11

Class I (HLA-A and -B) loci
diabetes association with, 12.3
HLA-B*39:06 (susceptible) in type 1 diabetes, 12.4
HLA-B*57:01 (protective) in type 1 diabetes, 12.4

Class II (HLA-DR, -DQ, and -DP) loci, 12.3

Classification of diabetes. See also Screening for diabetes
diabetes association with diabetes, 24:8
dementia characteristics, 24:2
depression effects on cognitive function, 24:11
diabetes and dementia mechanism relationships, 24:4
diabetes and vascular dementia relationship, 24:8
diabetes medications and dementia risk, 24:13
ethnic differences in dementia, 24:3
executive-frontal abilities, 24:12
functional impairment from hypoglycemic events, 24:12–13
histologic changes in, 24:3
hypoglycemia and dementia relationship, 24:12
intensive treatment effects, 24:6–7,10,12
lifestyle intervention effects, 24:1–2
non-amicotic impairment, 24:2,3
noncerebrovascular-diabetes links, 24:4
non-genetic risk factors for dementia, 24:3
in offspring with maternal diabetes, 5,75
performance testing methods for, 24:1–2
prevention and, 24:13
relation to cognitive performance, 24:13
subclinical cerebrovascular disease and, 24:3
vascular cognitive impairment, 24:3
white matter disease, 24:4
with and without type 2 diabetes, 24:8
Cohort study advantages and characteristics, 36:5
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE), 13:5
Collaborative Atorvastatin Diabetes Study (CARDS), 18:16; 19:10
College of American Pathology (CAP)
A1c measurement recommendations, 1:9,10
hemoglobinopathies effects on measurements, 1:12
Colorado Birth Certificate Registry, 5:49
Colorado Insulin Dependent Diabetes, 2:5
Colorado studies
change in type 1 diabetes genotype, 11:3
dyslipidemia and glycemic control in youth, 15:33
gestational diabetes prevalence, 4:7
neonatal seizures with maternal diabetes, 5:49
prevalence of diagnosed diabetes, 3:4
subclinical cardiovascular disease, 15:37
U.S. centers for SEARCH, 15:4
U.S. vs. non-U.S. countries diabetes prevalence, 2:2
Colorectal cancer with diabetes, 29:7
Combined types 1 and 2 diabetes, 1:5; 15:3
Community screening recommendations, 1:26
Comorbidity indexes, 5:4
Complications of diabetes
acute complications in youth, 15:1,13–17
acute metabolic complications, 17:1–19
bone and joint, 32:1–22
cancer and diabetes, 29:1–21
cardiovascular disease in youth, 15:34–38
cognitive impairment with, 24:1–19
conditions of aging, 16:15–16
delivery complications, 5:16,45
disability and, 34:1–15
foot ulcers, 20:19; 23:14–15
gastrointestinal manifestations of, 27:1–22
geriatric diabetes, 16:13–15
gestational diabetes, 4:1–17
heart disease and, 18:1–30
hyperglycemic hyperosmolar state, 17:6
infections associated with, 30:1–25
kidney disease in, 22:1–84
liver and gallbladder disease in, 26:1–23
lower urinary tract symptoms in men, 28:4–6
lower urinary tract symptoms in women, 28:10–20
maternal mortality with, 5:22
microvascular complications in youth, 15:17–27
mortality in type 1 diabetes, 35:1–16
mortality trends in type 2 diabetes, 36:1–14
ocular functions and diseases with, 20:1–49
oral health and, 31:1–49
peripheral and autonomic neuropathy in, 23:1–20
peripheral arterial disease, 20:1–34
with pregnancy, 5:1–101
pregnancy-related stroke and hypertensive disorders, 5:22–23
psychiatric/psychosocial issues, 33:1–34
sexual dysfunction in men, 28:6–10
sexual dysfunction in women, 28:20–21
sleep and circadian disturbances effects, 25:1–44
stroke and, 19:1–23
urologic diseases and sexual dysfunction in, 28:1–26
Computer assisted sensory examination (CASE), 23:6
Confocal microscopy of cornea, 23:6
Congenital generalized lipodystrophy (CGL), 7:13–17
AGPAT2 mutations, 7:15
BSCL2 mutations, 7:15–16
CAV1 mutation, 7:16
clinical presentation, 7:13–15
differential diagnosis in, 7:16
molecular diagnosis of, 7:16
prevalence and incidence, 7:13
PTRF mutations, 7:16
Congenital heart defects
obesity association with, 5:10
pregestational diabetes, 5:67
in utero diabetes exposure, 5:66
Cooperative Health Research in the Region of Augsburg (KORA). 13.19

Congenital malformations/anomalies. See also Major malformations/anomalies defined, 5.59

diabetes-obesity gene interactions for, 5.10–11
fetal sex-associated risk, 5.66
first trimester glycemic control prediction of, 5.10
interpregnancy interval for diabetic women, 5.7
with maternal diabetes, 5.99–67
multiple, same infant, 5.65–66; 7.11
neonatal diabetes association with, 7.10
periconception maternal nutrition and metabolic changes, 5.11
preconception care of diabetic women, 5.7–8
prediction by vascular disease, 5.10
pregnancy terminations for, 5.43
in second pregnancies, 5.10
stillbirth with, 5.43

Congenital rubella syndrome (CRS). 11.7–8

Congenital syndromes with diabetes risk
Alstrom syndrome, 6.16
Bardet-Biedl syndrome, 6.16
Down syndrome, 6.16
Prader-Willi syndrome, 6.16–17
Turner syndrome, 6.17
Williams syndrome, 6.17

Congenital viral infections

cytomegalovirus, 6.4–5
rubella, 6.4

Congestive heart failure
with diabetes in older adults, 16.5–7
economic impact of, 22.3
familial partial lipodystrophy, 7.18–19
Medicare budget expenditures, 22.2
prevalence in men and women, 18.4
risk with intensive treatment, 18.15
with rosiglitazone, 24.13, 38.9
statin therapy, 38.12
thiazolidinedione medications and, 18.15

Conjugated linoleic acid, 11.10

CONQUER randomized controlled trial, 38.10

Consolidation of memory, 24.1–2

Constipation, 27.2.8

Contact lens use with diabetes, 21.37

Continuous glucose monitoring, 17.12–13

Continuous subcutaneous insulin infusion (CSII), 5.25; 17.2

Contraception for diabetic women
ADA guidelines on, 5.7
hormonal contraceptive complications with diabetes, 5.12–13
not using contraception, 5.8
preconception care, 5.11–13
reasons for low utilization, 5.12
safety of methods for, 5.12

Contrast-induced nephropathy, 22.39

Corneal changes with type 1 diabetes, 21.37
confoocal microscopy, 23.6

corneal ulcers in type 1 diabetes, 21.37
dry eye association with diabetes, 21.37
epithelial fragility with type 2 diabetes, 21.37
lesions and dry eye, 21.37

Coronary artery calcification (CAC)
cardiac event prediction with, 15.37

coronary artery disease risk stratification, 18.13
coronary artery risk factors, 15.27–28
in diabetes of youth, 15.37–38
scores and glycemic control, 15.38
subclinical atherosclerosis, 15.34; 18.13

Coronary Artery Risk Development in Young Adults (CARDIA). See CARDIA study

Coronary heart disease (CHD). See Heart disease

Coronary vascular disease. See Cardiovascular disease (CVD); Heart disease

Cortical (lens) opacities, 21.34

Corticosteroids
fracture risk and, 32.12
hyperglycemic hyperosmolar state precipitation by, 17.6–7
inflammatory bowel disease treatment, 27.15
prevention trial with azathioprine, 22.13
in inflammatory bowel disease, 22.4–5
in juvenile idiopathic arthritis, 22.10
in juvenile idiopathic arthritis treatment, 22.12
in juvenile idiopathic arthritis with glucocorticoids, 22.14
in joint pain, 22.14
in pediatric CD, 22.10
in prevention studies, 22.3; 37.7
in risk score construction, 22.3; 37.7
in the treatment of juvenile idiopathic arthritis, 22.14
in the treatment of juvenile idiopathic arthritis with glucocorticoids, 22.14
in the treatment of juvenile idiopathic arthritis with glucocorticoids and methotrexate, 22.14

Cotiltol
in anxiety disorders, 33.19
in diabetes, 15.2–3
in insulin processing defects, 33.15

Cotton-wool spots, 21.12

Covert brain infarcts (CBI), 19.2–3

Cow’s milk exposure/consumption
autoimmunity development, 15.11
autoimmunity risk with, 11.16
breastfeeding and, 37.3
islet cell autoimmunity association, 11.10

Cox proportional-hazards models
death with/without diabetes, 36.9
physical activity impairment, 18.12
puberty vs. prepubertal diagnosis and death risk, 35.6
sRAGE levels and risk of type 2 diabetes, 19.11

Coxsackie virus, 11.4

CPAP (continuous positive airway pressure)
oBSTICL treatment, 25.18
treatment during pregnancy, 25.21

C peptide
with atorvastatin, 37.14
in cord blood, 4.9
in diabetes definition, 2.3
diabetes surveillance with, 2.4
diagnosis of type 2 diabetes in youth, 15.2–3
differentiating types 1 and 2 diabetes, 1.3
diabetes surveillance with, 2.4
in Donohue syndrome, 7.12
in early types 1 and 2 diabetes, 1.3
endogenous insulin production measurement, 2.3
fasting levels, 1.3
in hyperglycemic hyperosmolar state, 17.6
impaired signaling pathways, 23.7
with KCNJ1 and ABCC8 mutations, 7.10
in linomide study, 37.7
in MODY diagnosis, 7.4.8
in permanent neonatal diabetes, 7.10
pregnancy outcome with diabetes and, 4.8–9
pregnancy outcomes and cord serum levels, 4.9
in prevention studies, 37.7,11,12–13
response with anti-celiac disease intervention, 37.11
in risk score construction, 1.28
with rituximab, 37.13
in signaling pathways, 17.6
stimulated, in cyclosporine trials, 37.7
stimulated response, 2.3; 37.7
in symptomatic relief in peripheral neuropathy, 23.8–9
with teplizumab trial, 37.12–13
in type 1 diabetes diagnosis, 2.3–4.11; 3.2
in type 2 diabetes, 13.17; 15.2–3
in types 1 and 2 diabetes, 1.3

C-reactive protein (CRP)
abnormal pregnancy outcome risk and, 31.25
biomarker for type 2 diabetes, 13.18; 18.2
by diabetic status, 9.23
disease associations, 18.12
gingivitis and gestational diabetes effects, 31.25
levels with peripheral arterial disease, 20.9
liver secretion of, 13.19
periodontal disease association, 31.8–9
with peripheral arterial disease, 20.8
prediction of cardiovascular disease, 18.12
stroke predictor, 19.10
synthesis and secretion of, 13.19
type 2 diabetes risk association, 13.19

CRISPR/CAS9 editing, 14.10

Crohn’s disease. See Inflammatory bowel diseases

Crown-rump length, shortened, 5.67

CRY2 (circadian) gene

circadian rhythm, 37.6
fasting glucose association with, 14.8
fasting plasma glucose association with, 14.8

C-statistic, 13.24

CTLA4 gene, type 1 diabetes susceptibility, 11.16; 12.6–7

Cubans
diagnosed diabetes prevalence, 3.7

Index—13

DIABETES IN AMERICA, 3rd Edition
Cytokines
Cystitis
Curative Health Services prognostic system, 20:22
Cushing syndrome, 6:15
Cyclooxygenase (COX) inhibitor nephrotoxicity, 22:39
CYP2C9 enzyme, 14:9
Cystin C, 22:1.4
Cystic fibrosis-related diabetes (CFRD) complications and prognosis, 6:6–7
diagnosis of, 6:5–6
management, 6:6
pathophysiology, 6:5
screening for, 1:14
screening tests for, 1:14; 6:6
Cystitis
presentation of, 30:9–10
prevalence with type 1 diabetes, 22:56
risk with type 1 diabetes, 30:9
Cytokines. See also Adipocytokines/adipokines
in diabetic kidney disease, 22:8,31,34
doicosahexaenoic supplement effects on inflammatory, 37:5
with endocrinopathies, 6:16
with immune response to gluten, 27:9
in inflammatory response with sleep deprivation, 25:10
in obstructive sleep apnea, 25:20,21
periodontitis-diabetes association, 28:6
placental production of, 5:67,69
proinflammatory, 13:19; 25:10
prostatic growth factor stimulation, 28:4
in type 1 diabetes immune response, 37:2
in type 2 diabetes, 13:18
Cyto megalovirus (CMV)
fetal demise with congenital, 6:4–5
type 1 diabetes risk with, 11:8

D
Da Qing RCT of Lifestyle Modification
lifestyle treatment for impaired glucose tolerance, 1:25
prevention of type 2 diabetes studies, 38:5
screening benefits, 1:25
Daclizumab anti-CD25 study, 37:12
DAISY study
alpha-linoleic acid intake/FADS1 and FADS2 interactions, 11:16
cow’s milk consumption, 11:16
eye early cereal exposure, 11:9,16
eye early solid food exposure, 11:11
enteroviral infections, 11:4–5,6
islet autoimmunity and gastrointestinal illnesses, 11:17
islet autoimmunity and progression to type 1 diabetes, 11:12
islet autoimmunity risk with cereal exposure, 11:10
prevention of DKA in children, 17:4–5
seroconversion and progression to type 1 diabetes, 37:2
type 1 diabetes risk and cod liver oil, 11:16
Danish studies. See also Steno Hospital/Clinic studies
A1c levels in first trimester, 5:10
A1c pregnancy levels and offspring, 5:75
cesarean delivery in diabetic women, 5:46
hormonal contraceptive complications with diabetes, 5:12
legal blindness with retinopathy, 21:7
major malformations with type 2 diabetes, 5:62
maternal mortality ratio consecutive diabetic pregnancies, 5:22
microalbuminuria in nondiabetic women on oral contraception, 5:13
nephropathy prevalence data, 5:29
perinatal mortality with type 1 vs. 2 diabetes, 5:43
pre eclampsia rates in, 5:34
prevalence and progression of retinopathy in pregnancy, 5:27
retinopathy progression during pregnancy, 5:27
Dapagliflozin cardiovascular benefits, 18:15
Dapagliflozin Effect on Cardiovascular Events (DECLARE) trial, 18:15
Data from an Epidemiological Study of the Insulin Resistance Syndrome (DESIR). See DESIR study
DCCT study
A1c levels and incidence of, 15:27
A1c measures by, 1:7,9–10
condition at birth, 5:48
diabetes treatment in pregnancy, 5:3
hypoglycemic episode definition, 17:9
hypoglycemic episodes in pregnancy, 5:26–27
intensive glycemic control, 18:13
intensive insulin therapy and DKA incidence, 15:17
intensive treatment effects on neuropathy, 23:2
intensive vs. conventional glucose control, 19:13
long term effects of pregnancy on, 5:27
lower extremity amputation and glycemic control, 20:25
nephropathy reduction with, 15:24–25
peripheral arterial disease outcomes, 20:5
pregnancy effects on renal function, 5:29–30
progression of carotid media-intima thickness, 20:10
retinopathy progression, 5:26
retinopathy progression in adolescents, 15:18
spontaneous abortion rate, 5:36–37
DCCT/EDIC. See also EDIC study
A1c levels for diagnosis, 1:7
albuminuria effects, 22:46
cardiac autonomic neuropathy rates, 23:12–13
cardiac autonomic neuropathy with reduced A1c levels, 15:27
cardiovascular autonomic neuropathy in type 1 diabetes, 23:13
carotid intima media thickness improvement, 15:37, 20:12
cognitive impairment in adolescents and adults with type 1 diabetes, 24:6
coronary artery calcification, 15:38
coronary artery disease reduction, 15:28
distal symmetrical polyneuropathy incidence, 23:9
erectile dysfunction with diabetes, 28:10
gene associations with kidney disease, 22:43
glycemic control and mortality, 35:10
intensive therapy effects on mortality, 35:9
intensive vs. conventional insulin therapy, 15:18
joint complications with diabetes, 32:17–18
metabolic memory assessment, 18:13
metabolic memory with glycemic control, 21:22; 23:12–13
mortality classification used, 35:8
musculoskeletal disorder in upper extremity, 32:18
neuropathy reduction with, 15:24
neuropathy risk reduction, 23:11
peripheral neuropathy assessment, 23:4
persistent microalbuminuria in, 22:15
retinopathy progression in adolescents and adults, 15:18
sexual dysfunction association, 28:7–8
urinary tract infections, 28:6
visual impairment effects, 21:8
DCCT/EDIC intensive treatment/follow-up. See DCCT study; EDIC study
De novo mutations
monogenic diabetes from, 7:2,4
in permanent neonatal diabetes, 7:10
with SHORT syndrome, 7:20
“Dead-in-bed” syndrome, 35:10
Deafness. See Hearing loss/deficits
Death certificates, 36:3
Death rates. See Mortality and morbidity
Degenerative joint disease, 32:14
Delayed gastric emptying (GE), 27:4,7
Delivery complications
maternal mortality, 5:22
pregnancy-related stroke and hypertensive disorders, 5:22–23
preterm delivery, 5:45
prevalence by maternal age, 5:16
for types 1 and 2 diabetes, 5:45
Delta-5-desaturase encoding gene, 11:16
Delta-6-desaturase encoding gene, 11:16
Dementia. See AD dementia
DEND (developmental delay, epilepsy, and NDM), 7:10
Dental Atherosclerosis Risk in Communities (DARIC), 31:15
Dental care utilization, 31:39–40; 40:15
Depakote (valproic acid), 33:22
Department of Veterans Affairs, 41:2
Depressive episode or symptoms. See also Major depressive disorder diabetes distress, 33:4,10,15 gastrointestinal symptom association, 27:3 subthreshold depressive symptoms and diabetes distress, 33:4 type 2 diabetes risk factors, 13:15; 33:10–11
DESiR study A1c and fasting plasma glucose measures, 1:15 sex difference in A1c, 1:11
DETECT-2 study A1c assay standardization, 1:9 A1c for long-term complication risk, 1:12 retinopathy prediction, 1:12
Dextran sieving profiles, 22:9

Index–15
complications of, 15:1,13–17
coronary artery calcification in, 15:38
glycemia and cardiovascular disease in, 15:28
incidence of, 2:6–7; 15:2,5–6
international rate comparisons, 2:7
microalbuminuria regression in

type 1 diabetes, 15:23–24
mortality in, 15:38–39
prevalence, 2:5; 15:4–5
prevalence trends in, 1:14
projections for, 15:6–8
retinopathy in, 15:17–18
type 2 diabetes
characteristics of, 15:2
diabetic nephropathy in Pima Indians, 15:24
ESRD incidence in Pima Indians, 22:37
fetal overnutrition effects in, 15:12
kidney disease course in, 22:2
microalbuminuria at diagnosis, 15:24
mortality in, 15:39
prevalence and incidence, 15:8–9
projections, 15:10
retinopathy with, 15:18
risk factors, 15:11–13
screening for, 1:14
trends in, 15:9–10
in utero hyperglycemia exposure levels, 13:13
viruses and immunizations, 15:10–11
Diabetes insipidus, 7:8
Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, Deafness (DIDMOAD), 7:8
Diabetes Prediction and Prevention (DIPP) study. See DIPP study
Diabetes Prevention - Immune Tolerance study (DIAPREV-IT), 37:6
Diabetes Prevention Program (DPP). See DPP clinical trial
Diabetes Prevention Program Outcome Study (DPP OS). See DPPOS study
Diabetes Prevention Trial-Type 1 (DPT-1) Study Group
insulin trials, 37:6
prevention of DKA in children, 17:4–5
Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM), 38:9
Diabetes registries. See also SEARCH study Allegheny County Type 1 Diabetes Registry, 2:5; 15:6; 31:17; 35:3
Chicago Childhood Diabetes Registry, 2:5,7
childhood type 1 diabetes data, 15:4
Children’s Hospital of Pittsburgh, 35:3
Colorado Insulin Dependent Diabetics, 2:5; 15:6
EURODIAB, 210; 15:6
European nation-specific, 2:5
Finland, 2:5
Kaiser Permanente Northern California, 5:3,71
Kaiser Permanente Southern California, 5:15,16,18
New Zealand, 2:5
Philadelphia Pediatric Diabetes Registry, 15:4,6
Pittsburgh Epidemiology of Diabetes Complications, 35:3
in public health surveillance, 2:4
Sweden, 2:5
United Kingdom, 2:5
Wisconsin Epidemiologic Study of Diabetic Retinopathy, 2:5
Diabetes risk score, 1:28; 37:3
Diabetes surveillance
current systems for, 2:5
Finland, 2:4
HIT-based systems, 2:13
postpubertal males, 2:13
U.S. public health, 2:4
Diabetes-associated birth defects, 5:11
DIABETESMONDIAL (DIAMOND) project. See DIAMOND project
Diabetes-susceptibility genes, DPP study, 38:11
Diabetic amyotrophy. See Diabetic radiculoplexus neuropathy (DRPN)
Diabetic autonomic neuropathy (DAN). See also Cardiovascular autonomic neuropathy cardiovasual autonomic neuropathy, 23:3–4
gastrointestinal autonomic neuropathy, 23:4
kidney function with, 22:39–40
signs and symptoms of, 15:27
as stroke risk, 19:3
sudomotor dysfunction, 23:4
urogenital autonomic neuropathy, 23:4
Diabetic diarrhea. See Diarrhea
Diabetic foot ulcers. See Foot ulcers in diabetes
Diabetic kidney disease, 22:1–84. See also Chronic kidney disease (CKD)
A1C levels with renal failure, 1:12
ACEI and ARB for control of progression, 19:12
albumin excretion normalization with treatment, 22:5–6
albuminuria as marker for, 22:3
albuminuria classification, 22:3
albuminuria with type 2 diabetes, 22:7
arteriolar hyalinosis, 22:9
association with diabetes, 1:6
autonomic neuropathy and risk for, 22:39–40
biomarkers for, 22:1,3,9
blood lipid control in treatment, 22:51–52
blood pressure control in treatment, 19:12; 22:48–51
cardiovascular mortality prediction by, 35:4
classification of, 22:2
clinical course of, 22:5–10
comorbidity and mortality risks from, 22:19–24
control of blood lipids, 22:51
decline in incidence with type 1 diabetes, 22:16
definition of, 22:3
diagnosis of, 22:2
diagnostic criteria for, 22:3
diabetic modification in treatment, 22:52–54
dietary protein as risk factor for, 22:35–36
diagnostic of diabetes, 7:8
distal symmetrical polyneuropathy association, 23:2
drug nephrotoxicity and, 22:38–39
duration of diabetes as risk factor, 22:30
elevated urinary albumin excretion, 22:12–19
ELMO1 gene association, 22:43
epigenetic changes and, 22:45
epigenetic programming from in utero exposure, 22:42
ESRD and mortality with type 1 diabetes, 22:20–21
ESRD incidence and prevalence with, 22:25–30
ESRD survival, 22:27–30
familial and genetic risk factors for, 22:42–45
foot ulcer association, 20:19
FRMD3 gene association, 22:43
glomerular hemodynamic function, 22:6–7
glomerular-tubular junction abnormalities, 22:9
hemodynamic changes with diabetes, 22:6–7
histologic changes with diabetes, 22:7–8
hyperglycemia as risk factor, 22:30–31
hypertension as risk factor, 22:31–32
hypertension relation and, 35:11
insulin restriction by patient, 33:20
intensive glycemic control effects, 16:13,15; 22:46–47
intensive insulin therapy, 15:24
intensive treatment effects, 15:24–25
interstitial expansion with, 22:9
intrauterine factors in, 22:42
lesions in type 2 diabetes, 22:7
lipid abnormalities as risk factor, 22:32–35
living tissue imaging in, 22:10
maternal diabetes as risk for, 15:24–25
metabolic control for treatment, 22:46–48
microalbuminuria progression in youth, 15:20
morphometry, 22:7–9
as mortality risk with comorbid diseases, 22:19–20
mortality risk with type 1 diabetes, 22:20
multidisciplinary management for treatment, 22:54
noncardiovascular mortality causes with,
Diabetic nephropathy, 23:1–20
  - acute painful small fiber neuropathy, 23:3
  - assessment of, 23:5–7
  - bladder effects of, 28:14
  - burning mouth, glossodynia, 31:37–38
  - cardiovascular autonomic neuropathy, 23:3–4
  - cause of foot ulcers, 20:17
  - chronic inflammatory demyelinating polyneuropathy, 23:3
  - classification, 23:2–5
  - contribution to infections, 30:5
  - corneal mechanical sensitivity with, 21:37
  - criteria for diagnosis, 5:29
  - definition, 23:2
  - diabetic autonomic neuropathy, 23:3
  - diabetic radiculoplexus neuropathy, 23:3
  - diagnosis of sensory, 20:18
  - in disability with diabetes, 34:11
  - disease-modifying treatment for, 23:7–9
  - distal symmetrical polyneuropathy, 23:2–3
  - epidemiology, 23:9–14
  - focal peripheral neuropathies, 23:3
  - gastrointestinal autonomic neuropathy, 23:4
  - nerve fiber repair assessment, 23:6
  - pathogenesis of, 23:7
  - in pregestational diabetes, 5:28–29
  - during pregnancy, 5:28–29
  - secondary complications of, 23:14–15
  - sudomotor dysfunction, 23:4
  - symptomatic treatment of, 23:9
  - urogenital autonomic neuropathy, 23:4

Diabetic papillopathy, 21:39

Diabetic peripheral neuropathy (DPN). See Distal symmetrical polyneuropathy

Diabetic radiculoplexus neuropathy (DRPN), 23:3; 26:20

Diabetic retinopathy. See Retinopathy

Diabetic REINopathy Canadesartan Trials (DIRECT), 21:24–25

Diagnosed diabetes
  - diabetes prevalence in, 34:3
  - disability/impairment status, 34:7–8
  - functional limitations reported, 34:9
  - gallstone disease with diabetes, 26:15
  - lipid measures in, 9:17–21
  - lower extremity amputations in, 20:24
  - NHIS/NHANES estimates of type 2 diabetes, 3:15
  - physical activity, 10:12
  - risk factor control for care in, 41:3–5
  - 2-hour plasma glucose in untreated, 9:7
  - waist circumference measures in, 9:14

Diagnosed diabetes incidence
  - incidence by NHIS data, 3:16
  - trends in, 3:17
  - type 2 diabetes in youth, 3:16

Diagnosed diabetes prevalence
  - by age, 3:4–5
  - Asian subgroups, 3:7–8
  - county level, 3:8–9
  - HCHS/SOL study, 3:7
  - NHIS and NHANES comparison for, 3:15
  - in nonpregnant women of childbearing age, 5:4–5
  - in older adults, 16:2
  - overall in U.S. populations, 3:4
  - plateau in, 3:17
  - race/ethnicity patterns in type 2 diabetes and prediabetes, 3:5–6
  - by sex, 3:5

Diagnostic criteria for diabetes. See also specific glycemia measures
  - A1c/FPG/2-hour plasma glucose measures, 9:2
  - gestational diabetes, 4:1,5
  - glucose metabolism measures for, 36:2–3
  - impaired fasting glucose for prediabetes, 1:5–6
  - prediabetes, 1:5–6; 9:2
  - presymptomatic diabetes, 1:1
  - 2-hour plasma glucose, 36:1
  - type 1 diabetes, 1:3; 27–28
  - type 1b diabetes, 1:3; 15:2
  - type 2 diabetes, 1:3; 4–6,22–23

Diabetes Outcomes and Practice Patterns Study (DOPPS), 22:48

DIAMOND project
  - mortality in childhood type 1 diabetes, 35:12
  - type 1 diabetes prevalence/incidence age <20 years, 15:6
  - WHO diabetes surveillance, 2:5

DiaPep277 intervention studies, 37:12

Diarrhea
  - acarbose and, 38:8
  - autonomic neuropathy association, 23:9
  - with celiac disease, 27:12
  - Clostridium difficile infections, 30:14
  - diabetic, 23:4
  - diagnosis and management, 27:7–8
  - fecal incontinence, 27:8
  - with metformin, 27:7
  - nocturnal, 27:2

Diazoxide, 7:5

DIEP study
  - adult-onset diabetes mellitus, 5:2–3
  - prevalence in early pregnancy, 5:26
  - retinopathy progression, 5:27
  - spontaneous abortion data, 5:35–36
  - with type 1 diabetes, 5:2–3

Dietary Approaches to Stop Hypertension (DASH) diet, 22:54

Dietary factors/exposures
  - breastfeeding, 11:9
  - cereal/grain exposure and type 1 diabetes, 15:11
  - cow’s milk consumption, 11:9–10
  - diabetic kidney disease risk factors, 22:35–36
  - early cereal exposure, 11:9–10, 11:16;
  - 27:14
  - early life, 15:11
  - gene interaction with, 11:16
  - glycemic index, 11:14
  - HLA variants and exposures, 11:16
  - maternal diet, 11:9
  - polyunsaturated fatty acids, 11:12–13
  - type 2 diabetes risk factors, 13:6–10
  - type 2 diabetes risk reduction with, 13:10;
  - 29:6
  - vitamin D, 11:11–12
  - vitamin E, 11:13
  - weight gain, insulin resistance and beta cell stress, 11:13–14
  - whole grains and diabetes risk, 13:8
  - zinc, 11:13

Digit Symbol Substitution Test (DSST), 24:2,8,12,13

DiMe (Childhood Diabetes in Finland Study), 11:4,6

Dipeptidyl peptidase-4 (DPP-4) inhibitors
  - oral medication for glycemic control, 39:2
  - recent-onset diabetes and, 37:14
  - thyroid cancer and use of, 29:10

DIP study
  - antibodies in type 1 diabetes progression, 37:2
  - enteroviral RNA in stool, 11:5
  - progression to type 1 diabetes, 11:6

Disability, 34:1–15
  - activity of daily living disability, 34:3
  - with bipolar disorder, 33:21
  - definition and measurement, 34:2–4
  - demographic factors in, 34:4–7
  - diabetes risk and, 34:12
  - domains of, 34:1–2
excess disability with diabetes, 34.11
factors in disability with diabetes, 34.11–12
interventions to reduce risk of, 34.12
longitudinal association with disability, 34.9
national estimates trends, 34.9–11
physical functioning/mobility, 34.3–4
prediabetes, diabetes and morbidity status, 34.7–8
risk of diabetes with, 34.12
from stroke, 19.2
with visual impairment, 21.1
Distal symmetrical polyneuropathy (DSPN)
altered sensation in, 15.25
assessment instruments, 23.5
characteristics of, 23.2
clinical signs, 23.2.5
computer assisted sensory examination, 23.6
constitutional risk factors, 23.12
deep tendon reflexes in, 15.25
with diabetes in youth, 15.25
diagnostic criteria and staging of, 15.25–26
electrophysiology, 23.6
end-state complications of, 23.14
glycemic control in type 2 diabetes, 23.11
hyperglycemia in risk for, 15.25–27
incidence and prevalence, 15.25;
23.2.9–11
incidence estimates in type 1 diabetes, 23.9
late sequelae of, 23.2
myelinated fiber function, 23.6
natural history of, 23.11
nerve fibers affected, 23.2.5–6
onset and course of, 23.11
prevalence in types 1 and 2 diabetes, 23.10–11
quality of life assessment, 23.5
quantitative sensory testing, 23.5–6
race/ethnicity and prevalence, 23.10
risk factors for, 23.11–12
Semmes-Weinstein monofilament testing, 15.25;
23.6
skin biopsy/corneal confocal microscopy, 23.6
small fiber deficits in, 23.6
symptoms, 23.2.5
temporal trends neuropathy incidence, 23.9–10
thermal and cooling threshold testing, 15.27;
23.6
in type 1 diabetes in youth, 15.25–27
in type 2 diabetes in youth, 15.27
vibration perception testing, 15.25,27;
23.5
DKA (diabetic ketoacidosis), 17.1–5
complications of, 17.3
cost, 17.3–4
DCCT study, 5.25
definition as triad, 17.1–2
diabetes in youth presentation with, 15.2–3
diagnostic coding of, 17.1–2
eye early mortality with type 1 diabetes, 35.9
hospital discharge data, 17.2–3
incidence in established diabetes, 17.2
ketoacidotic episodes in pregnancy, 5.25
ketoacidotic episodes in types 1 and 2
diabetes, 5.25
maternal complications with diabetes, 5.25
morbidly and mortality, 17.3
pathogenesis, 17.1
pediatric treatment recommendations, 17.5
predictors and precipitating factors, 17.2
in pregestational diabetes, 5.25
prevalence at diagnosis, 17.2
prevention, 17.4–5
stillbirth comorbidities, 5.43
management, 17.5
in youth with types 1 and 2 diabetes, 15.13–17
Dihydroxyacetic acid (DHA)
sources and function of, 11.12
supplementation in pregnancy, 37.5
type 1 diabetes risk association, 11.12–13
Dominicans
diagnosed diabetes prevalence, 3.7
prediabetes prevalence, 3.14
undiagnosed diabetes prevalence, 3.12
Donabedian health care model, 41.2
Donohue syndrome, 7.12
Double diabetes. See Combined types 1 and 2
diabetes
Down syndrome (DS)
diabetes risk with, 6.16
prevalence in type 1 diabetes frequency with, 2.2
DPP clinical trial
cognitive impairment with diabetes, 24.13
conventional vs. intensive lifestyle treat-
mant of IGT, 11.9
ment of IGT, 11.9
cost effectiveness of screening, 1.27
diabetes development after gestational
diabetes, 4.12
diabetes-susceptibility gene typed in, 38.11
eye early treatment benefits, 1.22
follow-up plans, 38.12
and duration of diabetes, 28.7–8
fracture risks and, 32.14
glaucoma relationship with type 2 diabetes, 21.36–37
glucose control and, 39.2
glycated hemoglobin levels and, 9.3–4
glycemic control vascular events, 15.28
health insurance coverage and, 42.4
home health care needs and, 40.58
hospitalization and hospital utilization, 40.40
hypoglycemia events in type 2 diabetes, 17.10

Index–18
incidence of ESRD, 22:27
intensive glycemic control effects, 16.13; 19.13; 21.23
Kimmelstiel-Wilson nodules, 22.7
lower urinary tract symptoms in women, 28.16
mean fasting insulin levels, 9.12
mortality in type 1 diabetes, 15.38,39
musculoskeletal disorder in upper extremity, 32.18
nonproliferative diabetic retinopathy in type 2 diabetes, 21.15
in older adults, 16.5
prediction of complications, 16.5
prevalence of cystopathy in men, 28.4
prevalence of health insurance coverage, 42.4
progression of kidney disease, 22.16
progression to severe albuminuria, 22.15
prophylactic aspirin use, 39.6
proteinuria, 22.16,30
retinopathy in pregnant women, 21.26
retinopathy incidence in, 21.19
risk factors for diabetic kidney disease, 22.30
risk for diabetic retinopathy, 21.19–20
risk of peripheral arterial disease, 20.5
sarcopenia association, 34.11
self-care practices in, 39.7
tooth loss in type 1 diabetes, 31.33
visual impairment and blindness, 21.3–4,8
visual impairment in type 2 diabetes, 21.4–5

Dutch investigations
A1c levels in first trimester, 5.10
cesarean delivery in diabetic women, 5.48
famine exposure, 13.13
fasting and impaired glucose tolerance predictive power, 1.20
maternal mortality ratio with type 1 diabetes, 5.22
pregnancy planning and, 5.9
prenatal famine exposure, 13.13
Rotterdam Study, 38.11

Dysglycemia
drug/chemical-induced diabetes, 6.10
hyperthyroidism, 6.15
nonpregnant women of childbearing age, 5.4–5
prevalence of total dysglycemia, 3.14
race/ethnicity variations in, 3.14
stages of type 1 diabetes, 37.3,7

Dyslipidemia. See also Statin therapy in adolescents with diabetes, 1.14
cardiovascular outcomes with lipid modification, 18.15–16
comorbid condition in women 18–44 years, 5.6
control in geriatric diabetes, 16.14
in diabetes in youth, 15.33
diabetic kidney disease risk factor, 22.32–35
fenofibrate studies in, 18.16
heart disease risk and, 18.8–9
herbal contraception with, 5.13
insulin resistance association of, 19.9
kidney disease association, 22.32–35
lipid profiles in type 2 diabetes, 18.8
lipid-lowering medication in diabetes, 9.20–21
lipid-modifying trials, 18.16–17
in pediatric patients with type 2 diabetes, 15.2
statin therapy for macular edema, 21.25
treatment in management of diabetes, 39.5

Dysmorphism
Donohue syndrome, 7.12
Rabson-Mendenhall syndrome, 7.12
Williams syndrome, 6.17

Dysphagia, 23.4; 27.8

E

Early Treatment Diabetic Retinopathy Study (ETDRS) protocol
A1c for retinopathy, 1.9
incidence of visual acuity loss, 21.7
severity scale for, 21.16
visual angle measurement protocol, 21.3

Early-life environment. See also Dietary factors/exposure; Intrauterine diabetes exposure
birth weight, 13.13
breastfeeding effects, 13.13–14
Dutch famine exposure, 13.13
gladian exposure, 15.11
intrauterine exposure, 15.13

Early-onset familial dementia, 24.3

Eating disorders and behavior
anorexia nervosa, 33.19
association with treatment outcomes, 33.20–21
binge eating disorder in type 2 diabetes, 33.19
bulimia nervosa, 33.19
causal issues and mechanisms, 33.21
characteristics of, 33.19
family dysfunction in prediction of, 33.21
female adolescents with type 1 diabetes, 33.19
insulin omission or underuse in, 33.20
maladaptive eating behavior with type 1 diabetes, 33.20
measurement issues, 33.20
Night-Eating Syndrome, 33.20,21
overview and definitions, 33.19–23
prevalence in diabetes, 33.19–20
treatment and intervention, 33.21
type 1 diabetes mortality with, 35.4

Economic impact of diabetes
care after stroke, 19.2
cognitive impairment with, 24.2–3
complications and comorbidities, 40.67

data sources, 40.58
diabetes vs. without diabetes, 40.64
direct and indirect costs, 40.56
of geriatric diabetes, 16.16
geriatric population growth, 16.17
indirect costs of, 40.69
institutional care, 40.58–59
international comparison, 40.70–71
with kidney disease, 22.3
osteoarthritis and arthritis, 32.14
outpatient care, 40.59–61
outpatient medications and supplies, 40.61–64
per capita care expenditures, 40.64–66
persistent postpartum diabetes treatment, 1.29
preconceptual care use and, 5.8
productivity loss, 34.4; 40.69
race/ethnicity projections for type 1 diabetes in childhood, 2.10
screening costs and benefits, 1.27
trends in, 40.69–71
visual impairment costs, 21.11

EDIc study. See also DCCT/EDIC
A1c assays used, 1.7
cardiovascular complications effects, 18.13–14
cognitive impairment, 24.7–8.13
cystitis prevalence data, 22.56
insulin therapy in youth with retinopathy, 15.18
patient enrollment and follow-up, 19.13; 23.12
peripheral arterial disease outcomes, 20.5
prevalence of albuminuria, 22.12
urologic complications with type 1 diabetes, 22.56

Edinburgh Artery Study, 20.8
Edinburgh Claudication Questionnaire, 20.3

Education and Research Toward Health (EARTH) study, 13.23
EGFR (estimated glomerular filtration rate). See also GFR/eGFR

Egyptian population
retinopathy data and FPG cutpoints, 1.13
risk scores from clinical factors, 1.23

Eicosapentaenoic acid (EPA)
ALA conversion to, 11.16
effects on kidney function, 22.54
sources and function of, 11.12

EIF2AK3 (eukaryotic initiation factor 2 alpha kinase 3) mutation, 7.11

Eighth Joint National Committee (JNC 8)
blood pressure control recommendations, 18.17
hypertension management with kidney disease, 22.51
stroke risk control recommendations, 19.12,14

Elderly adults. See Geriatric diabetes

Elderly Program Cooperative Research Group (SHEP) trial, 19.12

Index–19
ELMO1 (engulfment and cell motility 1) gene, 22:43
Emerging Risk Factors Collaboration
adiposity measurement and cardiovascular disease, 18:10–11
C-reactive protein and cardiovascular risk, 18:12
heart disease risks with dysglycemia, 18:7
lipid and inflammatory markers in cardiovascular mortality, 18:8
Emotional distress, 33:23–24
Empagliflozin, 18:15
Emphysematous cholecystitis (EC), 30:16–17
Emphysematous pyelonephritis, 30:10
Enalapril retinopathy progression effects of, 21:25
Encephalocele, 5:65
Endocrinopathies associated with diabetes, 1:4; 6:15–16
Endophthalmitis, 21:36
Endothelial cell dysfunction
association with insulin resistance, 19:9
in diabetic kidney disease, 22:8
markers of, 13:18
End-stage liver disease (cirrhosis). See Cirrhosis
End-stage renal disease (ESRD). See ESRD in diabetes
England. See also United Kingdom (U.K.) studies
cognition and educational attainment of offspring, 5:75
diabetes classification criteria, 2:4–5
glycemic control in pregnancy, 5:9–10
independent diabetes association with, 5:37
long-term effects of pregnancy on, 5:27
maternal mortality ratio consecutive diabetic pregnancies, 5:22
nephropathy prevalence data, 5:29
neuropathy during pregnancy, 5:28
pregnancy planning and, 5:9
pregnancy with pregestational diabetes, 5:16
prepregnancy glycemic control, 5:10
Enterobacteriaceae, 30:13
Enteroviral infections
islet autoimmunity progression, 11:6
islet autoimmunity triggering by, 11:4–5
prospective cohort studies at type 1 diabetes diagnosis, 11:4
serology and type 1 diabetes association, 11:4
type 1 diabetes association, 10:42
Enterovirus infections, enterovirus RNA in blood samples, 11:4–6
Environmental exposures
accelerator and overload hypotheses, 15:11
bovine insulin, 37:3
genetic interaction in type 2 diabetes, 13:5
in initiation and progression of type 1 diabetes, 12:1; 37:1–2
toxins and pollutants, 6:13–14
for type 1 diabetes in childhood, 2:10
Environmental Triggers of Type 1 Diabetes. See MIDIA
EPIC Study
A1C and cardiovascular disease, 18:7
abdominal obesity and overweight, 13:12
coronary heart disease events and physical activity, 18:12
early postnatal exposure, 13:13
lipid and inflammatory markers in heart disease, 18:8
Reykjavik and Norfolk studies, 18:8
triglycerides and heart disease risk, 18:8
Epidemiology and Prevention of Diabetes Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus (EUCLID), 21:24
Epidemiology of Diabetes Complications Study (EDC)
A1C levels and albuminuria, 22:19
20-year mortality with type 1 diabetes, 22:19
albuminuria and heart disease relationship, 35:11
albuminuria prevalence with diabetes, 22:12
albuminuria with type 1 diabetes, 22:12
cardiac autonomic neuropathy with diabetes, 15:27
coronary artery calcification progression, 15:37
cumulative incidence of heart disease, 15:28
diabetes-periodontitis association, 31:17
diabetic nephropathy incidence, 22:16
distal symmetrical polyneuropathy incidence in type 1 diabetes, 23:9–10
long-term effects of pregnancy on, 5:27
microalbuminuria prevalence and diabetes duration, 15:23
microvascular complications, 15:17–18
mortality and renal disease trends, 35:4–5
mortality in type 1 diabetes, 35:3–4
mortality with youth-onset diabetes, 15:38
neuropathy in women, 31:38
neuropathy risk after pregnancy, 5:29
peripheral arterial disease with type 1 diabetes, 20:5
retinopathy (diabetic), 15:18
retinopathy and quality of life, 21:9
retinopathy development, 21:25
retinopathy prevalence and diabetes diagnosis, 21:12
risk of retinopathy, 15:18
stroke incidence and prevalence in type 1 diabetes, 19:4
study population, 31:37
symptomatic autonomic neuropathy incidence trend, 23:12
type 1 diabetes mortality, 35:3–4
Epidemiology of Diabetes Interventions and Complications (EDIC). See EDIC study
Epigenetic programming
in disease risk for next generation, 22:42
of famine exposure, 13:13
with kidney disease, 22:2,45
with maternal diabetes, 5:73
in periodontitis and diabetes risk, 31:23
in risk for persons with diabetic relatives, 11:2
tissue-specific changes and mechanism, 22:45
Epsilon4 allele polymorphism, 21:25
ERBB3 gene (12q13), 12:6
Erectile dysfunction, 23:4; 28:10
Erectile dysfunction and duration of diabetes, periodontitis severity and risk of, 31:16
Ertugliflozin, 18:15
Erythrasma, 30:12
Escherichia coli, 30:9,16
ESRD in diabetes. See also Diabetic kidney disease
ACR and GFR prediction of death rate for, 22:22
in diabetes of youth, 15:20
incidence and treatment of, 22:27
increased incidence and prevalence of, 22:25
NSAIDs and acetaminophen risks, 22:39
prevalence of diabetes-related, 22:25
PVT1 gene and susceptibility, 22:43
race/ethnicity survival rates with treatment, 22:29
risk with diabetic kidney disease, 22:19–24
risks with and without diabetes, 22:22–23
survival rates with treatment, 22:27–30
trends in incidence and mortality, 22:20
type 1 diabetes mortality with, 35:9
type 2 diabetes in, 22:27
Ethics
early termination of randomized studies, 38:14
limitations on randomized control trial use by, 5:74
Etiologic classification of type 1 diabetes
agreement with care provider report, 2:4
difficulties in, 2:3
markers for, 2:3–4
Euglycemia. See Glycemic control
Euglycemic hyperinsulinemic clamp, 13:17; 25:2,28; 26:17
EUROCAT registries of congenital anomalies
genital malformations/anomalies prevalence, 5:62
nonchromosomal anomalies, 5:65
EURODIAB (EUROpe and Diabetes) study
IDDM Complications Study, 15:25
neuropathy risk after pregnancy, 5:29
type 1 diabetes prevalence/incidence age <20 years, 15:6
Index–21


Fetal overnutrition effects of, 15:12–13 sources of, 5:73

Fib D-dimer, 20:8

Fibrinogen by diabetic status, 9:23 levels with peripheral arterial disease, 20:9 with peripheral arterial disease, 20:8 type 2 diabetes risk association, 13:20

Fibrinolysis hyperglycemia effects on, 20:1 plasminogen activator inhibitor-1, 13:19–20

Fifth International Workshop-Conference on Gestational Diabetes Mellitus, 4:12

Filipino populations dental visits with insurance, 31:39 metabolic syndrome prevalence, 13:23 type 2 diabetes prevalence in, 3:7–8

FINDRISC calculator, 1:23

Finnish Diabetes Prevention Study (DPS), 38:5–6 impaired glucose tolerance treatment, 1:19 prevention of type 2 diabetes studies, 38:5–6 weight loss interventions, 38:13

Finnish Diabetic Nephropathy (FinnDiane) study all-cause mortality prediction by albuminuria, 22:20 mortality rates in type 1 diabetes, 35:11 prevalence of albuminuria, 22:12

Finnish Dietary Intervention Trial for the Prevention of Type 1 Diabetes (FINDI), 37:3


First Nation peoples, 15:2

First-phase insulin response. See Acute insulin response (AIR)

Flatbush diabetes. See Type 1b diabetes

Florida Hispanic/Latino population, 3:7 pregestational diabetes prevalence during pregnancy, 5:18 total diabetes percentages, 8:9

Focal peripheral neuropathies, 23:3

Folic acid congenital malformation association with, 5:11 periconception and preconception use of, 5:10

Foot ulcers in diabetes (DFU), 20:16–22. See also Distal symmetrical polyneuropathy autonomic neuropathy, 20:18 BMI, weight, height, waist circumference, 20:18


Fournier’s gangrene, 30:12–14

Frailty defined, 16:10,11 diabetes comorbidity, 16:5 incidence of, 34:11 risk of falls and, 16:15 tooth loss association, 31:41 vertebral fracture association, 32:1

Framingham CVD risk score, 18:10

Framingham Eye Study, 21:33

Framingham Offspring Study  
changes in A1c with age, 1:11  
effects of smoking cessation, 18:12  
markers for type 2 diabetes risk, 13:20  
metabolic syndrome prevalence, 13:24  
prevalence trends in, 13:18  
sequential oral glucose tolerance test  
predictive value, 13:16  
stroke risk with diabetes and metabolic  
syndrome, 19:10  
type 2 diabetes incidence and vitamin  
D, 13:7  
France  
maternal mortality ratio consecutive  
diabetic pregnancies, 5:22  
nephropathy prevalence data, 5:29  
pediatric type 2 diabetes prevalence, 15:9  
FRAX algorithm, 32:12  
Free fatty acids  
in atherogenesis, 20:1  
effects on insulin sensitivity, 25:19  
fasting levels, 1:2  
in fetal overnutrition, 5:73  
in proteinuria progression, 22:35  
sympathetic nervous system activity  
effects on, 25:11  
“Free” foreign peptide, T cell recognition  
GAD-65  
Gastric parietal cell antibodies  
Gamma glutamyltransferase (GGT).  
Gallbladder disease  
Gastrointestinal (GI) tract manifestations  
fungal infections, 30:34  
fulminant diabetes  
Friedewald equation for LDL cholesterol, 9:2  
FRMD3 (FERM domain-containing protein  
3) gene, 22:43  
Fructosamine  
glycemic levels from, 1:12  
hazard ratio for diabetes, 1:21  
racial/ethnic variations in, 3:15  
Fructose, 13:9  
Fulminant diabetes, 1:3  
Functional impairment/disability, 16:15–16;  
34:1  
Fungal infections, 30:11,12,16; 31:23. See also Candida albicans  

G  
GAD-65. See Glutamic acid decarboxylase (GAD)  
GAD-Alum, 37:12  
Gallbladder disease, 26:13–18  
cholecystectomy with diabetes, 26:16  
directionality of diabetes association,  
26:18  
gallstone disease association with diabetes,  
26:18  
gallstone disease with diabetes, 26:13–15  
insulin resistance, 26:17–19  
Gamma glutamyltransferase (GGT). See GGT (gamma glutamyltransferase)  
Gastric parietal cell antibodies. See Parietal  
cell antibodies (PCA)  
Gastrointestinal (GI) tract manifestations,  
27:1–22  
abdominal pain, 27:9  
anxiety and depression associated with,  
27:3  
autoimmune gastritis, 27:15–16  
celiac disease, 27:9–14  
constipation/laxative use, 27:2,8  
data sources and limitations, 27:2  
diabetic diarrhea, 23:4  
diabetes diagnosis and management,  
27:7–8  
diabetes in celiac disease, 27:12  
dysmotility in diabetes, 27:3  
dysphagia and heartburn, 27:8  
fecal incontinence, 27:8–9  
functional disturbances and syndromes,  
27:2,4–7  
gastric emptying with diabetes, 27:4–5  
gastroprosopis course and management,  
23:4; 27:4–7  
heartburn, 27:2  
immune-related disorders, 27:9–16  
inflammatory bowel diseases, 27:14–15  
malformations with in utero diabetes expo- 
sure, 5:62  
risk factors for functional disturbances,  
27:2  
symptom turnover in, 27:5  
symptoms with and without diabetes,  
27:2–3  
type 1 diabetes and celiac disease, 27:9  
Gastroparesis  
autonomic function test for, 27:7  
course and management of, 27:4–7  
epidemiology of, 23:4,5  
iatrogenic, 27:2  
manifestation of autonomic neuropathy,  
23:9  
morbidity and mortality association of,  
27:6  
prevalence with diabetes, 27:2  
symptoms and pathophysiology, 23:4–5  
Gastrochisis, 5:11  
GATA4 haplinsufficiency, 7:11  
GCK (glucokinase) gene mutations  
glucose sensing function of, 7:5  
insulin synthesis/secrection, 7:4,5  
MODY2 clinical presentation, 7:4  
in neonatal diabetes, 7:5,11  
GCKR gene  
p.Pro446Leu with type 2 diabetes, 14:10  
whole grain intake and rs780994 variant,  
13:5  
Gemfibrozil, 22:52  
Gene expression  
defect in hepatocyte nuclear factor  
4-alpha, 1:4  
defects in MODY, 1:4  
diabetes-obesity gene interactions,  
5:10–11  
in diabetic kidney disease, 22:45  
dietary factors/exposure interactions,  
11:16  
environment x HLA genotype interaction,  
11:16  
epigenetic change mechanisms in expres- 
sion, 22:45  
functional consequences of variants, 12:8  
genetic risk in siblings, 12:1–2  
genotype association with function, 14:10  
genotype x treatment interactions, 38:11  
hepatic gene expression in MODY, 7:7  
heritable changes in, 22:45  
HLA and type 1 diabetes associations,  
12:3–4,12; 37:1,5  
penetrate of moderate-risk genotypes,  
11:3  
placental contribution with maternal  
diabetes, 5:67  
regulation of TCF7L2, 14:10–11  
risk markers for early development of type  
1 diabetes, 11:14  
susceptibility loci with type 1 diabetes,  
12:7  
Gene polymorphism evaluation, 38:9  
Gene-environment interactions. See also  
Epigenetic programming; Intrauterine  
exposure in early life, 13:12–14  
for fetal losses and malformations,  
5:59–60  
genetic risk score, 13:5  
hygiene hypothesis (natural protection),  
11:7; 15:11  
infectious agents, 13:3–6  
nutrition and type 2 diabetes, 13:6–10  
polio model of type 1 diabetes, 11:6–7  
for type 1 diabetes, 11:15–17  
type 2 diabetes risk factors, 13:5  
General Practice Research Database  
(GPRD)  
data included in, 5:36  
stillbirth rates, 5:43  
Generalized anxiety disorder, 33:16–19  
Genetic lipodystrophies  
congenital generalized lipodystrophy,  
7:13–17  
diabetes management in, 7:20  
epidemiology, 7:13–20  
estimated prevalence of, 7:13,20  
familial partial lipodystrophy, 7:17  
mendubuloacral dysplasia associated lipo- 
dystrophy, 7:17  
predisposition to diabetes with, 7:13–21  
Genetic risk ratio (β). 12:1–2  
Genetic risk score  
diabetes prediction by, 38:11  
epigenetic interaction, 13:5  
prediction of type 1 diabetes, 12:10  
Genetic susceptibility. See also Genetics  
of type 1 diabetes; Genetics of type 2 diabetes  
to autoimmunity, 15:3  
for diabetic kidney disease development,  
22:42–45  
genes/regions for type 1 diabetes, 12:6  
for progression to autoimmunity, 11:13  
in retinopathy development, 21:29  
in type 1 diabetes, 12:1
Genetics of Kidneys in Diabetes (GoKinD).

Genetics of type 1 diabetes, 12:1–16
autoantibody positivity, 12:11–12
autoimmune disease shared genetic risks, 12:6
candidate genes for, 11:3
12:7–8
case-control study design for genetic studies, 12:2
chromosome 6p21.3, 12:2–3
family history of, 11:2
gene-function relationships, 12:11
HLA alleles associated with, 12:4
DNA sequencing technology in, 12:6–7
initiation in susceptible individuals, 12:10,11–12
linkage mapping, 12:6
loci contributing to, 12:12
major HLA complex, 12:2
non-major HLA risk loci, 12:6–10
penetration of HLA genotypes, 11:3
pregestational diabetes, 12:5
single nucleotide polymorphism association, 12:6,10,11
susceptibility loci mapping, 12:6,7–10
whole-genome linkage analysis in, 14:1

Genetics of type 2 diabetes, 14:1–25
aminonucleotide polymorphism association, 12:6,10,11
susceptibility loci mapping, 12:6,7–10
whole-genome linkage analysis in, 14:1

DNA sequencing technology in, 14:9
early-onset type 2 diabetes, 15:11
environmental factor interactions with, 14:10
future research on, 14:11
gene functions in, 14:10
genetic architecture analysis for, 14:6–7
geographic disease emergence, 14:8
disease emergence, 14:8
DNA sequencing technology in, 14:9
early-onset type 2 diabetes, 15:11
environmental factor interactions with, 14:10
future research on, 14:11
gene functions in, 14:10
genetic architecture analysis for, 14:6–7
genetic information vs. clinical variables in prediction, 14:8
genetic predisposition for type 2 diabetes, 14:1–2
genetic risk score and type 2 diabetes, 13:5
genetic variation and drug response, 14:9
GWAS predictive properties, 14:10
heritability estimates of, 14:1
insights gained, 14:6–9
lifestyle characteristics intervention with, 14:9
limitations of current approaches, 14:9–11
in prevention of type 2 diabetes, 38:11
TCF7L2 gene, 14:1
for type 2 diabetes, 14:1–3
type 2 diabetes gene discovery, 14:2–6

Genome sequencing, 14:2

Genome-wide association studies (GWAS).
See GWAS (genome-wide association scans)

Genome-wide linkage analysis. See also GWAS (genome-wide association scans)

for lipodystrophies, 7:15,18
for type 2 diabetes, 14:2

Genotype risk score (GRS). 14:6

Genotype-phenotype. See also Epigenetic programming

effects of risk variants on genes, 12:12
12:12
14:6
17:10
HLA susceptibility genotype in celiac disease, 27:13

Genotyping. See GWAS (genome-wide association scans)

Geographic atrophy. See Macular edema

Georgia
A1c comparison with oral glucose tolerance, 11:2
major malformations with type 1 diabetes, 5:60
malformation risk with type 1 diabetes, 5:60
mortality comparison to general population, 35:5
oral health with diabetes, 31:21
pregestational diabetes prevalence, 5:5
racial/ethnic differences in stroke in diabetes, 19:7
total diabetes percentages in, 8:9

Geriatric diabetes, 16:1–22. See also Bone complications; Joint complications/mortality rates with, 16:2
activity limitation, 35:3–11
age-related conditions and prevention, 16:8–11
age-related malformations, 21:38
dementia, 16:15
depression, 16:9–10,15
falls, 16:8,15
functional impairment, 16:15–16
cardiovascular complications, 16:6–7
cardiovascular risk factors, 16:5–6
vascular complications, 16:13–15
cataracts with type 2 diabetes, 21:33
cognitive decline with diabetes, 24:8
chronic cognitive impairment, 16:10
comorbidities with diabetes, 16:5–11
complication/mortality rates with, 16:5
costs of, 16:16–17
data sources and limitations, 16:1
duration of diabetes, 16:4
economic consequences, 16:17–26
economic impact of, 16:16,17,40:64
etiologic factors in diabetes, 16:1
functional status, 16:11–13
34:8
general and abdominal obesity with, 9:14
generative population demographics, 16:2
glucose control in prevention, 16:13
growth in spending, 16:17
hyperglycemic hyperosmolar syndrome prevalence and risk, 17:6
hypoglycemia, 16:16
improving care and curbing cost, 16:17
lifestyle intervention for prevention, 16:12
lipid control effects in, 16:14
lower extremity amputation rates in, 20:23–24
Medicare costs, 16:16
microalbuminuria with, 16:7
microvascular complications, 16:7–8
mortality rates, 16:11
multifactorial control benefits in, 16:14–15
overweight/obesity in, 16:5–6
periodontitis prevalence, 31:4
polypharmacy, 16:10–11,15
population size and prevalence, 16:2–3
prevalence in nursing homes, 16:4
prevalence of persistent albuminuria, 22:12
preventing complications of, 16:13–16
quality of care standards, 16:16
quality of life with, 16:11
race/ethnicity in, 16:3
race/ethnicity with insurance, 42:1–22
retinopathy progression in, 21:26
sarcopenia and frailty, 16:10
urinary incontinence, 16:9
visual impairment incidence, 21:3

German (Deutsch) Nicotinamide Diabetes Intervention Study (DENIS), 37:5,14

German studies
cancer risks with glargine insulin, 29:11
deiht certificate reliability for mortality, 35:7–8
fetuin-A association with type 2 diabetes risk, 13:20
lower urinary tract symptoms with diabetes, 28:5
pediatric type 2 diabetes prevalence, 15:9
prevalence of albuminuria, 22:14
prevalence of DKA at diagnosis, 15:17;
17:2
prevalence of nephropathy in youth, 15:20

Gestational age
definition of, 5:35
fetal demise (stillbirth) age-specific rates, 5:37
preterm delivery rates by, 5:45

Gestational diabetes, 4:1–17. See also Maternal diabetes
A1c for screening, 4:5
A1c levels in, 1:12
association with rate in nonpregnant women, 4:8
background/history, 4:2–3
brachial plexus palsies risk with, 5:58
breastfeeding after, 15:13
cardiovascular risk factors with, 4:12
cost-effectiveness of screening, 4:4
cost-effectiveness of treatment, 4:11
definition, 4:1–2
diagnostic criteria for, 4:15
effects on offspring, 4:12–13
factors in increased prevalence, 13:12
glucose tolerance, 4:8
HAPO study, 4:8
increased risk with sleep disturbance, 25:21
long-term effects on offspring, 4:12–13
long-term implications of, 4:11
low-risk pregnancy management, 4:11
obstructive sleep apnea association with, 25:21
pathophysiology of, 4:3
perinatal outcomes with treatment, 4:1
periodontal disease and inflammation in, 31:25
periodontitis association with, 31:22
physical activity levels with, 31
prevalence of type 2 diabetes after, 4:12
progression to type 2 diabetes after delivery, 1:4, 4:11–12; 5:7, 13:21
randomized clinical studies with treatment of, 4:10
regression of, 1:29
risk with periodontitis, 31:15
screening criteria for, 1:4, 28–29; 4:3–5
skin autofluorescence discrimination in, 1:16
treatment, 4:10–12
Gestational hypertension (GHTN). See also Pre-eclampsia
diagnostic criteria, 5:30
with pregestational diabetes, 5:34
prevalence with pregestational diabetes, 5:34
sleep-disordered breathing association, 25:21
Gestational weight gain
childhood obesity and, 5:74
effects of, 5:72–73
fetal growth and birth size, 5:49–50
maternal obesity and, 5:56
risk for diabetes in youth, 15:1
small-for-gestational age with, 5:55
stillbirth rates, 5:43
Get With the Guidelines-Stroke program, 19:17
GFR/eGFR
cardiovascular disease risk association with, 22:21
confounding of association with mortality, 22:20
hemodynamic changes with diabetes, 22:6
hyperfiltration, 22:31
hyperfiltration in types 1 and 2 diabetes, 22:6–7
with hypertension or cardiovascular disease with diabetes, 22:12
infection rate with diabetes, 22:22
methods determination of, 22:3–4
obesity-associative changes in, 22:37
pathophysiology and clinical course, 22:3
predictive value of ACR, 22:22
pregnancy effects on, 5:30
prevalence in diabetic population, 22:12
prevalence of low, 22:12
renal insufficiency criteria, 20:9
in staging of chronic kidney disease, 22:3
and stroke risk, 19:3
GGT (gamma glutamyltransferase)
association with fetuin-A, 13:20
association with increased mortality, 26:5,7
in Fatty Liver Index, 26:3
increased diabetes risk with elevation, 26:5
liver injury measurement, 26:3–4
nonalcoholic steatohepatitis, 13:20
type 2 diabetes risk factors, 13:19
Ghrelin
levels with sleep restriction, 25:10–11
sleep disturbance and alterations in, 13:15
in sleep restriction, 25:10
Gila River Indian Community periodontitis study, 31:9,15,17,20
Glargine insulin, cancer risks with, 29:11–12
Glaucoma
definitions of, 21:36
in diabetic vs. nondiabetic persons, 21:36
duration of diabetes, 21:36
Glialin, early-life exposure, 15:11
Glibenclamide (glyburide), 7:10
Global Case-Control Study of Risk Factors for Acute Myocardial Infarction (INTER-HEART), 18:11
Glomerular filtration rate (GFR). See GFR/eGFR
Glomerular-tubular junction abnormalities, 22:8,9
Glucose. See also Burning mouth syndrome
neuropathy association, 31:38
Glucagon-like peptide-1 (GLP-1)
in diabetes induced by, 25
in distal symmetrical polyneuropathy, 38:7
in sitagliptin and lansoprazole effects, 37
in thyroid and use of agonists, 29:10
Glucocorticoids
bone marrow transplantation, 29:14–15
Cushing syndrome with, 24:13
in sitagliptin and lansoprazole effects, 37:14
in ZnT8, 7
Glucose-based diagnostic tests
Diabetes in America, 3rd Edition
vaccine prevention trials with, 37.6–7,12

**Gluten.** See also Celiac disease (CD)
- autimmune trigger, 27.14
- delayed exposure, 37.5
- interleukin-15 response to, 27.9
- islet autoimnunity risk with, 11.10
- T lymphocyte response to, 27.9

**Glycated albumin (GA)***
- fasting plasma glucose and A1c correlation, 1:15
- incident diabetes hazard ratio, 1:21
- inflammatory cytokine production with, 31.24
- racial/ethnic variations in, 3:15
- for screening, 1:15

**Glycated hemoglobin (A1c)***
- A1c levels and retinopathy prevalence, 1:26
- cataract association with, 25.9
- glycemic test comparisons, 1:36
- glycemic control in geriatric population, 16:13–14
- glycemic test comparisons, 1:14–15
- hemoglobinopathies effects on measurements, 1:12
- high/low glycation status, 1:12
- insomnia symptoms relation to, 25.9
- iron deficiency anemia effects on measurement, 1:12
- levels for screening, 1:21
- levels in MODY3, 7.6
- levels in treated diabetes, 9:3
- levels in undiagnosed diabetes, 9:3
- levels predicted by insufficient sleep, 25.3
- levels with obstructive sleep apnea, 25.17
- levels with prediabetes, 9:3
- levels with visual impairment, 21:1
- lower extremity amputation association with levels, 20:25
- malformation predictive value with fetal nuchal translucency, 5:67
- mean plasma glucose and, 1:12
- microaneuysms levels and, 1:16
- NHANES methods for, 9:2
- nonglycemic factors affecting, 1:11
- in normal pregnancy, 5:10
- optimal first trimester levels for, 5:10
- peripheral arterial disease and level of, 20:6
- physical activity effects, 18:18
- plasma glucose test discrepancies, 1:14–15
- postprandial hyperglycemia and, 5:72
- in prediabetes, 1:5–6
- prediction of fetal loss, 5:43
- predictive power of various levels, 1:20
- preferred test for diagnosis, 1:9
- racial/ethnic variations in, 1:11, 3:13,15
- red cell turnover effects on, 1:12
- relationship of other glycemia measures, 1:11–12
- in REM-related sleep apnea, 25:17
- renal failure effects on, 1:12
- retinopathy and levels of, 21:12
- retinopathy progression in adolescents and adults, 15:18
- retinopathy risk during pregnancy, 5:27
- as risk factor for diabetes, 1:20–21
- risk for retinopathy progression, 5:26
- screening cutpoint for, 1:26
- for screening for preventative interventions, 18:7
- screening for undiagnosed diabetes, 1:26;
- seasonal variations in, 1:12
- with self-reported diabetes prevalence, 18:7
- sensitivity of, 1:12
- sex differences in risk prediction, 1:20
- skin autofluorescence correlation, 1:16
- standardization of methods, 1:7
- undiagnosed/prediabetes detection, 3:15
- variations in measurement methods, 1:7
- vitamin B12 deficiency effects on measurement of, 1:12

**Glycemia**
- A1c and other indices of chronicity, 1:11–12
- acceleration of beta cell apoptosis, 11:13
- circadian gene effects on, 37.6
- direct effects on malformations, 5:11
- distal symmetrical polyneuropathy association with, 23:12
- heart disease risk and fasting glycemia, 18:7–8
- levels associated with visual impairment, 21:1
- lower extremity amputation association with levels, 20:25
- malformation predictive value with fetal nuchal translucency, 5:67
- mean plasma glucose and, 1:12
- microaneurysms levels and, 1:16
- NHANES methods for, 9:2
- nonglycemic factors affecting, 1:11
- in normal pregnancy, 5:10
- optimal first trimester levels for, 5:10
- peripheral arterial disease and level of, 20:6
- physical activity effects, 18:18
- plasma glucose test discrepancies, 1:14–15
- postprandial hyperglycemia and, 5:72
- in prediabetes, 1:5–6
- prediction of fetal loss, 5:43
- predictive power of various levels, 1:20
- preferred test for diagnosis, 1:9
- racial/ethnic variations in, 1:11, 3:13,15
- red cell turnover effects on, 1:12
- relationship of other glycemia measures, 1:11–12
- in REM-related sleep apnea, 25:17
- renal failure effects on, 1:12
- retinopathy and levels of, 21:12
- retinopathy progression in adolescents and adults, 15:18
- retinopathy risk during pregnancy, 5:27
- as risk factor for diabetes, 1:20–21
- risk for retinopathy progression, 5:26
- screening cutpoint for, 1:26
- for screening for preventative interventions, 18:7
- screening for undiagnosed diabetes, 1:26;
- seasonal variations in, 1:12
- with self-reported diabetes prevalence, 18:7
- sensitivity of, 1:12
- sex differences in risk prediction, 1:20
- skin autofluorescence correlation, 1:16
- standardization of methods, 1:7
- undiagnosed/prediabetes detection, 3:15
- variations in measurement methods, 1:7
- vitamin B12 deficiency effects on measurement of, 1:12
- fracture risk effects of, 32:14
- maladaptive eating behavior with type 1 diabetes, 33:20
- microalbuminuria fluctuation with, 15:24
- nerve fiber repair with euglycemia, 23:6
- neuropathy treatment with, 23:7–8
- normalization of albuminuria with, 22:12
- obstructive sleep apnea impact, 25:17
- optimal first trimester levels for, 5:10
- oral health and diabetes, 31:9
- periodontal therapy trials for, 31:12–14
- periodontal treatment effects on, 31:12,40
- preconception planning/counseling, 5:8
- pregestational diabetes complications, 5:25
- in pregnancy with preexisting diabetes, 5:25–26
- preterm delivery rates and, 5:46
- for prevention of preeclampsia, 5:35
- for reduction of retinopathy progression, 15:18
- sleep quality and glycemic control, 25:3–6,9
- spontaneous abortion rate confounding, 5:36
- stroke incidence with diabetes, 19:1
- visual impairment and, 21:7–8

**Glycemic index**
- carbohydrate quality, 13:6
- islet autoimmunity association with, 11:14

**Glycemic load**
- and alcohol consumption, 13:9
- beta cell stress by, 11:14
- defined, 13:6
- diabetes risk with, 13:6
- type 2 diabetes risk association, 29:6

**Glycemic risk factors for diabetes**
- criteria for type 2 diabetes screening, 1:22–23
- fructosamine measurements, 1:21
- glycated hemoglobin, 1:20–21
- high-risk glycemic state prevalence, 1:17
- impaired fasting glucose, 1:19
- impaired glucose and fasting glucose tolerance, 1:21–22
- impaired glucose tolerance, 1:18
- levels for screening, 1:21
- prediction by impaired fasting and glucose tolerance, 1:16–17,19–20
- screening for type 2 diabetes, 1:22–27

**Glycemic risk profile, 1:19**

**Glycemic traits.** See Quantitative glycemic traits

**Glycosuria**
- in diabetic screening, 1:15
- with hyperglycemic hyperosmolar state, 17:6

**Glycosylated hemoglobin.** See Glycated hemoglobin (A1c)

**Gram-negative bacterial infections, 30:8,9,16**

**Gram-positive bacterial infections, 30:13,17**
Granulocyte colony-stimulating factor (GCSF), pegylated, 37:14
Graves’ disease, 6:15; 12:12
Greater Cincinnati/Northern Kentucky Stroke Study (GCNKSS)
diabetes-specific ischemic stroke risks, 19:8
epidemiology of stroke in diabetes, 19:4
Greenlandic population
postprandial hyperglycemia, 14:6
TBC1D4 gene, 14:3–4, 6
type 2 diabetes analysis, 14:3–5
Group B Streptococcus (GBS), 30:9, 17
Group Health Cooperative of Puget Sound, 30:10
Growth hormone (GH)
diabetes after therapy with, 6:13
in DKA, 17:1
post-puberty retinopathy, 21:23
with sleep debt, 25:10
Gum disease. See Periodontal disease
GWAS (genome-wide association scans)
acarbose prevention effects, 38:11
additive model with, 14:10
circadian gene-fastiging glucose association, 14:8
developments in, 14:6
for diabetes screening, 1:16
HLA-DR, 5:105
incidence prediction, 38:11
meta-analysis of, 14:3
non-HLA loci and type 1 diabetes risk, 11:3
participants in, 12:6
phenotyping with, 14:9
single nucleotide polymorphism association in, 12:5
statistical association with type 2 diabetes, 14:2
targeted arrays for, 14:6
for type 1 diabetes, 11:3; 12:2, 4, 6
for type 2 diabetes, 14:1–3
Wellcome Trust Case-Control Consortium, 12:6

Hard exudates (retinal), 21:12, 25
Hawaii
age-adjusted total preexisting diabetes during pregnancy, 5:13–14
periodontitis prevalence, 31:4
U.S. centers for SEARCH, 15:4
HCBS/SOL (Hispanic Community Health Study/Study of Latinos)
baseline data, 3:12
diagnosed diabetes prevalence comparison with NHIS, 3:7
prediabetes prevalence, 3:14
sampling methods, 3:7
tooth loss in, 31:32

HDL (high-density lipoprotein) cholesterol albuminuria progression prediction by,
22:32
with chronic kidney disease, 22:32, 52
diabetic peripheral neuropathy association, 15:25
in diabetic persons, 9:19–20
evening chronotype association, 25:27
fenofibrate studies, 18:16
hearing loss association, 23:12
HNF1α and levels of, 7:7
measurement in NHANES study, 9:2
in metabolic syndrome, 13:24; 19:10;
21:26; 26:5
niacin effects on, 6:12
with peripheral arterial disease, 20:6
in prediction of diabetes probability, 1:23
type 1 diabetes mortality risk, 35:12

Health, Aging, and Body Composition Study, 13:20; 32:2–3, 8
Health and Retirement Study
disability/impairment status, 34:8
health, social and financial studies, 5:75
Health care quality model, 41:2
Health Discharge Database, 5:25
Health information technology (HIT) surveillance, 2:13
Health insurance coverage, 42:1–22
age and coverage, 42:2
comorbidity and mortality with, 42:12
data sources and limitations, 42:1–2
diabetes control and, 42:11–12
diabetes duration and, 42:4
expected payment sources, 42:12–13
family income of persons without coverage, 42:16
glycemic medication use, 42:5–6
healthcare utilization and, 42:11, 12
income spent on family medical care, 42:14
length of time without coverage, 42:15
Medicaid/public coverage with diabetes, 42:4
Medicare and combination plans, 42:9
Medicare coverage, 42:4–5, 9
number of sources for coverage, 42:6
payment for medical care, 42:12
percent distribution for care expenses, 42:12
persons without coverage, 42:15
plans for private insurance, 42:7
prescription and dental coverage, 42:8–9
prevalence of private insurance, 42:16–17
private combination plans, 42:9
private health insurance sources, 42:6
private insurance prevalence, 42:6
private vs. Medicaid/public sources, 42:4–5
proportion of income for private coverage, 42:13–14
quality of care and, 42:10–11
race/ethnicity coverage prevalence, 42:2–3
reasons for lack of coverage, 42:15–16
socioeconomic characteristics and sex with coverage, 42:3
sources for, 42:6
trends in type and prevalence of, 42:16–17

Health Professionals Follow-up Study (HPFS)
cardiovascular disease mortality, 18:12
depression and type 2 diabetes risk, 13:15
erectile dysfunction and duration of diabetes, 28:7
gene-environment interaction, 13:5
periodontitis and glycemic control, 31:21
peripheral arterial disease risk with diabetes, 20:5

Health Technology Assessment (HTA), UK, 1:23
Healthcare Cost and Utilization Project, 1:26
Healthcare Effectiveness Data and Information Set (HEDIS)
oral health assessment data, 31:42
organizational-level quality measures, 41:11
quality improvement activities, 41:2

Healthcare utilization and costs of diabetes, 40:1–78
ambulatory medical care, 40:1–25
economic impact, 40:59–72
health insurance coverage and, 42:11
hospitalization and hospital utilization, 40:26–42
long-term care, 40:43–58
pregnancy planning and, 5:8–9

Healthcare utilization and insurance coverage
adverse effects of screening on, 1:22
economic analysis of screening, 1:26–27
physician visits after diagnosis, 1:27

Health-seeking behaviors
changing dietary intake, 10:18
implications for health professionals, 10:20
physical activity behavior change, 10:19
practicing weight control, 10:19
regular physician visits, 10:20
smoking cessation, 10:18–19

Hearing loss/deficits
congenital cytomegalovirus, 6:4
with diabetes, 23:10
malignant otitis externa, 30:16
mechanism of, 7:9
risk factors for, 23:12
SHORT syndrome, 7:20
Wolfram syndrome, 7:8

Heart disease. See Cardiovascular disease (CVD)

Heart disease and diabetes, 18:1–30. See also Cardiovascular disease (CVD)
aprotective platelet/aspirin management trial, 18:17–18
biomarkers for prediction of, 18:12
blood pressure association, 18:9
blood pressure control and coronary vascular disease risk, 18:9
blood pressure control trial, 18:17
cardiocvascular disease prevalence in, 18:2–3,19
contribution to disability with diabetes, 34:11
coronary artery calcification score for, 18:13
C-reactive protein association with, 18:12
diabetes association and, 18:1–3
fibrinogen biomarker for, 18:12
hyperglycemia as risk, 18:7–8
hypertension as risk, 18:1,9
insulin resistance as risk, 18:11–12
intensive glycemia control, 18:13–16
lifestyle management trial for risk factors, 18:18–19
lipid or inflammatory makers in, 18:8
lipid-modifying trials, 18:16–17
lipids and lipoproteins as risk, 18:8–9
low serum RAGE associations, 19:11
macro- and microvascular association with blood pressure, 18:9
new glucose-lowering agent outcomes, 18:15–16
obesity and risk for, 18:2–3,6,9–11
physical activity and risk, 18:12
prevalence in diabetes vs. nondiabetes in U.S., 18:3–7
proinsulin prediction of heart disease, 18:12
risk factors with diabetes, 18:7–13
risk with and without diabetes, 18:2
risk with metabolic syndrome, 18:9–10
smoking as covariate of risk, 18:12–13
subclinical atherosclerosis, 18:13
Heart Outcomes Prevention Evaluation (MICRO-HOPE) substudy, 19:12
Heart Protection Study (HPS), 18:16
Heart rate variability (HRV), 15:27, 23:6–7
Heartburn, 27:2

Helicobacter pylori (H. pylori), bidirectional periodontitis relationship, 31:24
Heme-iron intake, 13:6
Hemochromatosis
characteristics of, 6:9
secondary diabetes from, 1:3
types and prevalence, 6:9
Hemodialysis infection rate with diabetes, 22:22
Hemoglobin Glycation Index, 1:12
Hemoglobinopathies, effects of A1c measurements, 1:12, 3:15
Hemolytic anemia effects on A1c measurement, 1:12
Hemorrhagic stroke, 19:2–3
Hepatic insulin resistance
fibrinogen biomarker for, 6:11
in pancreatitis, 6:7
Hepatic lipase gene, 38:11
Hepatitis
with EIF2AK3 mutation, 7:11
hepatitis B and diabetes risk, 26:10–11
hepatitis C and diabetes association, 26:8–9
insulin resistance and hepatitis treatment, 26:9
insulin resistance in hepatitis C, 26:9
post–transplant diabetes risk with infection, 26:13
Hepatocellular carcinoma (HCC)
with cirrhosis and nonalcoholic fatty liver, 26:2,6
diabetes as risk factor for, 26:12
diabetes risk for, 26:6
liver transplantation for, 26:11
risk factors for, 29:7
risk with hepatitis B virus, 26:10
Hepatocyte nuclear factors
HNF1α mutation, 1:4, 7:4–7, 15:3
HNF1β mutation, 7:4,7
HNF4α mutation, 7:4,7, 15:3
phenotype characteristics with HNF1α mutation, 15:3
Hereditary/genetic pancreatitis, 6:8
Heterodimeric (αβ) protein receptors, 12:4
HFE gene mutation inheritance, 6:9
High blood pressure. See Hypertension
High glycators
immunoassays, 6:4
HIV (human immunodeficiency virus)
diabetes induced by antiretroviral therapy, 6:12
immune complex kidney disease, 22:56
HLA (human leukocyte antigen) genotypes
allelic variations in, 12:5
amino acid residues effects on type 1 diabetes, 12:4–5
class I alleles, 12:2–3
class I and II encoding of, 12:2
class III alleles, 12:2–3
diabetes association with, 12:3
gene x environment interactions, 11:16
genetic predisposition to celiac disease, 27:9
haplotype transmission, 12:3
high-risk genotype in children, 37:1
high-risk genotypes for type 1 diabetes, 12:1
intervention in newborns, 37:6
MHC and type 1 diabetes risk, 12:2–6
moderate-risk penetrance of, 11:3
in predisposition to type 1 diabetes, 37:1
relation to age at onset, 12:12
risk alleles in SEARCH study, 2:4
type 1 diabetes association, 12:3
type 1 diabetes protective, 12:4
type 1 diabetes susceptibility, 12:4
HLA and Immunogenetics Workshop, 12:4
HLA haplotypes
autoimmune polyendocrine syndromes, 6:14
autoimmunity after rubella, 6:4
with Down syndrome, 6:16
fine-mapping for, 14:10
protective in type 1 diabetes, 37:1
single nucleotide polymorphism and, 14:10
type 1 diabetes, 12:2–5
HLA-DR3, -DR4. See HLA
HMG Co-A reductase inhibitors, 6:12
HNF1α gene p.Glu508Lys SNP, 14:6
HOMA-IR (homeostasis model assessment-insulin resistance)
A1c and oral glucose tolerance test, 1.26 fasting insulin and glucose measurement, 13.18
with gallstone disease, 26.17 with HCV, 26.9
islet autoimmunity status and, 11.13 measurement of insulin, 18.11
obstructive sleep apnea, 25.18 with periodontal disease, 31.8
risk for type 2 diabetes, 13.18–19 sleep quality and, 25.9
stroke risk, 19.9–10
Home health care
activity of daily living limitations, 40.57
duration of home care, 40.58
environment of, 40.51
living arrangements, 40.55
medical conditions, 40.55–56
patient characteristics, 40.51–54
Homocysteine levels, 20.8
Honolulu Heart Program, 19.8–9, 20.14
Hormone-sensitive lipase, 25.19
Hospitalization and hospital utilization
adult hospital use, 40.38
adult hospitalization
length of stay, 40.41–42
multiple, 40.41
adult hospitalization by demographics, 40.39
adult hospitalization by diabetes duration, 40.40
adult hospitalization by diabetes type, 40.38
data sources, 40.26
discharge data
2010 discharge data, 40.27–28
listing complications, 40.33–37
trends with listing of diabetes, 40.28–32
Human leukocyte antigen (HLA) genotypes. See HLA (human leukocyte antigen) genotypes
Hungary
major malformations with type 2 diabetes, 5.62
malformations with utero diabetes exposure, 5.65
Hybrid diabetes, 15.3
Hydatidiform mole
gene association, 7.10
spontaneous abortion, 5.35
Hydrocephaly, 5.60
Hygiene hypothesis (natural protection), 11.7, 15.11
HYMAI (hydatidiform mole associated and imprinted gene), 7.10
Hyperfiltration, 22.6–7.31
Hyperglycemia. See also Metabolic memory albuminuria with, 22.12
with androgen-deprivation therapy, 29.13
cancer steroid therapy and, 29.13–14
contribution to disability with diabetes, 34.11
diabetic complications with, 1.6, 15
effects on osteoblasts, 32.3
extended follow-up of adverse health conditions, 38.12–13
gastric emptying delay with, 27.4–5
with globulostoma multiforme treatment, 29.13
with glucocorticoids, 6.11
H. pylori status and glucose levels, 31.24
heart disease risk with, 18.7–8
heart rate and hyperglycemia association, 23.13–14
hypothesized in cancer cause, 29.7
infections in diabetes patients, 30.5
kidney disease risk factor, 22.30–31
levels defining DKA, 17.1
obstructive sleep apnea association, 25.14
osmotic diuresis with, 1.1
peripheral arterial disease association with, 20.6
peripheral neuropathy risk, 15.25–27
prenatal famine exposure and, 13.13
proinflammatory processes with, 19.3
renal dysfunction with, 19.3
risk factors for heart disease, 18.7–8
with steroid therapy, 29.13
stroke risk and outcomes with, 19.9
symptoms of, 1.2
thiazide association with, 6.12
transcription changes from, 22.45
type 1 diabetes mortality association, 35.4
Hyperglycemic hyperosmolar state (HHS)
corticosteroid precipitation, 17.6–7
cost, 17.6–7
diagnostic criteria, 17.6
incidence and prevalence, 17.6
mortality and morbidity, 17.6
pathogenesis, 17.6
precipitating factors in, 17.6
prevention and treatment, 17.7
vulnerable patients, 17.7
Hyperinsulinemia
benign prostatic hyperplasia etiology, 28.5
cognitive impairment with diabetes, 24.4–5
dementia risks with, 24.4
gallstone formation with, 26.16
insulin resistance syndrome type A, 7.12
insulin-cardiovascular disease association, 18.11
prevalence trends in, 13.18
risk factor for dementia, 24.4
risk factor for familial, 7.5
risk factor for recurrent, 29.6
Hyperinsulinemic clamp study. See Euglycemic hyperinsulinemic clamp studies
Hyperinsulinemic hypoglycemia
of infancy, 7.5
Ks, Channel mutations in, 7.5
Hyperleptinemia, 22.38
Hyperproinsulinemia, 7.11
Hypertension. See also Blood pressure control
in adolescents with diabetes, 1.14
association with insulin resistance, 19.9
chronic hypertension and placental abruption, 5.25
comorbid condition in women, 5.6
genital malformation prediction by, 5.10
epigenetic programming in next generation, 22.42
geriatric diabetic population, 16.6
gestational hypertension, 5.34
heart disease risk factor, 18.9
maternal mortality from pregnancy related, 5.22
metabolic syndrome traits, 13.24
nephropathy with, 5.29
in pediatric patients with type 2 diabetes, 15.2
preeclampsia, 5.34–35
in pregestational diabetes, 5.33–34
pregnancy-related myocardial infarction risk, 5.23
risk factor for diabetic kidney disease, 22.31–32
stillbirth morbidities, 5.43
stroke risk with, 19.3
stroke with pregestational diabetes, 5.22
management in treatment of diabetes, 39.4–5
type 1 diabetes mortality, 35.11
Hypertension Optimal Treatment (HOT) trial, 18.17
Hypertensive disorders of pregnancy
antenatal and delivery-related stroke, 5.22–23
blood pressure criteria for, 5.30
chronic hypertension, 5.33–34
gestational hypertension, 5.30–33, 34
grading in U.K., 5.30
preeclampsia-eclampsia, 5.30, 34–35
pregnancy outcomes with, 5.33
prevalence in pregestational diabetes, 5.33
severe hypertension criteria, 5.30
prevention recommendations, 5.35
Hyperviscosity syndrome, secondary, 5.68
Hypoglycemia
acute metabolic complications, 17.9–13
with autonomic neuropathy, 23.4
classification of, 17.9
CYP2C9 and sulfonyl-related, 14.9
economic impact of, 17.12
fractures with falls during, 32.12–14
with GCK mutation, 7.5
geriatric diabetes complications, 16.5
glycemic control in geriatric population, 16.16
guidelines for glycemic control, 18.15
increased frequency with nateglinide, 38.9
insulin pump and episodes of, 15.17
from insulin secretagogues, 16:16, 38:9,12
insulin-induced in pregnancy, 5:26
morbidity and mortality with, 17:11–12
in older adults, 16:16
pathogenesis of, 17:9
pregnancy risk with severe, 5:26
prevention, 17:12
risk factors, 17:10–11
risks with insulin, 17:12
so socioeconomic status and episodes of, 33:23
treatment of, 17:13
in types 1 and 2 diabetes, 17:10

**Hypoglycemia-associated autonomic failure (HAAF).** 35:10

**Hypoplastic left heart syndrome.** 5:11

**Hypopnea**
definition, 25:12
quantification of, 25:13

**Hyposalivation**

**Hypoplastic left heart syndrome**

**Hypopnea**
definition, 25:12
quantification of, 25:13

**Hypoglycemia-associated autonomic failure (HAAF).** 35:10

**Hypoplastic left heart syndrome.** 5:11

**Hypopnea**
definition, 25:12
quantification of, 25:13

**Hyposalivation**

**Hypothalamic-pituitary-adrenal axis (HPA)**

**Hypoplastic left heart syndrome**

**Hypopnea**
definition, 25:12
quantification of, 25:13

**Hyposalivation**

**Hypothalamic-pituitary-adrenal axis (HPA)**
anxiety in dysregulation of, 33:19
depression impact on type 2 diabetes, 33:13
modification by hypoxia, 25:19
pathway for diabetes-depression association, 33:14
sleep and circadian disturbances, 25:19
stress-related cortisol secretion, 25:10

**Hypoxic conditions**
effects on leukocytes, 25:20
hypothalamic-pituitary-adrenal axis effects of, 25:19
lactic acidosis precipitation, 17:8
with obstructive sleep apnea, 13:14;
25:1–2,13
in retinopathy progression, 21:12
with smoking, 21:27

**Hypoxia**

**Hypoplastic left heart syndrome**

**Hypopnea**
definition, 25:12
quantification of, 25:13

**Hyposalivation**

**Hypothalamic-pituitary-adrenal axis (HPA)**
anxiety in dysregulation of, 33:19
depression impact on type 2 diabetes, 33:13
modification by hypoxia, 25:19
pathway for diabetes-depression association, 33:14
sleep and circadian disturbances, 25:19
stress-related cortisol secretion, 25:10

**Hypoxic conditions**
effects on leukocytes, 25:20
hypothalamic-pituitary-adrenal axis effects of, 25:19
lactic acidosis precipitation, 17:8
with obstructive sleep apnea, 13:14;
25:1–2,13
in retinopathy progression, 21:12
with smoking, 21:27

**IADPSG**
definitions of diabetes in pregnancy, 5:3
fetal complication definitions, 5:35–36
gestational diabetes diagnosis and classification, 4:9–10
guidelines for diagnosis/treatment and cost, 4:11
hyperbilirubinemia treatment, 5:71
polycythemia definition, 5:68–69
pregnancy outcome codification, 5:50
screening for gestational diabetes, 1:28–29

**Icelandic population**
cataract prevalence, 21:34
Reykjavik participants, 18:8
whole-genome sequences of, 14:6

**Identity-by-descent (IBD) sharing.** 12:6

**Idiopathic diabetes.** See Type 1b diabetes

**IDL (intermediate-density lipoprotein) particles.** 22:32

**IFIH1 gene**
cesarean delivery interaction with, 11:16–17
response to picornaviruses, 12:6
type 1 diabetes susceptibility, 12:6–7,8

**IGF-binding protein (IGFBP)-1,-3**
breast cancer association, 29:6
in glucose homeostasis, 19:11, 20:1
possible link to diabetes, 13:20

**IL2 gene, 12:12**

**IL2-IL21 gene locus, 32:15**

**IL2RA/CD25 gene, 12:6**

**Illinois**

**Immune response**
antigen presentation in, 12:2
genes involved with, 12:2–3
initiation in type 1 diabetes, 37:2
sympathetic nervous system activity effects on innate, 25:20
in type 1 diabetes, 37:1,2

**Immune Tolerance Network (ITN)**
alectcept, 37:13
human insulin B chain, 37:13
IL2 and rapamycin, 37:13
prevention of type 1 diabetes, 37:13
tepilizumab efficacy, 37:12
thymoglobulin, 37:13

**Immune-mediated diabetes**
anti-insulin receptor antibodies, 6:15
autoimmune type 1 diabetes, 6:18
B cell and T cell roles in type 1 diabetes, 1:3
beta cell destruction in type 1 diabetes, 15:2
classification of diabetes, 1:4
early life exposures and, 15:11
genetic susceptibility to autoimmunity, 15:3
with immune-mediated syndromes, 6:1
rare forms of, 6:15
sharing of genetic risk, 12:6
Stiff man syndrome, 6:15

**Immunochip data, 12:9**

**Impaired fasting glucose (IFG).** See also specific conditions

**ADA revision of classification, 1:14**
definition and predictive value of, 13:16
diabetes risk indicator, 1:19–20
gene in, 25:29
heart disease risk association, 18:7
metabolic syndrome criteria, 13:24
in NHANES data, 15:9
odds ratios for progression, 1:19
in offspring with intrauterine diabetes exposure, 4:12
pathophysiology of, 1:17
periodontitis effects on, 31:8–9
prevalence of, 1:19
prediabetic diagnostic criteria, 1:5–6
predictive value of, 1:20

**Impaired glucose tolerance (IGT).** 1:16–17
See also specific conditions
after in utero diabetes exposure, 13:12,13
AGES association with, 1:16
association with insulin resistance, 1:17
cardiovascular autonomic neuropathy, 23:13
ciracadian misalignment effects on, 25:2
in cystic fibrosis-related diabetes management, 6:6
definition and cutpoints for, 1:13,18
definition and predictive value of, 13:16
diabetes prevalence with hemochromatosis, 6:9
diagnostic criteria, 1:18–19
in endogenous Cushine syndrome, 6:15
fetal overnutrition effects in, 15:12–13
gestational diabetes definition, 4:2–5
with history of intrauterine growth retardation, 6:18
kidney abnormality association, 22:12
lifestyle intervention with, 23:8,13, 38:10
metabolic syndrome criteria, 18:9
NAVIGATOR trial, 38:9
neonatal effects of, 13:12
neuropathy with, 23:7,11
in offspring with intrauterine diabetes exposure, 4:12
with oral contraceptive use, 6:13
oral health effects on, 31:8
in patients with tuberculosis, 30:17,18
periodontitis effects on, 31:9–9
post-transplant diabetes onset and, 26:13
predictive value of, 1:20
progression in Pima Indians, 1:3
progression to diabetes, 1:18
in progression to type 2 diabetes, 13:16–17, 15:2
regression with lifestyle treatment, 1:19
risk factor for diabetes, 1:16
with schizophrenia, 33:22
in Turner syndrome, 6:17
type 2 diabetes risk link, 13:15
in Williams syndrome, 6:17

"Impaired glucose tolerance" neuropathy.

See Distal symmetrical polyneuropathy

**Intrauterine diabetes exposure.** See Intrauterine diabetes exposure

**InCHIANTI study, 20:9**

**Incidence.** See specific conditions and populations

**Incretin-based diabetes therapy, 29:12**

**Indapamide (thiazide diuretic), 19:12, 21:25**

**India, epithelial fragility with type 2 diabetes, 21:37**
Indian Diabetes Prevention Programme (IDPP), 38:8–9
Indian Health Service (IHS), 2:5
Indiana, preconception planning/counseling, 5:8
Inducing Remission in New-Onset Type 1 Diabetes with Alefacept (T1DAL) trial, 37:13
Infant mortality and morbidity, 5:45–71
Infection-caused diabetes, 1:4; 6:4–5
Infections associated with diabetes, 30:1–25
asymptomatic bacteriuria, 22:55–56; 28:20; 30:9
bacterial skin and soft tissue, 30:11–12
cystitis and pyelonephritis, 30:9–10
deep subcutaneous tissue, 30:13–14
emphysematous cholecystitis, 30:16–17
emphysematous pyelonephritis, 30:10
foot ulcers and osteomyelitis, 30:12–13
fungal skin and soft tissue, 30:11
Group B Streptococcus, 30:17
hospital-acquired, 30:13–15
hyperglycemic hyperosmolar state precipitated by, 17:6
influenza and pneumonia, 30:7–8
malignant/invasive otitis externa, 30:16
maternal mortality from, 5:24
mortality and morbidity from infections, 30:1–4
organisms in urinary tract infections, 30:9
overview, 30:1–5
pathogens in respiratory tract infections, 30:8
periodontal disease, 30:14–15
renal and perinephric abscess, 30:10
rhinocerebral mucormycosis, 30:16
sepsis risk with, 5:24
sinusitis and bronchitis, 30:8
skin and soft tissue, 30:10–14
tuberculosis, 30:17–18
urinary tract infections, 30:9
Infectious agents, 11:3–9
natural infection protection hypothesis, 11:7
polio model of type 1 diabetes, 11:6–7
prenatal enterovirus infections, 11:6
seasonality of type 1 diabetes diagnosis, 11:3
type 1 diabetes, 11:7
viral infections, 11:4–8
Inflammation. See also Systemic inflammatory response
in diabetes/stroke risk, 19:10
influence on benign prostatic hyperplasia risk, 28:2
pancreatic effects of chronic, 6:7
subclinical inflammation in prediabetes, 13:18–19
Inflammatory bowel diseases (IBD)
management of, 27:15
shared genetic predisposition with type 1 diabetes, 27:15
Inflammatory markers
adipose tissue-derived, 23:7
with cardiac misalignment, 25:26
dental disease and, 31:1,14
for major cardiovascular disease, 18:8–9,12
periodontal therapy effects on, 31:14
in peripheral arterial disease, 20:7,8–9
Inflammatory response. See also Systemic inflammatory response
asymptomatic bacteriuria, 28:20
in beta cell destruction, 37:2
against beta cells, 6:5
from C fiber destruction, 30:5
in celiac disease, 27:9–10
changes in podocytes in kidney disease, 22:8
from dental plaque, 31:1,3,19,24
with diabetic foot ulcers, 20:21
by diabetic status, 9:23
during gestational diabetes, 31:25
markers for, 9:23
in pathogenesis of neuropathy, 23:7
in prostatic growth, 28:4
type 1 diabetes process for, 37:2
Informatics in Diabetes Education and Telemedicine Study (IDEATel), 24:11–12
Inpatient and Birth Registers (Sweden), 5:23–24
INS (insulin) gene
association with type 1 diabetes, 11:3
defects, 7:11
insulin synthesis/secretion defects, 7:8
in MODY, 7:4–5,7
neonatal diabetes mellitus, 7:10–11
NEUROD1 expression regulation by, 7:29
beta cell destruction by, 7:11
regulation of transcription, 7:2
in classification of diabetes, 1:1–4
Insomnia
glucose metabolism with, 25:9,29
with major depressive disorders, 33:2
melatonin supplementation in, 25:29
symptoms of, 25:6
Institute of Medicine, 5:43; 41:2
Instrumental activities of daily living (IADL)
See also Activities of daily living (ADL)
definition of, 34:2
diabetes and morbidity status, 34:8
diabetes association with, 34:3
disability prevalence in, 34:4–5
trends in national estimates, 34:9–11
Insulin
albuminuria with treatment, 22:12
amyloid cascade effects of, 24:3
biomarkers for, 18:12
bone mineral density effects of, 32:10
cancer risk with gliclazide, 29:13
cancer risks in type 2 diabetes, 29:11
cataract surgery risk with use, 21:35
diabetes expenditures for, 40:62
effects on osteoblasts, 32:3
gallstone disease relationship with, 26:17
glaucoma incidence in type 2 diabetes with use, 21:36
glucose intolerance progression to diabetes effects, 1:19
heart disease predictor, 18:11–12
insulin-like growth factor homology, 13:20
levels in hyperglycemic hyperosmolar state, 17:6
long-acting, 6:7; 29:11; 37:6
measures of endogenous production, 2:3
NPH and hypoglycemic episodes, 15:17
omission with eating disorders, 33:20
oral insulin early intervention, 37:5,11
oral trials, 37:5,7,11
parenteral injection of ultralente insulin, 37:6
radioimmunoassays for, 18:11
rapid-acting, 6:7
use with pancreatitis-related diabetes, 6:7
Insulin action and defects
in definition of diabetes, 2:3; 7:2
Donohue syndrome, 7:12
heritability of, 14:7
insulin resistance syndrome type A, 7:12
PCSK2 mutation effects, 7:12
Rabson-Mendenhall syndrome, 7:12
resistin effects on, 25:20
secondary diabetes types, 1:4
Insulin autoantibodies (IAA)
beta cell destruction by, 15:2
identification of, 37:2
screening for preclinical type 1 diabetes, 1:28
Insulin deficiency
in classification of diabetes, 1:6; 15:3
diagnosis of type 1 diabetes in youth, 2:3
DIDMOAD syndrome, 7:8
DKA and, 15:13; 17:1
with hemochromatosis, 6:1,10
INS mutations in neonatal diabetes mellitus, 7:11
in MODY, 7:2
with pancreatitis, 6:7
progression in MODY, 7:6–7
in single gene defects, 7:8
in type 1 and type 1b diabetes, 6:18; 7:2
with type 1 diabetes in youth, 15:2
in type 1 vs. type 2 diabetes, 1:3–4
type 1a diabetes, 1:3
type 1b diabetes, 6:18
in type 2 diabetes, 7:2
in types 1 and 2 diabetes, 1:3; 7:2
types 1 and 2 diabetes in youth, 15:2–3
Insulin processing defects
genetic defects in, 7:11–12
hyperproinsulinemia, 7:11
prohormone convertases in, 7:11
Insulin receptor/postreceptor defects
Donohue syndrome, 7:12
insulin resistance syndrome type A, 7:12
in lipodystrophy, 7:20

Insulin Resistance Atherosclerosis Study (IRAS)

Insulin Resistance Intervention after Stroke (IRIS) trial, 19:13–14

Insulin resistance syndrome type A, 7:12

Insulin resistance syndrome type B, 6:15

Insulin response

Insulin secretagogues, 16:16; 38:9,12


Insulin-degrading enzyme, 24:4

Insulin-dependent diabetes. See Type 1 diabetes

Insulinemia, breastfeeding and, 15:13

Insulin-induced hypoglycemia, 5:26

Insulin-like growth factor-1 (IGF-1)
Index—34

obesity and, 4:12
omphalocele, 5:65,66
renal agenesis with, 5:60,65
type 2 diabetes risk with maternal diabetes, 15:13

Intrauterine growth retardation
diabetes risk with, 6:18
Donohue syndrome, 7:12
factors in, 22:42
SHORT syndrome, 7:20

Intravenous glucose tolerance test (IVGTT)
acute insulin response, 13:17
insulin secretion measurement in, 13:17–18
insulin sensitivity assessment, 18:11
in Prader-Willi syndrome, 6:16
sleep restriction effects on, 25:2

Inuit ancestry. See Greenlandic population

Inward rectifying potassium channel
(Kir6.2), 7:5

IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked)
diabetes with, 6:14–15
neonatal diabetes mellitus, 7:11

IPF1 (insulin promoter factor), 7:7

Irbesartan Diabetic Nephropathy Trial
(IdNT), 22:49

Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2), 22:49

Irish studies
gestational hypertension prevalence in, type 2 diabetes, 5:34
major malformations with type 2 diabetes, 5:62
malformations and preconceptual care use, 5:8
nephropathy prevalence data, 5:29
preconceptual care use by diabetes type, 5:10
preeclampsia rates in, 5:34–35
preeclampsia with preconception care, 5:35
retinopathy progression during pregnancy, 5:27
severe maternal morbidity, 5:25
severe obstetric morbidity, 5:25

Iron deficiency anemia, 1:12

Iron poisoning, 6:9–10

Ischemic stroke
carotid artery disease and, 19:17
classification of, 19:2
control of systolic hypertension with, 19:12
diabetes as independent risk factor, 19:17
glucose toxicity effects on, 19:9

Islet amyloid polypeptide toxicity, 1:6

Islet autoantibodies
identification of, 37:2
metabolomic studies for prediction of, 11:14
seasonality, 11:3

Islet autoimmunity. See also Type 1 diabetes risk factors
conjugated linoleic acid association, 11:10

early cereal exposure, 11:9,10,16
early respiratory infections and, 11:7
tenteroviral infections, 11:4
tenteroviral infections, 11:6
gene/dietary exposure interaction, 11:16
linoleic acid, 11:13
milk and meat consumption association with, 11:10
monounsaturated palmitoleic acid isomers association, 11:10
peak incidence in high-risk children, 11:3
risk factors for, 11:1
risk with early cereal exposure, 27:14
subclinical phase of type 1 diabetes, 11:1
25-Hydroxyvitamin D (25(OH)D) and, 11:11–12

Islet cell antibodies (ICA)
identification of, 37:2
marker for beta cell injury, 37:2
in MIDD, 7:9
MOYD screening, 7:6
prediction of type 1 diabetes development, 15:2
screening for preclinical type 1 diabetes, 1:27–28
screening for type 1 diabetes, 7:6
type 1 diabetes in youth, 15:3

Islet cell transplants for diabetes treatment, 39:10

Islet cells
ageing effects on, 16:1
enterovirus tropism for, 11:4

Isoniazid, 30:17

Israeli studies
everal induction for birth trauma prevention, 5:59
everal mortality with type 1 diabetes, 35:9
mortality in childhood-onset type 1 diabetes, 35:8,12
periconception glycemic control, 5:10

Italian population/studies
cardiovascular risk with metabolic syndrome traits, 18:9
gallstone association with diabetes, 26:15
gestational hypertension prevalence in type 1 diabetes, 5:34
hypoglycemic episodes in pregnancy, 5:26
insulin-cardiovascular disease association in, 18:11
ketoacidotic episodes in types 1 and 2 diabetes, 5:25
major malformations with type 2 diabetes, 5:62
maternal mortality ratio with type 1 diabetes, 5:22
nephropathy prevalence data, 5:29
new-onset diabetes with compensated cirrhosis, 26:11
preeclampsia rates in, 5:34
type 1 diabetes classification criteria, 2:4
ultrasound-detected gallstones, 26:15

Jadad score, 18:15

Japanese Americans
diabetes and prevalence of dementia, 24:4–5
diabetes as risk for stroke, 19:1
diabetes risk in, 13:4

Japanese Diabetes and Pregnancy Study Group, 5:69

Japanese population/studies. See also Asian/Pacific Islander
caries risk with macrosomia, 31:37
childhood-onset mortality in type 1 diabetes, 35:8,12
chronic hypertension with pregestational type 2 diabetes, 5:33,35
in DECODE and EPIC studies, 18:7
diabetes risk in Hawaii, 13:4
diabetes-periodontitis interactive effects, 31:21–22
everal mortality with type 1 diabetes, 35:9
ELMO1 gene association with kidney disease, 22:43
gestational hypertension prevalence in type 1 diabetes, 5:34
glucose measures and diabetes risk, 1:20,21
glycated albumin and fasting glucose correlation, 1:15
intensive and cardiovascular autonomic neuropathy, 23:13
intensive insulin treatment and distal symmetrical polyneuropathy, 23:11
lifestyle intervention, 38:10
major malformations with type 2 diabetes, 5:62
metabolic syndrome and sleep duration, 25:29–30
MOYD clinical presentation, 7:7
neonatal polycythemia frequencies with diabetes, 5:69
nephropathy prevalence data, 5:29
with peripheral arterial disease, 20:14
physical activity and type 2 diabetes risk, 13:11
preeclampsia in types 1 and 2 diabetes, 5:35
prevalence of type 2 diabetes, 3:8
prostate-dietes association, 29:9
proteinuria prevalence in youth, 15:24
short sleep duration and A1c levels, 25:3
shoulder dystocia and brachial plexus palsy, 5:59
stroke risk with diabetes, 19:8–9
triglycerides as predictor of heart disease, 18:8
type 1b diabetes in, 6:18
type 2 diabetes prevalence in Asian subgroups, 3:8

Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD), 18:17
Joint complications
Charcot joint/neuropathic arthropathy, 32:18
diffuse idiopathic skeletal hyperostosis, 32:18
Dupuytren’s contractures (trigger fingers), 32:17
frozen shoulder/adhesive capsulitis, 32:18
osteoarthritis and diabetes risk factors, 32:16–17
osteoarthritis prevalence with type 2 diabetes, 32:15–16
osteoarthritis/arthritis, 32:14–15, 17
rheumatoid arthritis prevalence, 32:17
stiff hand syndrome (cheiroarthropathy), 32:17
type 1 diabetes-rheumatoid arthritis association, 32:15
upper extremity musculoskeletal disorder prevalence, 32:17
Joslin Clinic studies
advanced glycation endproducts with retinopathy, 21:22
bovine insulin availability and mortality, 35:2
cardiovascular and renal mortality, 35:3
ESRD and mortality with type 1 diabetes, 22:20
glycemic control in youth, 15:28
life expectancy for type 1 diabetes, 35:5
mortality with eating disorders, 35:4
retinopathy incidence diabetes duration, 21:19
selection bias in studies from, 35:3
severe hypoglycemia in youth, 17:10
Juvenile idiopathic arthritis, 32:15
Juvenile-onset diabetes mellitus, 1:1; 5:3.
See also Type 1 diabetes
K
Kaiser Permanente Colorado (KPSC), 4:7
Kaiser Permanente Northern California (KPNC)
cancer risk with insulin glargine, 29:11
cancer risk vs. insulin glargine, 29:11
deliveries with pregestational diabetes, 5:16–17
gestational diabetes prevalence trends, 4:7
gestational hypertension/pregestational diabetes, 5:34
KCNJ11 gene
in MODY, 7:4–5
mutations in permanent neonatal diabetes, 7:10
neonatal diabetes mellitus, 7:10,11
p.Glu23Lys, 14:2,10
Ketones
in diagnosis of diabetes, 1:16
in DKA, 17:1
in hyperglycemic hyperosmolar state, 17:6
in lactic acidosis, 17:8
Ketosis
in classification of diabetes, 1:2,3; 6:19;
7:2, 15:2
resistance in congenital generalized lipo-
dystrophy, 7:15
in type 2 diabetes in African Americans, 17:2
in types 1 and 2 diabetes, 15:2–3
KIAA0350 gene, 12:6
See also Chronic kidney disease; Diabetic kidney disease; ESRD (end stage renal disease)
HIV infection, 22:56
kidney cancer, 29:9
MODY5 clinical presentation, 7:4
renal papillary necrosis, 22:56
urinary tract infections, 22:55–56
Kidney Disease: Improving Global Outcomes (KDIGO), 22:4
Kidney Early Evaluation Program (KEEP), 22:36
Kidney failure. See also ESRD in diabetes
A1c levels with, 1:12
albuminuria as risk factor for, 22:3
albuminuria with type 2 diabetes, 22:17
Alstrom syndrome, 7:12
definition by GFR, 22:3
with EIF2AK3 mutation, 7:11
excess mortality risk with type 1 diabetes, 35:11–12
fracture risk factor, 32:12
metformin use with, 17:8
proteinuria phase with diabetes, 15:20
in relatives of MODY patients, 7:7
risk with type 2 diabetes in youth, 15:24
in type 1 diabetes, 22:16
type 1 diabetes mortality, 35:11
in types 1 and 2 diabetes, 22:25
Kidney injury molecule 1 (KIM-1), 22:1,9
Kidney-specific leptin resistance, 22:38
Kilham rat virus (KRV), 11:8
Kimmelstiel-Wilson nodules, 22:7
Klebsiella pneumonia, 30:8,9,16
KLF14 gene, 14:11
Korean Genome and Epidemiology Study, 25:29
Korean studies. See also Asian/Pacific Islander
A1c sex differences in prediction, 1:20
chronic hypertension in diabetic pregnancy, 5:35
gallstone disease and insulin resistance, 26:17–18
maternal morbidity rates, 5:25
preeclampsia superimposed on nephrop-
athy, 5:17
prevalence of preexisting diabetes during pregnancy, 5:17
prevalence of type 2 diabetes, 3:8
proteinuria prevalence in youth, 15:24
puerperal sepsis, 5:24
severe obstetric morbidity and pregesta-
tional diabetes, 5:25
type 2 diabetes prevalence in Asian subgroups, 3:8
urinary tract infections with pregestational diabetes, 5:24
venous thromboembolism during first pregnancy with pregestational diabetes, 5:23
Kruppel-like factor 11 (KLF11), 7:7
Kuopio Ischemic Heart Study, cardiovascular risk with metabolic syndrome traits, 18:9
L
Labor and delivery
birth weight of liveborn infants, 5:55–56
brachial plexus palsy by duration of, 5:58
brachial plexus palsy with operative vaginal delivery, 5:59
early induction for birth trauma prevention, 5:59
gestational age at delivery with diabetes, 5:45
neonatal deaths with preexisting diabetes with pregnancy, 5:47
Lactic acidosis
diagnostic criteria, 17:8
incidence, 17:8
metformin-associated in type 2 diabetes, 17:8
morbidity and mortality, 17:8–9
precipitating factors, 17:8
prevention and treatment, 17:9
Lansoprazole, 37:14
Large-for-gestational age infants (LGA) adverse outcomes with, 5:56
birth trauma with, 5:56–58–59
criteria for, 5:49
hyperbilirubinemia in, 5:71
insulin-treated gestational diabetes, 4:11
neonatal hyperbilirubinemia, 5:71
neonatal hypoglycemia, 5:70
neonatal hypoglycemia rates, 5:70
neonatal morbidities in, 5:56
odds ratio with maternal diabetes, 5:50
with in utero diabetes exposure, 13:12
Latent autoimmune diabetes of adults (LADA)
celiac disease autoimmunity and, 27:9
glutamic acid decarboxylase autoantibodies in, 1:5
Late-onset AD dementia. See AD dementia
Latinos. See Hispanic ethnicity
Lawson Wilkins Pediatric Endocrine Society, 17:1
LDL (low-density lipoprotein) cholesterol association with mortality, 35:11
cardiovascular event effects of reduction, 18:15–16; 36:10
characteristics in diabetic persons, 18:8
control in patients with health insurance, 42:11
density correlation with dysglycemia, 15:28
by diabetes status, 9:20–21
fenofibrate studies, 21:25
Friedewald equation for, 9:2
in geriatric diabetes, 16:6
with intensive glycemic control, 20:12
management in diabetes, 19:14
measurement in youth, 15:33
oxidized autoantibodies in apneic patients, 25:19
progression of kidney disease with type 1 diabetes, 22:32
reduction and vascular mortality, 36:10
screening recommendations with diabetes, 41:3
type 1 diabetes mortality, 35:11
Leber’s hereditary optic neuropathy (LHON), 7:8–9
Lens opacities, 21:33–34
Leprechaunism, 7:12
Leptin
with circadian disruption, 25:26
congenital generalized lipodystrophy, 7:15
factors modulating secretion, 25:11
functions of, 22:37–38
in glucose homeostasis, 25:20
hypoxic condition effects on, 25:20
leptin-stimulated glucose uptake in regulation, 25:11
kidney-specific resistance to, 22:38
levels with obstructive sleep apnea, 25:20
receptor gene and weight loss, 38:11
role in obesity-related nephropathy, 22:37–38
signaling impairment in Bardet-Biedel syndrome, 6:16
sleep disturbance effects on, 13:15
in sleep restriction, 25:10–11
Leukocoria, 24:4
Life expectancy
improvement for type 1 diabetes, 35:5
persistent postpartum diabetes treatment, 1:29
predictions for diabetes in youth, 36:8
for types 1 and 2 diabetes, 35:5
Lifestyle characteristics with diabetes/prediabetes, 10:1–42
alcohol consumption, 10:9–10
data sources and limitations, 10:1–2
health-seeking behaviors, 10:18–20
implications for health professionals, 10:20
modifiable risk factors for type 2 diabetes, 13:1
nutrition, 10:2–11
physical activity, 10:12–15; 13:11–12
smoking, 10:16–18
Lifestyle intervention
with antipsychotic treatment, 33:22
with cardiovascular autonomic neuropathy, 23:13
clinical trials with impaired glucose tolerance, 1:19
diabetes development after gestational diabetes, 4:12
Diabetes Prevention Program, 38:6–8
Diabetes Prevention Program-based, 38:15
with gestational diabetes, 5:7
for gestational diabetes progression, 4:12
heart disease and diabetes, 18:18–19
with high genetic burden of risk alleles, 14:9
individual-based, 38:15
neuropathy treatment with, 23:8
in sexual dysfunction with diabetes, 28:10
type 2 diabetes prevention, 38:11
urinary incontinence with type 1 diabetes, 28:19
Zensharen study, 38:10
Lifestyle Intervention in Japanese Men with IGT, 38:8
Linkage analysis. See Genome-wide linkage analysis
Linkage disequilibrium (LD), 12:3–4
Linkage mapping, 12:6
Linoleic acid, islet cell autoimmunity association, 11:10,13
Linomide, 37:7
Lipids and lipoproteins
cholesterol, 9:19–21
total cholesterol, 9:19
triglycerides, 9:21–22
in vascular and heart disease risk, 18:8–9
Lipodystrophy
diabetes management in, 7:20
genetic lipodystrophies, 7:13–20
Lipolysis
adipose triglyceride lipase in, 7:19
beta-hydroxybutyrate levels with, 17:1
diagnosis of type 2 diabetes in youth, 15:2
Liraglutide, 38:10–11
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, 18:16
Lisinopril, 21:24
Lithium, 33:21–22
Liver and gallbladder disease, 26:1–23
ALT estimates of injury in, 26:3,4
AST for injury estimation, 26:3
biomarkers for liver disease, 13:20
cirrhosis, 26:11
diabetes prevalence with transplantation, 26:11–12
fatty infiltration with insulin resistance, 13:18
Fatty Liver Index, 26:3
gallstone disease, 26:13–16
gallstone disease and insulin resistance, 26:16–18
hepatitis B and diabetes, 26:10–11
hepatitis C and diabetes, 26:8–10
liver cancer, 29:7
liver disease diagnosis in patients with diabetes, 26:12–13
liver transplantation, 26:2,11–13
liver transplantation donor characteristics, 26:12
liver transplantation indications, 26:8
NHANES data, 26:2
nonalcoholic fatty liver disease and steatohepatitis, 26:2
nonalcoholic steatohepatitis, 26:2
post-transplant diabetes risk, 26:13
Scientific Registry of Transplant Recipients, 26:2
Liver fatty acid-binding protein (L-FABP), 22:1,9
Lixisenatide, 18:16
LMNA gene
adipocyte distribution with mutations in, 7:19
atypical progeroid syndrome, 7:20
diseases associated with mutations in, 7:19
familial partial lipodystrophy and type 2 diabetes, 7:18–19
familial partial lipodystrophy association, 7:13
glycemic control in lipodystrophy, 7:1
mandibulocalar dysplasia, 7:17
mutation with familial partial lipodystrophy, 7:1,18,19
Long-acting insulin
insulin glargine, 29:11
ultralente insulin, 37:6
use with pancreatitis-related diabetes, 6:7

Longitudinal studies. See also Pima Indian studies; SEARCH for Diabetes in Youth study alcohol consumption and type 2 diabetes risk, 13:9
antidepressant use association with incidence of diagnosed diabetes, 33:13
birth cohorts identified by genetic screening, 37:2
BMI increases and incidence of diabetes in children, 22:37
cardiovascular mortality risk with diabetes, 16:11
changes in glucose levels and periodontitis, 31:9
data with cohort studies, 36:5
depression in types 1 and 2 diabetes in youth comparison, 33:4
depression prediction of diabetes complications, 33:10
depressive symptoms and glycemic control association, 33:13
diabetes association with disability risk, 34:9
disability and diabetes association, 34:12
duration of depressive symptoms, 33:4
tenteroviral infection study, 11:4–5,6
epigenetic gene regulation with intrauterine diabetes exposure, 22:42
factors affecting prevalence rates, 36:3
fetal overnutrition, 15:2
fracture data with type 1 diabetes, 32:2–3
fracture incidence with and without diabetes, 32:6
Gila River Indian Community, 31:9,15,17,20
Health and Retirement Study, 10:12
health behaviors over time, 1:27
hypertension in types 1 and 2 diabetes, 22:31
hypoglycemic events and cognitive impairment, 24:12
incidence of type 2 diabetes in youth, 3:16
incident periodontitis progression with diabetes, 31:19
islet autoantibodies with rotavirus infection, 11:8
life expectancy changes with type 1 diabetes, 35:5
maternal glucose levels effect on offspring, 4:13
metabolic syndrome and periodontitis two-way causal effects, 31:21
microvascular complications and psychomotor slowing with type 1 diabetes, 24:7
pathogenesis of foot ulceration in diabetes, 23:14
periodontitis and diabetes-related medical expenses, 31:40
periodontitis/new type 2 diabetes development, 31:14
Pima Indians, 31:20–21
prediabetes and periodontitis severity, 31:22
progression of obstructive sleep apnea, 25:20
proteinuria incidence and diabetes duration, 22:17
psychiatric disorders with type 1 diabetes, 17:11
REGARDS study, 19:7
renal lesions with chronic kidney disease, 22:7
reported falls with and without diabetes, 32:11
school-aged children with diabetes, 2:2
sexual dysfunction incidence in American men, 28:8
smoking and GFR decline in type 1 diabetes, 22:36
Study of Osteoporotic Fractures, 16:8
TEDDY study, 15:10
Tohono O’Okham (Papago) Indian residents, 31:15
type 2 diabetes and periodontitis incidence, 31:20
Long-term care. See also Home health care; Nursing home
data sources, 40:43
Look AHEAD
behavioral intervention for cardiovascular disease, 18:18
erectile dysfunction with diabetes, 28:10
lifestyle characteristics, 10:2,7,9–11,16–17
lifestyle intervention for weight loss, 34:12
lifestyle intervention results, 38:17
sexual dysfunction in diabetes, 28:10
therapeutic strategies and cognitive decline, 24:12
urinary incontinence prevention, 28:19
Los Angeles Latino Eye Study (LALES)
association of diabetes and glaucoma, 21:37
with diabetes, 21:2–3
racial/ethnic differences in retinopathy, 21:28
Losartan
atenolol comparison on blood pressure and vascular events, 19:12
effects on retinopathy progression, 21:25
modification of ESRD risk with, 22:31
Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
Louisiana
blood pressure/heart disease association, 18:9
insulin resistance and periodontitis, 31:15
periodontitis prevalence, 31:6
racial/ethnic differences in stroke in diabetes, 19:7
Low glycators, 1:12

Low-density lipoprotein (LDL) cholesterol.
See LDL (low-density lipoprotein) cholesterol
Lower extremity amputation (LEA), 20:23–25
characteristics associated with, 20:25
functional status outcome, 20:25
glycemia as risk, 20:25
intensive vs. conventional glycemic control, 20:25
pathophysiology, 20:24
physical activity, 10:12
prevalence and incidence, 20:23–24
racial/ethnic risk factors, 20:24–25
reamputation, 20:25
risk with diabetes type, 20:24
Sickness Impact Profile for functional status, 20:25

Lower urinary tract symptoms (LUTS) in men
benign prostatic hyperplasia and, 28:5–6
bladder denervation/detrusor contractility, 28:2
bladder outlet obstruction, 28:2
data sources, 28:2–4
diabetes and prostate cancer association, 29:4
diabetic cystopathy symptoms and prevalence, 28:4
intensive treatment effects, 28:6
lower urinary tract symptoms associated with diabetes, 28:5–6
measurement and classification of, 28:2
prevalence and incidence of, 28:4
prostatic hyperplasia mechanisms, 28:4

Lower urinary tract symptoms (LUTS) in women
bladder storage symptoms, 28:10
cystitis with type 1 diabetes, 22:56
30:9
cystopathy symptoms and prevalence, 28:4
diabetes treatment and prevention of incontinence, 28:19–20
duration of type 2 diabetes and, 28:16
glycemic control and, 28:18
impaired detrusor muscle function with cystopathy, 28:14
incontinence with type 1 diabetes, 28:18–19
incontinence with type 2 diabetes, 28:14,16
involuntary detrusor muscle contractions, 28:14
lifestyle intervention with type 2 diabetes, 28:19
overactive bladder syndrome, 28:10
pathophysiology and clinical course, 28:14–16
pharmaceutical vs. insulin treatment, 28:18
racial disparities in urinary incontinence, 28:14
remission and improvement with type 2 diabetes, 28:16
Symptoms of, 28:10
Type 2 diabetes association with, 28:11
Urinary incontinence measurement and diagnosis, 28:10–14
Voiding and postmicturition symptoms, 28:10

Macronutrients. See Nutrition

Macroalbuminuria. See also Albuminuria; Microalbuminuria; Proteinuria
development in diabetes, 22:15
diagnostic criteria, 5:29
dyslipidemia with, 22:31
excess mortality risk with type 1 diabetes, 35:11
excess mortality with, 22:19–20
macromolecular shunt contribution to, 22:9
mortality with macroalbuminuria, 22:20
prevention in type 1 diabetes, 22:15
prevalence of elevated, 22:12
prevalence of in EURODIAB, 15:23
risk factor for cardiovascular disease, 22:19–20

Macrosomia. See also Birth weight; Fetal growth
birth weight categories, 5:50
excess fetal size, 5:49
neonatal and long-term morbidities, 5:56
neonatal hypoglycemia association, 5:56
polyhydramnios association, 5:46
postprandial hyperglycemia driving of, 5:72
reduction with treatment, 4:3
risk factors for, 4:11
small-for-gestational age with, 5:55
with types 1 and 2 diabetes, 5:49

Macrovascular complications. See also Heart disease and diabetes; Peripheral arterial disease; Stroke and diabetes
blood pressure association, 18:9
definition of, 19:11
effects of lowering A1c, 1:7
IGFBP-1 protective effect on, 19:11
multifactorial intervention, 22:54
pathophysiologic mechanisms of, 22:22–23
risk with retinopathy, 21:30
stroke with, 19:3
in type 1 and type 2 diabetes, 1:4

Macular edema
age-related, 21:38
association with elevated blood pressure, 21:24
with cataract surgery, 21:35–36
causes, prevalence and incidence, 21:12–30
clinically significant, 21:16–18
fenofibrate effects on, 21:25
during gestational diabetes, 5:27
during pregnancy, 21:26
race/ethnicity distribution, 21:27
risk factors with type 2 diabetes, 21:7–8
smoking and alcohol consumption, 21:27
socioeconomic status, 21:29
statin treatment with dyslipidemia, 21:25–26

Magnesium, 13:6

Major depressive disorder (MDD). See also Depressive episode or symptoms
age relationship to reported symptoms and risk for, 33:8–9
antidepressant use and type 2 diabetes development, 33:13
association with treatment outcomes, 33:10
bidirectional relationship with type 2 diabetes, 33:10–15
biologic pathways for association, 33:13–14
cognitive behavioral therapy effects, 33:15
definitions, 33:2
depression as risk marker for type 2 diabetes, 33:13
diabetes distress, 33:15
diabetes of youth, 33:4
in diagnosed, undiagnosed, and prediabetes, 33:6–7
elevated diabetes distress with, 33:10
emotional distress, 33:3,13
functional limitations and, 33:7
measurement issues with symptom overlap, 33:9–10
patient factors in course of diabetes, 33:8–9
presence of diabetes complications, 33:8
presentation, 33:1
prevalence and course, 33:2–4
treatment and intervention, 33:15–16
treatment effects on glycemic control, 33:15
type 1 diabetes effects on brain structure, 33:14
with types 1 and 2 diabetes, 33:2–4
variation by race/ethnicity, 33:9

Major histocompatibility complex (MHC). See MHC (major histocompatibility complex)

Major malformations. See also Congenital malformations

European rates for, 5:62
fetal sex-associated risk, 5:66
first trimester glycemic control, 5:10
musculoskeletal, 5:62
nuchal translucency prediction, 5:67
preconception care in diabetic women, 5:8,10
pregnancy terminations, 5:62
prenatal detection of, 5:67
shortened crown-rump length prediction, 5:67
with type 2 diabetes, 5:62
in utero exposure to diabetes, 5:60
Malignant/invasive otitis externa (MOE), 30:16
Malmöhus County, Sweden, study, 38:2–3,5,12
Malnutrition-related diabetes, 6:18
Mandibulofacial dysplasia (MAD) associated lipodystrophy, 7:17
Markov modeling framework
estimation of youth burden, 2:10
life expectancy predictions for youth, 36:8
Maryland
cognitive status with diabetes, 24:8
Multi-Ethnic Study of Atherosclerosis, 31:6
Massachusetts
acute metabolic complications in youth, 15:17
electronic health records study/data, 2:4
incidence of blindness, 21:5
prevalence of visual impairment, 21:3
Massachusetts Commission for the Blind register, 21:3
Massachusetts Male Aging Study
benign prostatic hyperplasia diagnosis with diabetes, 28:6
diabetes risk with short sleep, 25:3
incidence with diabetes, 28:8
MATE1 (multidrug and toxin extrusion 1 transporter protein), 38:11
Maternal complications before and during pregnancy
hypertensive disorders, 5:30–35
insulin-induced hypoglycemia, 5:26
maternal diabetes as risk factor, 5:24
maternal morbidity with acute myocardial infarction, 5:23
maternal mortality, 5:21
myocardial infarction rates, 5:23
nephropathy, 5:29
neuropathy prevalence in pregnancy, 5:28
proliferative diabetic retinopathy prevalence in early pregnancy, 5:26
sepsis association with, 5:24
venous thromboembolism, 5:23–24

Maternal diabetes. See also Gestational diabetes; Pregestational diabetes
association with sepsis, 5:24
association with stroke in pregnancy, 5:22
birth condition and sequelae, 5:48–50
birth defects with, 5:11
cesarean delivery, 5:46
cognitive ability in offspring, 5:75
comorbidities with, 5:2,67–68
comorbidities with stillbirth, 5:43
genital heart defects, 5:67
consequences for offspring, 4:12
definition of, 5:24
diabetes diagnosis in offspring, 4:12
effects on brachial plexus palsy, 5:58
beacapermin treatment of DFU, 20:22
birth weight and type 1 diabetes risk, 11,13
bladder cancer association with TZD/pioglitazone, 29:11
breastfeeding vs. formula-feeding, 13:13
cancer risk and metformin, 29:10–11
cardiovascular disease mortality and diabetes, 36:8
cardiovascular disease/diabetes association, 18:1,2
cognitive impairment in adults, 24:5–6
cognitive impairment with childhood-onset diabetes, 24:5
colon cancer risk with diabetes, 29:7
cow’s milk consumption, 11:9; 37:5
CRP levels and type 2 diabetes risk, 13:19
depression and diabetes complications, 33:10
depression and incident diabetes, 13:15
depression prevalence, 33:4
type 2 diabetes, 33:2
undiagnosed diabetes in adults, 33:6
depressive symptoms and treatment adherence, 33:13,15
diabetes and bladder cancer risk, 29:9
diabetes and hip fracture risks
  type 1 diabetes, 32:3
diabetes, 32:2
  diabetes and prostate cancer relation, 29:9
diabetes mortality/specific cause mortality, 36:9
diabetes/fasting glycemia/CHD, 18:7
disability risk with diabetes, 34:11
DKA frequency in type 2 diabetes, 5:25
glucose and incident cardiovascular disease, 12:8–9
endothelial function and diabetes, 29:9
enterovirus in blood samples, 11:4–5
ESRD relative risk with diabetes, 22:22
fetuin-A association with type 2 diabetes, 13:20
gene and alcohol consumption interaction, 13:9
genetic risk for type 1 diabetes, 12:10
glucose and incident cardiovascular disease, 18:7
GWAS data, 14:3
H. pylori infection and fasting glucose levels, 31:24
HCV and diabetes frequency, 26:8
hem-iron gene-diet interactions, 13:6
heritability estimate of type 2 diabetes, 14:1–2
HMG Co-A reductase inhibitors, 6:11
hyperinsulinemia/cardiovascular disease association, 18:11–12
hypoglycemic episodes with insulin therapy, 5:26
incident diabetes with thiazide, 6:11
intensive glucose control and cardiovascular disease mortality, 18:15
intensive glycemic control, 18:1; 22:47
life expectancy with type 2 diabetes, 36:8
lipids and lipoproteins in vascular risk, 18:8
liver cancer risk with diabetes, 29:7
liver enzymes and type 2 diabetes, 13:20
lower extremity amputations and glycemia association, 20:25
metabolic syndrome and incident type 2 diabetes prediction, 13:24
microalbuminuria and stroke risk association, 19:3
novel loci identification, 12:8–9
obstructive sleep apnea and diabetes risk, 25:15
obstructive sleep apnea and gestational diabetes association, 25:21
obstructive sleep apnea with type 2 diabetes, 13:14
oral contraceptive effectiveness, 5:13
oral hygiene with diabetes, 30:15
pancreatic cancer risk with diabetes, 29:8
periapical lesions with diabetes, 31:23
periodontitis and gestational diabetes risk, 31:14
periodontitis with adjuvant antimicrobials, 31:14
physical activity trials in type 2 diabetes, 18:2
polycystic ovary syndrome and glycemia association, 13:21
postoperative mortality in cancer types, 29:13
post-transplant diabetes, liver, 26:13
preconception care of diabetic women, 5:8
preclampsia with chronic hypertension, 5:33
preterm birth association with type 1 diabetes, 11:13
prognostic implications for chronic kidney disease, 22:1
relative breast cancer risk with diabetes, 29:8
retinopathy as chronic kidney disease indicator, 22:4
retinopathy diagnostic protocols, 21:33
risk of cardiovascular disease with type 1 diabetes, 18:13
risk of kidney cancer with diabetes, 29:9
risk with beta blocker treatment, 6:11
shift work and diabetes association, 25:26
sitagliptin/exenatide use and pancreatitis, 29:12
sleep duration and incident diabetes, 25:13
sleep quantity and quality, 13:14–15
sleep-disordered breathing and gestational hypertension, 25:21
smoking, 13:15; 29:6
socioeconomic status association with type 2 diabetes, 13:14
somatic symptom/cognitive-affective in undiagnosed diabetes, 33:6
statin therapy, 18:16; 19:12; 36:10
steatosis vs. steatohepatitis differentiation, 26:2
temperature monitoring with DFU, 20:19
testosterone association with type 2 diabetes, 13:20
trans-ethnic meta-analyses, 14:3
triglycerides and heart disease risk, 18:8
tuberculosis risk with diabetes, 30:17
type 1 diabetes risk loci, 12:7–8
type 2 diabetes risk factors, 13:1,10,11
vaccinations diabetes association, 11:9
vascular events and statin therapy, 16:14
vitamin D intake during pregnancy, 11:11
waist circumference and BMI with heart disease, 18:1
whole grain diet-gene interactions, 13:5,8
Meta-analysis Of Observational Studies in Epidemiology (MOOSE), 30:17
Metabochip custom-made array, 14:2,3–5
Metabolic dysfunction
  hypothalamic-pituitary-adrenal axis, 25:19
  with obstructive sleep apnea, 25:13–20
  with type 2 diabetes risk factors, 13:16–21
Metabolic Equivalent of Task (MET) hours, 10:15
Metabolic memory
  assessment of, 23:12
  in cardiac autonomic neuropathy, 23:13
  with cardiovascular disease risks, 18:13
  distal symmetrical polyneuropathy and,
  23:12
  for glycemic control in retinopathy, 15:18; 21:22
  prior hyperglycemic exposure in kidney disease, 22:45
  in types 1 and 2 diabetes, 22:2
Metabolic syndrome
  abdominal obesity, 18:9
  abdominal obesity assessment with, 13:1,21
  children with diabetic mothers, 5:74–75
  coronary vascular disease risk factors in,
  18:9
  C-reactive protein and peripheral arterial disease, 20:8
  cross-association with retinopathy, 21:26
  diagnostic criteria for, 18:9
evening preference and, 25:27
  with gestational diabetes, 4:12
  glaucoma links, 21:37
  neuropathy with, 23:7
  nonalcoholic fatty liver disease risk with,
  26:4
  number of traits and diabetes risk, 13:24
  obstructive sleep apnea association, 25:14
  periodontitis risk with, 31:21
  physical activity effects on, 18:12
  posttraumatic stress disorder as risk factor for,
  33:16
  prevalence of, 13:21–23
  with previous gestational diabetes, 4:12
  risk factors for heart disease, 18:9–10
sleep duration with, 25:30
stratification by race/ethnicity, 13:21
stroke risk with, 19:1,10
type 2 diabetes, 13:21–25
Metabolic Syndrome and Atherosclerosis in South Asians Living in America study, 13:22
Metabolomic studies, 11:14
Metformin
Canadian Normoglycemia Outcomes Evaluation, 38:9–10
cost-saving of prediabetic treatment, 1:22
diabetes intervention, 27:7
facilitation of weight loss, 33:22
fracture rates with, 32:12
glucose intolerance progression to diabetes effects, 1:19
guidelines for use, 18:15
GWAS for treatment with, 14:9
lactic acidosis precipitation, 17:8
MATE1, 38:11
recommendations for use, 38:16
response association of SLC4A1 gene, 38:11
retinopathy treatment/intervention in youth, 15:18
single nucleotide polymorphisms interactions, 38:11
stroke events with, 19:13
trends in use of, 39:3–4
use in geriatric population, 16:14
for weight loss with antipsychotic treatment, 33:22
Metreleptin replacement therapy, 7:1,20–21
Mexican Americans. See also Hispanic ethnicity
apolipoprotein E gene and retinopathy, 21:25
diagnosed diabetes prevalence, 3:7
functional status with lower extremity amputation, 20:25
functional status with lower extremity amputation, 20:25
functional status with lower extremity amputation, 20:25
functional status with lower extremity amputation, 20:25
functional status with lower extremity amputation, 20:25
glaucoma prevalence in, 21:37
insulin resistance indices for prediction of type 2 diabetes, 13:18
prediabetes prevalence, 3:14
retinopathy prevalence and severity, 21:28–29
total cholesterol, 3:12
undiagnosed diabetes prevalence, 3:12
whole exome sequencing of, 14:6
MHC (major histocompatibility complex) amino acid residues and type 1 diabetes association, 12:5
high-risk genotypes for type 1 diabetes, 12:1
linkage disequilibrium in, 12:3
type 1 diabetes genetic risk, 12:2–5,10
Michigan
preconception planning/counseling, 5:8
total diabetes percentages, 8:9
Microalbuminuria. See also Albuminuria; Macraobuminuria
association with stroke risk, 19:3
cardiac autonomic neuropathy association, 15:27
criteria for diagnosis, 15:20
criteria for diagnosis, 15:20
with diabetes in youth, 1:14; 15:20,23–24
with geriatric diabetes, 16:7
glomerular filtration barrier in, 22:9
in nondiabetic women on oral contraceptives, 5:13
prevalence in early pregnancy with type 1 diabetes, 5:29
prevalence of elevated, 22:12
progression of, 22:5
risk factor for retinopathy, 21:25
sodium-lithium countertransport activity, 22:32
stroke risk with, 19:10
Microaneurysms. See also Retinopathy as diabetes indicator, 1:16
Micronutrients. See Nutrition
Microvascular complications blood pressure association, 18:9
chronic hypertension treatment in pregnancy, 5:33
in dementia, 24:4
effects of lowering A1C, 1:7
with geriatric diabetes, 16:7–8
microvessel retinal disease with distal symmetrical polynuropathy, 23:2
multifactorial intervention, 22:54
nephropathy in diabetes in youth, 15:20–25
neuropathy in diabetes in youth, 15:25–27
obstructive sleep apnea impact on, 25:17
pathophysiologic mechanisms of, 22:22–23
perindopril and indapamide retinopathy effects, 21:5
physical activity effects on, 18:18
retinopathy in diabetes in youth, 15:17–20
risk with retinopathy, 21:30
stroke with, 19:3
in type 1 and type 2 diabetes, 1:4
MIDD (maternally inherited diabetes and deafness), 7:9
MIDIA (Environmenal Triggers of Type 1 Diabetes), 11:5
Mid-sleep time on free days (MSF), 25:27–28
Migraine history, 5:22
Migration and acculturation, 13:14
Mild cognitive impairment (MCI)
antihyperglycemic medication trials, 24:13
consolidation effects in, 24:1–2
definition and classification of, 24:2
hypoglycemia and, 24:12
progression of, 24:3
with type 1 diabetes and, 24:5
type 2 diabetes and, 24:8
vascular impairment as component of, 24:2
Mysterious white matter hyperintensities in, 24:2
Millennium Cohort, 25:3
Mini Mental Status Examination, 24:1
Cognitive status measurement, 19:17
global cognitive status measure, 24:8
Minnesota
cognitive status with diabetes, 24:8
Multi-Ethnic Study of Atherosclerosis, 31:6
Rochester cohort, 32:2–3
Miscarriages
with celiac disease, 27:10
criteria for defining, 5:35
maternal glycemic control, 5:36
with gestational diabetes, 5:16
with type 2 diabetes, 5:14
Mississippi
cognitive status with diabetes, 24:8
pregestational diabetes prevalence, 5:5
racial/ethnic differences in stroke in diabetes, 19:7
Mitchell-Riley syndrome, 7:11
Mitochondrial diabetes, 6:18
Mitochondrial DNA mutations
A3243G mutation and diabetes, 6:18
with HIV antiretroviral therapy, 6:12
maternally inherited diabetes, 7:9
retinopathy association with, 21:29
3243A>G mitochondrial DNA point mutation, 7:9
Wolfram syndrome and, 7:8
Mitochondrial gene defects, 7:9
Mixed diabetes, 15:3
Mixed meal tolerance test (MMTT), 37:13
Model for End-Stage Liver Disease (MELD) score, 26:11–12
Moderate albuminuria. See Microalbuminuria
Modification of Diet in Renal Disease (MDRD), 22:3
MODY (maturity-onset diabetes of youth), 7:2–8.
See also Monogenic forms of diabetes characteristics of, 7:2–4
clinical presentation, 7:4
differential diagnosis of, 7:8
differentiating from types 1 and 2 diabetes, 7:8
epidemiology, 7:4
genetic bases for, 7:2–4
genetic counseling with diagnosis, 7:6
linkage mapping/linkage analysis, 14:2
management of, 7:4
MODY1, 7:5
MODY2 prevalence and presentation, 7:6
MODY3 mutations, 7:4–5
MODY4, 6–10, X, 7:7
MODY5 clinical presentation, 7:7
MODY10, 7:7
monogenic diabetes, 7:2
sulfonlyurea medications in, 7:6
type 1 diabetes in youth, 15:2
types of diabetes, 1:4; 7:1–2
Molecular mimicry, 6:5, 11:8
Monoclonal antibody studies
anti-CD3 intervention studies, 37:11–12
anti-CD5 trials, 37:11
anti-CD20 monoclonal antibody, 37:12
anti-CD25 (daclizumab), 37:12
anti-IL-1β monoclonal antibody, 37:13
Monogenic forms of diabetes, 7:1–27. See also MODY
abnormal cilia function, 7:12
classification and diagnosis of, 1:4
defective insulin synthesis/secreotion, 7:8
differential diagnosis of, 7:8
exome sequencing, 7:2
linkage mapping/linkage analysis, 14:2
maternally inherited diabetes, 7:9
neonatal diabetes mellitus, 7:9–10
pigmented hypertrichosis and insulin-dependent diabetes, 7:8–9
thiamine-responsive megaloblastic anemia, 7:8
type 1β diabetes, 7:8
Wolfram syndrome, 7:8
Monounsaturated palmitoleic acid isomers, islet cell autoimmunity association
in older patients, 17
35
36
1
36
antepartum hemorrhage, 22
albumin:creatinine ratio, 22:4
Muscularkeletal system malformations, 5:4
Musculoskeletal system malformations
Myelodysplastic syndrome, 5:6
Myocardial infarction
adiposity measurement association with, 24:25
dyslipidemia and hormonal contraception risks, 5:13
outcomes with intensive glucose control, 18:15
physical activity and risk for, 18:18
pregestational diabetes and, 5:23
pregestational diabetes, 5:23
pregestational diabetes and, 5:23
pregestational diabetes, 5:23
Myonecrosis, 30:14
Myristic acid, 11:10
Myoglobinuria
Molecular mimicry, 6:5, 11:8
emphysematous cholecystitis, 30:16–17
gestational diabetes prevalence trends, 4:5
hospital utilization, 40:26
hyperglycemic hyperosmolar state morbidity and mortality, 17:6
incidence of lactic acidosis, 17:8
lactic acidosis in diabetic patients, 17:9
lower extremity amputation, 16:8;
20:23,25
polynuropathy and autonomic neuropathy, 23:9
prevalence of stroke, 20:25
National Inpatient Sample
chronic hypertension/gestational diabetes risks, 5:33
deliveries with pregestational diabetes, 5:16
maternal death rate at delivery, 5:22
“near-miss” morbidity evaluation, 5:25
pregnancy-related stroke and hypertensive disorders, 5:22
risk factors for myocardial infarction, 5:23
sepsis prevalence and mortality, 5:24
stillbirth rates, 5:37
stroke before or during delivery, 5:22
types 1 and 2 diabetes in pregnancy trend, 5:14,16
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2:2
National Institutes of Health (NIH)
antibody measurement standardization, 15:2
diabetes definition, 2:3
National Kidney Foundation (NKF)
glomerular filtration rate determination, 22:3
screening for diabetic kidney disease, 22:4
National Maternal and Infant Health Survey (NMIIHS), 4:5,5:3
National Nursing Home Survey (NHHS)
diabetes prevalence in nursing homes, 16:4
diabetic complications predisposing to, 30:4
infections associated with diabetes, 30:7
long-term care utilization, 40:43
prevalence of dementia in diabetes, 24:10
rare trends in infections, 30:4
National Survey for Family Growth
contraceptive methods and use, 5:11–12
preexisting diabetes with pregnancy, 5:7,17
self-reported prevalence of diabetes, 5:6
National Vital Statistics Report
diabetes mortality from, 36:7
risks with chronic hypertension in pregnancy, 5:33
National Vital Statistics System (NVSS)
Apgar scores in newborns, 5:48
chronic hypertension with pregestational diabetes, 5:33
deliveries with pregestational diabetes, 5:16
diabetes mortality from, 36:5,8
gestational hypertension/pregestational diabetes, 5:34
hyperglycemic hyperosmolar state mortality trends, 17:6
infections associated with diabetes, 30:7
maternal mortality statistics, 5:21
mortality and morbidity with infections, 30:1
pregestational diabetes data, 5:3
pregestational diabetes prevalence during pregnancy, race/ethnicity, 5:17
Near-Miss Sample of Delivery Admissions
chronic hypertension with pregestational diabetes, 5:33
stroke and pregestational diabetes, 5:22
Native Americans. See American Indian/Alaska Native
Near-neighbor population
impaired glucose tolerance in, 1:18
impaired glucose tolerance progression to diabetes, 1:18
plasma glucose concentrations in, 1:13
NAVIGATOR trial, 6:12,38:9
Near-miss morbidity/mortality, 5:25
Necrotizing fasciitis, 30:13–14
NEI-VFQ-25 scores, 21:9
Neonatal complications
hyperbilirubinemia/jaundice, 5:71
hypertrophic cardiomyopathy, 5:68
hypocalcemia/hypomagnesemia, 5:71
large-for-gestational age infants, 5:55–56
major congenital malformations, 5:59–67
with maternal diabetes, 5:69–71
placenta characteristics, 5:67
placental contribution, 5:67
polycythemia, 5:68–69
pregestational diabetes and, 5:47–59
respiratory distress, 5:67–68
seizures, 5:49
shoulder dystocia, 5:55–59
small-for-gestational age with, 5:55
Neonatal diabetes mellitus (NDM)
6q24 imprinting defects with, 7:10
epidemiology, 7:9–10
gene defects, 7:1,9–10
INS gene mutations in, 7:10–11
monogenic diabetes, 7:2
other mutations, 7:11
permanent, 7:10–11
presentation, 7:9
transient, 7:10
Neonatal encephalopathy (NE), 5:2,49
Neonatal hyperbilirubinemia, 5:71
Neonatal hypoglycemia
association with macrosomia, 5:56
breastfeeding for prevention, 5:73
with maternal diabetes, 5:49,69
MODY3 clinical presentation, 7:4
with pregestational diabetes, 5:70–71
Neonatal mortality and morbidity
early induction for birth trauma prevention, 5:59
interpregnancy interval for diabetic women, 5:7
in large-for-gestational age infants, 5:56
polycythemia, 5:68–69
with pregestational diabetes, 5:47–71
respiratory distress, 5:67–68
Nephropathy. See Diabetic kidney disease
Nervous system
myelinated fibers in neuropathy, 23:5
nerves susceptible to focal neuropathy, 23:3
quantitative sensory testing, 23:5–6
Netherlands. See Dutch investigations
Neuroarthropathy. See Charcot neuroarthropathy
NEUROG3 (Neuregulin3) gene, 7:11
Neurologic impairment in lactic acidosis, 17:8
Neuropathic arthropathy. See Charcot neuroarthropathy
Neuropathic foot, 23:5
Neuropathic pain, 23:2,9,28:18
Neuropathy Disability Score (NDS), 20:18,23:5
Neuropeptides
appleton regulation, 7:11,25:20
prohormone convertase cleavage of, 7:11
Neurotoxic effects of glucose, 19:9
Neutral Protamine Hagedorn (NPH) Insulin cancer risk vs. insulin glargine, 29:11
hypoglycemic episodes with insulin pump, 15:17
Neutrophil gelatinase-associated lipocalin (NGAL) 22:2,9
Nevada, total preexisting diabetes during pregnancy, 5:14
New Hampshire, periodontitis prevalence, 31:4,6
New Jersey
mortality by race, 35:7
stillbirth rates with diabetes, 5:37
New Jersey 725 study
hypothesis predictor of mortality, 35:11
macular edema-socioeconomic status association, 21:29
retinopathy in African Americans, 21:27
type 1 diabetes mortality and race, 35:4–5
New Mexico
age-adjusted total preexisting diabetes during pregnancy, 5:14
periodontitis prevalence, 31:4,6
prevalence of diagnosed diabetes, 3:4
U.S. centers for SEARCH, 15:4
U.S. vs. non-U.S. countries diabetes prevalence, 2:2
U.S. vs. non-U.S. Native American populations, 2:2
New York City. See also Northern Manhattan Study (NOMAS)
Hispanic/Latino population, 3:7
metabolic syndrome prevalence, 13:22–23
New York City Health and Nutrition Examination Survey, 13.22–23

New York State. See also Northern Manhattan Study (NOMAS)
Multi-Ethnic Study of Atherosclerosis, 31.6
self-reported periodontal disease, 31.6
total diabetes percentages, 8.9

New Zealand
diabetes registries, 2.5
diabetic retinopathy prevalence in youth, 15.20
type 1 diabetes incidence in children, 2.10
type 1 vs. type 2 diabetes pregnancy losses, 5.43

NF-kappaB activation in pathogenesis of neuropathy, 23.7

NHANES data
A1c, fasting glucose, and 2-hour plasma glucose combination, 9.5
A1c and fasting glucose cutpoints, 1.26
A1c levels and insomnia symptoms, 25.9
A1c levels in diagnosed and undiagnosed diabetes, 20.6
A1c sensitivity and specificity vs. oral glucose tolerance, 1.12
ADA A1c vs. fasting glucose measures, 1.20
albumin:creatinine ratios and risk with diabetes, 22.19
alcohol consumption, 10.9
awareness before screening, 1.27
cardiovascular complications in older adults, 16.6–7
chronic kidney disease prevalence by type of diabetes, 22.12
data collected, 3.9
data on type of diabetes, 2.2–3
depression prevalence, 33.2
diabetes and anti-HCV antibodies, 26.8–9
diabetes burden in youth, 15.8–10
diabetes definition in, 2.4
diabetes in older adults, 16.1–3
diabetes risk factor control, 41.3
diabetes risk with short sleep, 25.3
diabetes type and level of amputation, 20.24
diabetic foot ulcers, 20.20
diagnosed/undiagnosed trends, 3.19–20; 36.3
disability/impairment status, 34.7–8
estimated prediabetes prevalence, 13.16
estimated prevalence of retinopathy and vision-threatening retinopathy, 21.12
experimental design of, 3.3–4
eye examination in persons with diabetes, 21.31
fatty liver disease prevalence in diagnosed diabetes, 26.3
foot lesions on presentation with diabetes, 20.16
fracture prevalence, 32.3–4

gallstone disease with diabetes, 26.15

gingival bleeding and retinal hemorrhage risk, 31.15
glucose tolerance in women age 20–44 years, 4.8.10
glycemic control trends, 41.3–4
HCHS/SOL study prevalence comparison, 3.12
healthcare utilization and insurance coverage, 42.11
hearing deficits with diabetes, 23.10
heart disease prevalence with/without diabetes, 18.4
heart rate and hyperglycemia association, 23.13–14
hepatitis and diabetes, 26.8, 10–11
hyperinsulinemia prevalence trends, 1.18
incident fractures, 32.2
intermittent claudication risk factors, 20.7–8
liver and gallbladder disease, 26.2
lower urinary tract symptoms with diabetes, 28.5
measurement and criteria, 9.2
medication use and self-care practices, 39.1–14
metabolic syndrome and cardiovascular risk, 18.9–10
oral health and diabetes, 31.2–3
overall all-cause mortality rate, 36.5
periodontal disease and kidney disease relationship, 22.38
periodontitis prevalence, 31.6
peripheral arterial disease associations, 20.9–10
physical activity, 10.12, 14–15
physical limitations associated with diabetes, 34.3
population factors in increased prevalence, 3.19
pregestational diabetes prevalence during pregnancy, 5.18
prevalence and trends in diabetic persons, 21.1.2
prevalence in women of childbearing age, 5.4–5
prevalence of cataracts with diabetes, 21.33
prevalence of diabetes, 36.3
prevalence of elevated albumin excretion, 22.12
prevalence of elevated AST and ALT, 26.3
prevalence of rheumatoid arthritis, 32.17
prevalence of type 1 diabetes, 11.12;
2.10–11
prevalence of type 1 diabetes in youth, 15.5
race/ethnicity differences in retinopathy, 21.29–27
race/ethnicity variations in A1c levels, 1.11
racial/ethnic diabetes trends, 1.12
retinopathy cross-association with metabolic syndrome, 21.26
retinopathy data and FPG cutpoints, 1.13
risk factor control trends, 41.3–10
risks factors for hearing loss, 23.12
self-care practices with diabetes, 39.1.8–9
self-reported healthy and ulcer diagnosis, 20.20
sensory impairment and A1c levels, 23.12
sociodemographic characteristics, 8.3–4
soda consumption, 10.11
stroke risk without diabetes, 19.9–10
survey characteristics and use, 41.3
surveys for diabetes surveillance, 2.5
total diabetes prevalence, 3.9
type 2 diabetes incidence and prevalence, 3.3–4
undiagnosed diabetes detection, 3.3–4, 9
urinary albumin excretion, 22.12
urinary incontinence association with neuropathic pain, 28.18
U.S. adult prevalence and incidence data, 2.2–3

NHIS data
adult diabetes hospital use, 40.39
age-related macular edema, 21.38
ambulatory care services use, 42.2
(cancer in adults with and without diabetes, 29.2
cataracts with type 2 diabetes, 21.33
cost of diabetes model, 40.59
data collected, 8.3
dental care utilization, 31.39
diabetes in older adults, 16.1–2, 5

diabetes mortality from, 36.7
diagnosed diabetes estimates, 3.15
diagnosed diabetes prevalence, 3.4–9
diagnosed diabetes prevalence plateau in, 3.17
diagnosed diabetes prevalence trends, 3.17
disability and diabetes, 34.3
diabetes diagnosis and trends from, 31.32
diabetes examination in persons with diabetes, 21.31
HCHS/SOL study prevalence comparison, 3.7
health insurance coverage, 42.11
healthcare utilization and diabetes costs, 40.2
healthcare utilization and insurance coverage, 42.11
hospital utilization, 40.26
insurance prevalence and types of coverage, 42.16–17
lower extremity amputation frequency, 20.23
lower extremity amputations, 16.8
medication and self-care practices, 39.1–14
neuropathy manifestation prevalence, 23.10
physical activity, 10.12–13
prevalence of diabetes, 36.3
prevalence of heart disease with/without diabetes, 18.4
prevalence of screening, 1:25 self-reported glaucoma with diabetes, 21:36

Niacin, 6:12 Nicotinamide trials, 37:5, 14


Nitric oxide (NO), 19:3 in adaptive immunity, 30:18 hemodynamic regulation of kidney, 22:35, 37 interleukin-18, 13:19 in peripheral arterial disease, 20:1 susceptibility to stroke, 19:3

Nitric oxide synthase (eNOS) expression in diabetic kidney disease, 22:8 in podocyte injury, 22:8 retinopathy, 21:29

Nonalcoholic fatty liver disease (NAFLD) in Alstrom syndrome, 7:12 description/diagnosis, 26:2–3 and diabetic medication effects, 26:4 mortality with type 2 diabetes, 26:6 pathophysiology and progression, 26:5–6 prevalence in U.S., 26:2

Nonalcoholic steatohepatitis (NASH) all-cause mortality association, 26:7 directionality of diabetes association, 26:6 hepatocellular carcinoma risk with, 26:6–7, 12 liver enzymes with, 13:20; 26:4 liver transplantation, 26:12 necroinflammatory condition, 26:2–3 nonalcoholic fatty liver progression to, 26:5 progression to cirrhosis, 26:6


North American studies. See also DCCT study; Meta-analyses; SEARCH for Diabetes in Youth birth weight and type 2 diabetes risk, 13:13 disability and diabetes association, 34:3 gestational age at delivery with diabetes, 5:45 nephropathy risk with type 2 diabetes, 15:17 preeclampsia risk with type 1 diabetes, 5:34 prevalence of DKA at onset, 15:17 prevalence of preexisting diabetes during pregnancy, 5:17 proinsulin prediction of heart disease in men, 18:11 seafood consumption and type 2 diabetes risk, 13:8 shoulder dystocia with vaginal delivery, 5:56

sleep apnea rates, 25:12 stillbirth rates in, 5:37


North Dakota. See also American Indian/Alaska Native albuminuria with type 2 diabetes, 22:18, 30 metabolic syndrome in, 13:23

Northern Manhattan Study (NOMAS). See also New York City; New York State hyperglycemia as stroke risk, 19:9 insulin resistance and stroke risk, 19:9 ischemic stroke and metabolic syndrome, 19:10 stroke incidence ratio racial differences, 19:7 stroke subtypes in diabetes, 19:8

Northwestern University Diabetes and Pregnancy Center, Pima Indian study, 4:12


Nuchal translucency, 5:67

Nuclear cataract, 21:34


Nursing home activity of daily living limitations, 40:48 chronic conditions, 40:47
duration of stay, 40–49
ev environment, 40–44
living arrangements before admission, 40–46
payment sources, 40–50
resident demographics, 40–44–46
**Nutrition**

alcohol consumption, 13:9
calculus, 10:10
carbohydrates, 10:4–5
cereal/grain exposure and type 1 diabetes, 15:11
cholesterol, 10:7
coffee, 13:9
dairy, grains, beverages, 10:11–12
dietary carbohydrate and fiber, 13:6
dietary fat, 13:6
dietary patterns, 13:9
fetal exposure to famine and diabetes risk, 13:13
fiber, 10:7–9
food items and groups, 13:8–9
fruits and vegetables, 10:10–11
gluten-free diet effects, 27:14
high-protein diet and diabetes with risk for kidney damage, 22:35–36
islet cell autoimmunity and early cereal exposure, 27:14
micronutrients, 13:6–7
periconception and maternal, 5:11
protein, 10:5
restricted protein intake with kidney disease, 22:52–53
saturated fat, 10:5–6
seafood consumption and type 2 diabetes risk, 13:8
sodium intake, 10:10
sodium intake modification, 22:53–54
sugar-sweetened beverages, 13:10
tooth loss consequences, 31:34–36
total calories, 10:2
total fat, 10:2–4,7
vitamins, 10:10
whole-grain/fasting insulin levels, 13:5

congenital heart defect association, 5:10
contraceptive nonuse in, 5:11
contribution to disability with diabetes, 34:11
in diabetes of youth, 15:33–34
duration of, 13:11
eye early childhood breastfeeding and, 13:13
with eating disorders, 33:20–21
effects on gestational diabetes prevalence trends, 4:8
fetal overweight pathway for, 15:12
general and abdominal, with diabetes, 9:14
in geriatric population, 16:5–6
increased risk with sleep disturbance, 25:10–11
insulin resistance with, 1:3
insulin resistance with binge eating disorder, 33:21
intrauterine exposure to diabetes, 4:12
leptin modulation by, 25:10–11
macrophage infiltration of adipose tissues, 13:18
major malformation association with, 5:67
measures for, 18:10,11
metabolic syndrome prevalence with, 13:21
nonpregnant women age <20 years, 5:6
obesity in offspring with exposure to maternal diabetes, 5:73–74
in older adults, 16:1
oral contracptive effectiveness in, 5:13
pregestational diabetes prevalence in pregnancy, 5:19
prevalence in youth population, 2:3
pro-opiomelanocortin and, 7:11
relation to diabetes prevalence, 3:17
risk factor for diabetic kidney disease, 22:37–38
risk factor for heart disease, 18:2–3,9–11
risk factor for type 2 diabetes, 13:12;
18:10
risk for type 2 diabetes with, 18:10
signaling to melanocortin receptors, 7:11
sleep and circadian disturbances with, 25:10–11
stratification by BMI and waist measures, 13:12
structural changes in kidney with, 22:37
“thirsty” obesity pathway for, 15:12
in treated type 1 diabetes, 1:5
in type 1 diabetes in youth, 15:11
in type 2 diabetes in youth, 15:2
in utero exposure to maternal diabetes, 15:13
**Obesity. See also Abdominal obesity adipocyte function, 25:11
adiposity measurement for, 18:10
amniotic fluid insulin concentration, 15:12–13
anthropometric measures of fat distribution, 13:11–12
BMI criteria for, 13:11
body fat distribution, 13:11–12
breastfeeding and, 15:13
breastfeeding protective effect from, 13:13–14, 15:13
changes in children’s diets, 15:12
children with diabetic mothers, 5:74–75
in classification of diabetes, 2:3

**Odds ratio (OR) definition, 12:3

**Ohio**
diabetes in youth burden, 15:4
fetal overweight, 5:56
large-for-gestational age with pregestational diabetes, 5:70
preconceptual care use, 5:8
prevalence of diagnosed diabetes, 3:4
spontaneous abortion, 5:36
standardization of type 1 diabetes cohorts, 35:12
subclinical cardiovascular disease, 15:34,37
total diabetes prevalence, 8:9
type 2 diabetes incidence trends, 15:9
U.S. vs. non-U.S. countries for type 1 diabetes, 2:2

**Ojibwa-Cree community, 15:12. See also American Indian/Alaska Native**

**Oklahoma Indians. See also American Indian/Alaska Native**
albuminuria with type 2 diabetes, 22:18,30
metabolic syndrome in Native Americans, 13:23
neuropathy prevalence, 23:10
retinopathy/socioeconomic status relationship, 21:29

**Older adults. See also Geriatric diabetes Omega-3 fatty acids, 11:12
Onphalocele, 5:65,66
1,5-anhydroglucitol (1,5-AG), 1:21
1-acylglycerol-3-phosphate-O-acyltransferase 2, 7:15
1-hour plasma glucose, 1:19
1000 Genomes Project, variants in type 2 diabetes genetics, 14:9–10
Ongoing Telsimarten Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET), 22:49
Onychomycosis, 30:11
Open-angle glaucoma. See Glaucoma
Operative vaginal delivery. See Vaginal delivery
Ophthalmoscopy
glycemia assessment on, 1:16
retinopathy detection by, 21:31
Opportunistic screening, 1:24
Optic nerve
damage in glaucoma, 21:36
diabetic papillopathy, 21:39
in diabetic retinopathy, 21:12
in optic neuropathy, 21:37
Optic neuropathy, 21:37–38
Oral contraceptive use
diabetes induced by progestins and, 6:13
eye pregnancy use and structural birth defects, 5:11
retinopathy risk with, 21:26
Oral diabetes medications
diabetes treatment, 39:2–3
guidelines for use, 18:15
with pancreateitis-related diabetes, 6:7
Oral glucose tolerance test (OGTT)
A1c comparisons, 1:15
A1c sensitivity and specificity vs. 1:12
criteria for testing in pregnancy, 4:2
disadvantages for diabetes diagnosis, 1:12
gestational diabetes follow-up, 4:12
in gestational diabetes screening, 4:4,7
glycemia cutoffs and definitions, 13:16
heart disease risk association, 18:7
insulin secretion indices from, 13:17
NHANES methods for, 9:2
presymptomatic diabetes diagnosis, 1:1
in screening vs. A1c, 1:26
with short sleep and insomnia, 25:29
Oral health and diabetes, 31:1–49
burning mouth/diabetic neuropathy, 31:37
candidiasis, 31:38
caries, 31:36
dental care utilization, 31:39–40
dental plaque, 31:3
diabetes effects on peri-implant disease, 31:23
dry mouth, 31:38
geographic location disparities in, 31:6
gestational diabetes risk with periodontitis, 31:14–15
gingivitis, 31:3,4
heart disease risks with periodontitis, 31:15
insurance claims data, 31:40–41
multidisciplinary treatment, 31:40–41
new type 2 diabetes with periodontitis, 31:14
NHANES data and critique of, 31:2–3
oral health-diabetes links, 31:41–42
periapical periodontitis, 31:22–23
periapical periodontitis/diabetes interaction, 31:7,15,16,17
peri-implant disease, 31:7,15,23
race/ethnicity disparity in periodontitis, 31:3–6
root fragments, 31:34
sociodemographic disparity in periodontitis, 31:6
tooth eruption rate with diabetes, 31:36
tooth loss consequences, 31:34–36
tooth loss risk with diabetes, 31:34
tooth loss/missing teeth with diabetes, 31:27–36
Oral insulin trials, 37:6–7
Oregon, preexisting diabetes during pregnancy, 5:13–14
Orexigenic neuropeptides, 25:20
Orlistat prevention trials
Pancreas or gut endocrine tumors, 32:4
Pancreatic cancer
increment-based diabetic therapy, 29:12
mortality from, 29:7–8
pancreaticogenic diabetes, 6:8–9
risk factors for, 6:7,8–9
Pancreatitis polypeptide (PP), 6:7
Pancreatitis-related (pancreaticogenic) diabetes
diagnosis and clinical characteristics, 6:7–8
F cells in, 6:7
hereditary/genetic pancreatitis, 6:8
increment-based therapy for, 29:12
pancreatic cancer, 6:8–9
pathophysiology, 6:7
Panic Disorder, 33:16
Panretinal photocoagulation, 21:7
Parasympathetic nervous system function
in cardiac autonomic neuropathy, 15:27;
23:6–7,13
cardiovascular autonomic function, 23:6
detrusor muscle dysfunction, 28:4
in functional gastrointestinal disorders, 27:3
Parietal cell antibodies (PCA), 11:16; 12:12;
27:16
Parvovirus infections, 11:8
Pathophysiology/pathogenesis
cystic fibrosis-related diabetes, 6:5–7
diabetic kidney disease, 22:5
gastrointestinal manifestations of diabetes, 27:4,8
gestational diabetes, 4:3
hemochromatosis, 6:10
hypoglycemia, 17:9
lower extremity amputation, 20:24
lower urinary tract symptoms, 28:4,14
malnutrition-related diabetes, 6:18
metabolic syndrome, 13:21
nonalcoholic fatty liver disease progression, 26:5
pancreatitis-related diabetes, 6:7
peripheral arterial disease, 20:17
sexual dysfunction, 28:6–10
stroke in diabetes, 19:3
subcategories of diabetes, 1:1
transient neonatal diabetes, 7:10
type 1 diabetes autoantibodies, 1:3
viral-mediated mechanisms for diabetes, 6:1–5
PAX4 (paired homeobox 4) gene, 7:7
PCS\textsubscript{K} (proprotein convertase subtilisin/kexin type)-1/3 and -2, 7:11–12
PDX1 (pancreatic and duodenal homebox) gene, 7:7, 11
Pediatric diabetes. See Children and adolescents
Pegylated granulocyte colony-stimulating factor (GCSF), 37:14
Penn State Cohort, 25:29
Pennsylvania, total diabetes percentages, 8:9
Pentadecanoic acid, 11:10
Pentamidine, 6:13
Pentoxifylline effects on kidney function, 22:54
Peptide-binding groove, 12:5
Peri-implant mucositis, 31:23
Peri-implantitis, 31:23
Peri-implant disease (PPD), 31:3–4, 8
Periodontal disease
complication rates with diabetes, 30:15
definitions of, 31:4
infections associated with diabetes, 30:15; 31:3
risk factors for diabetic kidney disease, 22:38
Periodontal probing depth (PPD), 31:3–4, 8
Periodontitis
bidirectional relationship with diabetes, 31:23–26
children and adolescents with type 1 diabetes, 31:18, 21
chronic periodontitis in U.S., 31:4–7
diabetes complication effects on, 31:19
diabetes complication risks with, 31:15
 diabetes-periodontitis interactive effects, 31:21
effect on diabetes, 31:8–9, 17
epigeneic programming of risk, 28:5
geographic location disparities, 31:6
gestational diabetes, 31:14–15, 22
glycemic control, 31:9–14, 17–18
HOMA-IR model and, 31:8
hyperglycemia effects on, 31:21
indicator for undiagnosed prediabetes, 31:21
measurement and definitions for, 31:3
metabolic syndrome interactions with, 31:21
overt diabetes relationship with, 31:17
prediabetes effects on, 31:22
prevalence in type 2 diabetes, 31:17
prevalence in U.S., 31:4–6
prevalence in well-controlled diabetes, 31:17
racial/ethnic disparity in, 31:4–6
risk factors for diabetes/hyperglycemia and, 31:23
risk with type 2 diabetes in adults, 31:19–21
Sea Island Gullah African Americans, 31:21
socioeconomic status disparity, 31:6
type 2 diabetes development in, 31:14
U.S. state level prevalence, 31:6
Peripheral arterial disease (PAD), 20:1–34.
See also Foot ulcers in diabetes
abdominal adiposity association, 20:11
adiposity relation with, 20:11
ankle-brachial index, 20:2, 3
atherosclerosis pathophysiology, 20:1–2
calcium blood association, 20:9
cardiovascular outcomes with, 20:14–15
data sources and limitations, 20:3–4
diabetes and risk factors for, 20:5–7
diabetes treatment and disease risk, 20:12
diagnostic criteria for, 20:6
in disability with diabetes, 34:11
exercise testing for diagnosis, 20:3
frequency of insulin use, 20:12
homocysteine levels association, 20:8
hypercholesterolemia as risk factor for, 20:8
hypertension as risk factor for, 20:7
inflammation and, 20:8–9
invasive measurement of, 20:2
lower extremity amputation with, 20:24
noninvasive measurement, 20:2–3
presentation symptoms, 20:1–2
prevalence of, 20:4
progression and cardiovascular outcomes, 20:12–14
renal dysfunction association, 20:9–11
renal dysfunction with, 20:10
revascularization with, 20:13–14
smoking as risk factor for, 20:7
symptom-based diagnosis, 20:3
Peripheral Nerve Society, 23:5
Peripheral neuropathy. See Diabetic neuropathies
Perivascular nitrergic nerves, 19:3
Permanent neonatal diabetes (PNDM), 7:9, 10–11
Pernicious anemia, 27:15, 16
Peroxisome proliferator-activated receptor gamma (PPAR\(\gamma\)). See PPAR\(\gamma\)
Persistent albuminuria. See Albuminuria
Persistent postpartum diabetes, 1:29
Petamidine, diabetes induced by, 6:13
Pharmacologic intervention, type 2 diabetes prevention, 38:5, 11
Phenformin, lactic acidosis precipitation, 17:8
Phenotype
autoimmune type 1 diabetes and obesity, 15:3
correlation with genotype, 12:12
diabetes, 6:2
diabetes with IFP, 6:14
epigeneic changes and, 22:45
factors determining diabetes, 6:4
genotype correlations in INS mutations, 7:12
for insomnia, 25:29
linkage analysis in type 2 diabetes, 14:2, 6, 10
linkage analysis of, 14:2
with lipodystrophies, 7:13, 16–18, 20, 21
metabolic syndrome, 13:24, 18:9
with mitochondrial diabetes, 6:18
with MODY, 7:7–8
neonatal diabetes mellitus, 7:11
with pancreatitis-associated diabetes, 6:7
single nucleotide polymorphism and, 14:10
in Williams syndrome, 6:17
Phenotypic type 2 diabetes antibodies found in, 1:5–6
disease complexity, 14:6
insulin processing defects, 7:12
Phentermine-topiramate combination trial, 38:10
Pheochromocytoma, 6:15
Philadelphia Pediatric Diabetes Registry, 2:5, 7, 15:4
Physical activity
by age, 10:14
covariates for heart disease risk, 18:12
decline in children and adolescents, 15:12
effects on A1c levels, 18:18–19
inactivity risk factor for type 2 diabetes, 13:10–11
leisure-time, 3:17
MET hours, 10:15
in older adults, 16:1
relationship to retinopathy, 21:27
with type 2 diabetes, 10:12
Picornaviruses, 12:6
Pigmented hypertrichosis and insulin-dependent diabetes (PHID), 7:8–9
Pima Indian studies. See also American Indian/Alaska Native
ALT level and risk for diabetes, 26:5
breastfeeding and type 2 diabetes, 15:13
candidate genes for ESRD in, 22:43
diabetic ESRD in, 22:27
epigeneic programming from in utero exposure, 22:42
ESRD incidence and in utero diabetes exposure, 22:42
fetal overnutrition effects in, 15:12
gallstone prevalence in, 26:13
GGT levels association with diabetes, 26:5
glomerular filtration in, 22:9
Index—48
glucose intolerance to type 2 diabetes conversion, 13:16–17
heritability of type 2 diabetes, 21:29
hyperglycemia as risk for kidney disease, 22:30
incidence of ESRD with obesity, 22:37
incidence of proteinuria, 22:16
increasing prevalence of type 2 diabetes, 15:9
insulin resistance measures in, 13:17
longitudinal periodontitis study, 31:20–21
microalbuminuria prevalence in, 15:24;
22:14
mortality from kidney or cardiovascular disease, 22:20–21
mortality in diabetes of youth, 15:38
nephropathy with type 2 diabetes, 15:24
obesity trends in, 22:37
overweight prevalence in youth, 15:12
periodontitis severity, 31:17, 21
plasma glucose concentrations in, 1:13
predictive power of impaired fasting glucose and glucose tolerance, 1:20
proteinuria in offspring, 22:43
proteinuria in offspring with intrauterine exposure, 15:24
proteinuria with type 2 diabetes in offspring, 22:32
retinopathy data and fasting glucose cutpoints, 1:13
retinopathy incidence in, 15:18; 21:29
survival with normal albuminuria, 22:19–20
type 2 diabetes development in, 1:3, 13, 20, 22
type 2 diabetes prevalence in, 31:15–16
type 2 diabetes risk with maternal diabetes, 15:13
type 2 diabetes/periodontitis association, 31:15–16
in utero exposure to maternal diabetes, 4:12–13; 22:42
worsening kidney function and death rates in, 22:20–21
Pioglitazone
ACT NOW prevention study, 38:10
bladder cancer association with, 29:11
bone loss and fractures with, 32:12
cancer risk in preclinical studies, 29:11, 13
diabetes risk reduction with, 38:13
myocardial infarction risk with, 24:13
safety update on, 38:13
type 2 diabetes and macrovascular disease, 19:13–14
Pittsburgh Epidemiology of Diabetes Complications Study (EDC). See Epidemiology of Diabetes Complication Study (EDC)
Pittsburgh Sleep Quality Index (PSQI), 25:9
Placenta previa, 5:24–25
Placental abruption, 5:24–25, 43
PLAGL1 (pleiomorphic adenoma gene-like 1) gene, 7:10
Plasma glucose measurements
A1c comparisons, 1:14–15
criteria for diabetes diagnosis, 1:2
cutpoints for diagnosis, 1:13
in pediatric age group, 1:14
Plasmid-encoded proinsulin effects, 37:14
Plasminogen activator inhibitor-1 (PAI-1), 13:19–20
PLIN1 gene
mutation in familial partial lipodystrophy, 7:1, 19
Pneumocystis carinii, 6:13
Podocytes
alterations induced by diabetes, 22:8
type 1 diabetes changes in, 22:8–9
type 2 diabetes changes in, 22:8–9
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy), 6:16
Poland
immunotherapy trials, 37:14
prepregnancy glycemic control, 5:10
type 1 diabetes incidence, 2:7
Polio model of type 1 diabetes, 11:1, 6–7
Polycystic ovary syndrome (PCOS), 13:21;
33:22
Polycythemia, neonatal, 5:68–69
Polyhydramnios, 5:45–46
Polymerase chain reaction
in Rabson-Mendenhall and Donohue syndrome, 25:18
Polyphylla
impaired glucose tolerance, 3:12
Postprandial glucose intolerance
type 2 diabetes development in, 1:3, 13, 20, 22
type 2 diabetes prevalence in, 31:15–16
type 2 diabetes risk with maternal diabetes, 15:13
type 2 diabetes/periodontitis association, 31:15–16
in utero exposure to maternal diabetes, 4:12–13; 22:42
worsening kidney function and death rates in, 22:20–21
Prediabetes
A1c definition of, 3:3
A1c detection of, 3:15
A1c levels and insomnia symptoms, 25:9
2-hour plasma glucose, 9:6
cutpoints of biomarkers, 9:2
data sources, 3:2–4
detection by A1c/FPG/2-hour plasma glucose, 3:15
diabetes and anti-HCV antibodies, 26:8–9
diagnostic criteria for, 1:5–6; 9:2
disability/impairment status, 34:7–8
effects on periodontitis severity, 31:22
estimated rate of, 13:16
fetal effects in, 4:2
fracture incidence, 32:6
gallstone disease prevalence in, 26:15–16
glycemia cutoffs and definitions, 13:16
glycemic criteria for, 1:1
high-risk range for diabetes, 1:13
increased risk with short sleep duration, 25:3
inflammatory response, 9:23
insomnia and lifestyle, 25:9
maternal, 4:4
Postprandial insulin response. See Insulin response
Posttraumatic stress disorder (PTSD), 33:16
Poverty Income Ratio (PIR), 8:12
PPAR (peroxisome proliferator-activated receptor)
alpha gene and acarbose, 38:11
delta gene and acarbose, 38:11
gamma gene, 38:11
PPARG (peroxisome proliferator-activated receptor-gamma) gene
cod liver oil interaction type 1 diabetes risk, 11:16
in familial partial lipodystrophies, 7:19
gamma coactivator (PGC-1), 38:11
ligand for anti-inflammatory actions, 11:16
mutation in familial partial lipodystrophy, 7:1
single nucleotide polymorphisms of, 14:2;
38:11
thiazolidinedione target coding, 7:20;
14:11
type 2 diabetes risk factor, 7:11
PPAR-γ (peroxisome proliferator-activated receptor gamma)
bone loss with, 32:12
in familial partial lipodystrophies, 7:19
omega-3 fatty acids and, 11:16
risk factor for type 2 diabetes, 7:11
stroke incidence with diabetes, 19:1
in type 2 diabetes, 14:2
Prader-Willi syndrome (PWS), 6:16–17
Preconception diabetes. See also Preexisting diabetes with pregnancy
definition, 5:3
low utilization of care, 5:8
Preconception planning/counseling/care, 5:35
missing teeth in, 31:32
in nonpregnant women of childbearing age, 5:4–5
in older adults, 16:3
oral health effects in, 31:8
overall prevalence, 3:13
periodontitis as indicator of, 31:21
periodontitis prevalence, 31:17
prevalence by A1c/FPG/2-hour PG, 3:15–16
prevalence of, 3:13–14
prevalence trends by A1c/FPG measures, 3:20
prevalence trends in, 3:18–21
preventive behavior in, 1:27
race/ethnicity, 3:13–14
screening for, 1:27
sex differences in, 3:13–14
subclinical proinflammatory condition in, 13:18
use as classification, 1:17

“Prediabetic” neuropathy. See Distal symmetrical polyneuropathy

Prediction models for type 2 diabetes risk, 13:24

Preeclampsia
complications with vaginal delivery, 5:25
diabetes vs. control, 5:34
diagnostic criteria, 5:30
gestational diabetes treatment effects, 4:11
gestational diabetes with chronic hypertension, 5:33
microalbuminuria predictive value of, 5:29
planned preterm delivery with, 5:45
preeclampsia diagnostic criteria, 5:30
pregestational diabetes and with chronic hypertension, 5:34–5
prophylactic aspirin treatment, 5:35
rates with types 1 and 2 diabetes, 5:34
reduction with treatment, 4:3
retinopathy with type 2 diabetes, 21:26
risk factor for venous thromboembolism, 5:23
risk factors for preeclampsia, 5:35
risk with sleep disturbances, 25:21
stillbirth complications, 5:43
stroke association with maternal diabetes, 5:22
type 1 vs. 2 diabetes, 5:35

Preexisting diabetes with pregnancy, 5:1–106. See also Maternal diabetes
birth certificate/hospital record data, 5:13
birth condition and sequelae, 5:48–49
breastfeeding, feeding, 5:73–74
cesarean deliveries, 5:46–47
chronic hypertension prevalence with, 5:33
genital heart defects, 5:67
genital malformation with, 5:59–67
contraception for diabetic women, 5:10–11
data sources and limitations, 5:3–4, 13
definition, 5:3
delivery complications, 5:45–46
diabetes development, 5:73
disparities by race/ethnicity, 5:17–19
DKA in, 5:25
everterm deliveries with, 5:16
epidemiologic studies of management in, 5:72–73
fetal complications before delivery, 5:35–44
gestational hypertension prevalence in, 5:34
historical context, 5:2–3
hyperbilirubinemia and jaundice, 5:71
hypertensive disorders in, 5:30–35
hypocalemia/hypomagnesemia, 5:71
hypoglycemia, 5:26
large-for-gestational age, 5:55–56
major maternal morbidity with, 5:24
management for, 5:72–73
maternal age, 5:16
maternal complications before and during pregnancy, 5:21–35
maternal risks, 5:2
mental and psychomotor development of children, 5:75–76
metabolic control and outcomes in, 5:3
micro/macroalbuminuria prevalence with, 5:29
mild/severe preeclampsia/eclampsia, 5:34
neonatal, perinatal, and infant mortality, 5:47
neonatal cardiomyopathy with, 5:68
neonatal complications with, 5:47–71
neonatal hypoglycemia and, 5:69–71
nephropathy with, 5:29–30
neuropathy with, 5:28–29
non-Hispanic Asian/Pacific Islander, 5:17
nonpregnant women age 15–19 years, 5:6–7
obesity, metabolic syndrome, 5:74–75
objective and historical context, 5:2–3
obstetric morbidity in, 5:24–25
peripartum myocardial ischemia, 5:23
placental characteristics in, 5:67
polycythemia, 5:68–69
preconception care utilization with, 5:7–8
preconception glycemic control and malformations, 5:10–11
preeclampsia frequency in, 5:34–35
pregnancy outcomes with diabetes, 5:37
pregnancy planning, 5:4–13
pregnancy planning and contraception, 5:6–7
pregnancy-related myocardial infarction risk, 5:23
prepregnancy neuropathy frequency, 5:28–29
preterm delivery in, 5:45–46
prevalence during pregnancy, 5:13–17
prevalence in women of childbearing age, 5:4–7
prevalence of preexisting diabetes during pregnancy, 5:13–21
rates with pregnancy, 4:7–8
respiratory distress, 5:67–68
retinopathy, 5:26–28
risk factor for thromboembolism, 5:23
risk for antepartum venous thromboembolism, 5:23
“at risk” prevalence at age 15–44 years, 5:4
sepsis likelihood with, 5:24
simulated estimates of, 5:18
smoke-for-gestational age with, 5:55
spontaneous abortion, 5:35–36
stillbirth rates, 5:37, 43
stroke and hypertensive disorder, 5:22
studies on, 5:102–106
total during pregnancy, 5:13–14
type 2 diabetes, 5:14–15
type 2 diabetes in pregnancy trends, 5:16
types 1 and 2 diabetes in pregnancy trend, 5:14
undifferentiated diabetes in pregnancy trends, 5:15
vaginal delivery with shoulder dystocia, 5:56–59
in women of childbearing age, 5:3–4

Pregestational diabetes. See Preexisting diabetes with pregnancy

Pregnancy
A1c levels in, 5:10
cesarean delivery, 5:46
chronic proteinuria with, 5:29
complications and maternal age, 5:16
consecutive diabetic pregnancy mortality, 5:22
depression risks with diabetes, 33:9
depressive symptoms with diabetes in, 33:9
DKA with type 2 diabetes, 5:25
elements of care for glyceromic control, 5:72
insulin-induced hypoglycemia, 5:26
intensive vs. conventional insulin therapy in, 5:26
interpregnancy interval for diabetic women, 5:7
kidney function in diabetic vs. nondiabetic pregnancy, 22:40
maternal deaths with diabetes, 5:21
neuropathy prevalence in pregnancy with type 1 diabetes, 5:28–29
oral glucose tolerance testing in, 4:2
outcome with mild chronic hypertension, 5:33
perinatal morbidity and mortality with twin, 5:67
periodontal bacteria and inflammation with, 31:25
planning for diabetic women, 5:7
preconception care utilization, 5:7–10
preconception planning/counseling, 5:8
with pregestational diabetes, 5:1–76
pregnancy effects on, 5:29
prenatal hyperglycemic testing, 5:10
preterm delivery, 5:46

Index—50
prevalence of complication by diabetes status, 5:3
prevalence of preexisting diabetes during pregnancy, 5:13–21
retinopathy development or progression with, 21:26–27
retinopathy progression time course in, 5:26–27
risk factors for diabetic kidney disease, 22:40–41
sleep changes during, 25:21
sleep disturbances during, 25:21
slow wave sleep during, 25:21
spontaneous abortions with type 1 diabetes, 5:35–36
terminations for malformations, 5:43,62
with type 1 diabetes, 5:2
unintentional with diabetes, 5:8
unplanned, 5:11
Pregnancy Risk Assessment Monitoring System (PRAMS)
2009 postpregnancy survey, 5:17
limitations of data, 5:5
pregestational diabetes prevalence during pregnancy, 5:18
prevalence in women of childbearing age, 5:4
prevalence of preconception diabetes, 5:15–16
unintended pregnancies, 5:8
Pregnancy-induced hypertension (PIH). See Hypertensive disorders of pregnancy
Premature placental separation, 5:25
Presymptomatic diabetes. See Prediabetes
Preterm and Diamicron MR Controlled Evaluation. See ADVANCE trial
Preterm delivery, 5:45–46
chronic hypertension/ gestational diabetes risks, 5:33
preconception care of diabetic women, 5:7
sleep disturbance relation to, 25:21
spontaneous, 5:45
Preterm premature rupture of membranes, 5:46
Prevalence of total diabetes. See also other specific conditions and populations
NHANES and NHS data on, 3:4
prevalence, 3:9
prevalence age <20 years, 3:19
prevalence estimation, 3:3
state ranking for, 8:9
Prevention of Progression of Arterial Disease and Diabetes (POPADAD), 18:17
Prevention of type 1 diabetes, 37:1–21
alefacept trial, 37:13
alpha-1 antitrypsin, 37:13–14
anti-CD3 and anti-CD5 monoclonal antibody studies, 37:11–12
azathioprine early intervention, 37:7
bacille Calmette-Guerin vaccine early intervention, 37:7–11
cow’s milk consumption meta-analysis, 37:3
cyclosporine early intervention, 37:7
docosahexaenoic acid supplement, 37:5
etiology of type 1 diabetes, 37:1–3
glutamic acid decarboxylase intervention studies, 37:12
gluten exposure, 37:5
immunologic interventions, 37:3,13–14
interleukin-2 and rapamycin, 37:13
intranasal insulin trial safety trial, 37:6
nicotinamide trials, 37:5,14
oral insulin trials, 37:5,11
parenteral insulin trial, 37:6,7
primary prevention trials and enrollment criteria, 37:3–5
secondary prevention trials and enrollment criteria, 37:5,6,7
staging criteria, 37:2–3
tertiary prevention trials, 37:7
tertiary prevention trials and enrollment criteria, 37:7,11–12
thyroglobulin (antithyroglobulin) trial, 37:13
25-hydroxyvitamin D (25(OH)D) and, 11:11–12
vitamin D effects, 37:5
Prevention of type 2 diabetes, 38:1–21
See also Genetics of type 2 diabetes
acarbose in prevention study, 38:8,10
Bedford study, 38:2
Canadian Normoglycemia Outcomes Evaluation, 38:9–10
Da Qing study, 38:5
Diabetes Prevention Program, 38:6–8
early U.K. and Swedish studies, 38:2–5
extended follow-up of outcomes, 38:12–13
Finnish prevention study, 38:5–6
genetic contribution to, 38:11–13
glutamic acid decarboxylase vaccine trials in, 37:6–7
Indian Diabetes Prevention Programme, 38:8
intention-to-treat analysis, 37:3;
38:5–6,9,12
lifestyle intervention with Japanese men, 38:8,10
liрагlutide weight management study, 38:10–11
ramipril and rosiglitazone trial, 38:9
randomized controlled trials discussion, 38:13–16
SEQUEL secondary analysis/CONQUER, 38:10
troglitazone in Prevention of Diabetes, 38:8
vitamin D effects, 13:7
voglibose study, 38:9
Primary hyperaldosteronism, 6:15
Primary Oral Insulin Therapy Study (Pre-POINT), 37:5
Primary Prevention Project (PPP), 18:17
Proinflammatory cytokines
in adipose tissue dysregulation, 13:18
cortisol exposure and levels of, 33:14
with docosahexaenoic acid supplements, 37:5
pathway for diabetes-depression association, 33:14
with periodontal disease, 31:24
in response to sleep deprivation, 25:10
type 2 diabetes risk and adiponectin levels, 13:19
Proinflammatory processes
association with insulin resistance, 19:9
in atherosclerosis, 20:1
gut microbiome effects on, 11:8,14
hyperglycemia promotion of, 19:3
in kidney disease, 22:34,38
periodontal disease, 31:24
in prediabetes and insulin resistance, 13:18–19
with sleep and circadian disturbance, 25:10,21
Proinsulin
beta cell dysfunction assessment by, 13:17
effects of plasmid-encoded, 37:14
heart disease prediction by, 18:11
insulin processing defects, 7:11
meta-analysis for, 14:9
in metformin-treated patients, 38:6
plasmid-encoded proinsulin effects, 37:14
processing to insulin, 7:11
risk factor for cardiovascular disease, 18:11–12
SGSM2 gene and, 14:6
Proinsulin peptide effects, 37:14
Proinsulin-to-insulin ratios, 13:17
Proliferative diabetic retinopathy (PDR)
prevalence in early pregnancy, 5:26
risk factors, 21:7
risk for vision loss, 21:7
Pro-opiomelanocortin (POMC), 7:11
PRoSpective pioglitAzone Clinical Trial In macroVascular Events (PROactive), 19:13
Prostaglandin synthesis
DIABETES IN AMERICA, 3rd Edition
Protein metabolism
amino acid tissue uptake in diabetes, 1:6
diabetes, 1:2
Proteinuria. See also Albuminuria
definition of, 5:30
effects on serum creatinine in type 1 diabetes, 22:48–49
glucose intolerance prediction of, 1:18
incidence of proteinuria in type 2 diabetes, 22:16–17
preeclampsia diagnostic criteria, 5:30
in pregnancy, 22:40
in renal disease with diabetes of youth, 15:20
risk factor for retinopathy, 21:25
role of free fatty acids in, 22:35
visual impairment association, 21:7–8
Proximal motor neuropathy. See Diabetic radiculoplexus neuropathy (DRPN)
Proyecto Vision Evaluation and Research (VER)
- racial/ethnic differences in retinopathy, 21:28
- retinopathy/socioeconomic status relationship in Mexican Americans, 21:29

PRSS1 (cationic trypsinogen) gene, 6:8

Pseudomonas aeruginosa infections, 30:13,15,16; 37:14

Psychiatric/psychosocial issues, 33:1–34
- Bipolar Disorder prevalence with type 2 diabetes, 33:21
- depressive disorder and diabetes-related distress, 33:4–16
- diabetes care with, 41:12
- diabetes-related emotional distress, 33:3
- dysthymia prevalence, 33:2
- emotional distress, 33:4
- public health implications, 33:23–24
- schizophrenia, 33:21–22
- schizophrenia/autism risks in offspring, 33:21
- socio-cultural context/psychosocial issues, 33:23
- substance use and related disorders, 33:23
- subthreshold depressive symptoms and diabetes distress, 33:4
- treatment with comorbid Schizophrenia, 33:22
- type 1 diabetes risk and psychological stress, 11:15

Psychosomatic symptom checklist, 27:2

Psychotropic medications
- for addressing diabetes risks, 33:22
- mood stabilization with, 33:21–22
- type 2 diabetes risks with, 33:24

PTF1A (pancreas transcription factor 1A) gene, 7:11

PTPN22 gene
- dietary exposure interactions, 11:16
- mode of delivery interaction, 11:17
- single nucleotide polymorphism variant, 12:11
- type 1 diabetes association with, 11:3; 12:1; 32:15
- type 1 diabetes risk, 11:16; 12:6

PTRF gene
- caveolin-1 and -3 regulation, 7:16
- in congenital generalized lipodystrophy, 7:15,16
- mutations with congenital generalized lipodystrophy, 7:1

Puberty
- retinopathy relationship to, 21:23
- type 1 diabetes mortality onset at, 35:6

Public health surveillance/implications
- of childhood/adolescent diabetes, 2:4
- classification for pediatric surveillance in, 15:4
- definition, 2:5
- oral health-diabetes links, 31:41
- surveillance of type 1 diabetes, 2:4

Puerperal sepsis, 5:24

Puerto Ricans
- diagnosed diabetes prevalence, 3:7
- prediabetes prevalence, 3:14
- total cholesterol prevalence, 3:12
- undiagnosed diabetes prevalence, 3:12

Pulmonary embolism (PE)
- chronic hypertension/gestational diabetes risks, 5:33
- maternal mortality from, 5:22
- prevalence of, 5:24

Pulse-wave velocity (PWV), 15:34

PVT1 (plasmodia variant 1) gene, 22:43

Pyelonephritis
- acute renal failure with, 30:10
- emphysematous, 30:10
- with pregestational diabetes, 5:24
- in pregnancy, 5:24
- presentation of, 30:9–10
- prevalence of histologic, 22:55
- renal papillary necrosis with, 22:56
- risk with asymptomatic bacteriuria, 30:9
- urologic complications with type 1 diabetes, 22:56
- in women with diabetes, 28:20

Pyorrhea. See Periodontal disease

Q

Quality of care, 41:1–19
- age-related differences in risk factor control, 41:6–7,12
- appropriate measurements for, 41:11–12
- blood pressure, 41:6
- blood pressure control, 41:4–5
- clinical practice guidelines, 41:2–3
- defining quality care, 41:1–2
- evidence base for definition, 41:2–3
- foot and eye care with diabetes, 41:7
- geriatric diabetes care standards, 16:16
- glycemic control, 41:3–4,5–6
- high-quality care definitions, 41:2
- improvements needed, 41:13
- measurement tool for, 41:10,11
- monitoring groups for, 41:2
- performance measures and improvement initiatives, 41:10–11
- psychiatric/psychosocial issues in, 41:12
- racial/ethnic differences in risk factor control, 41:5–6,8,12
- regional variations in, 41:12
- retinopathy care, 41:5
- risk factor control trends, 41:2–10
- risk factor management for, 41:3,6–7
- for special populations, 41:12
- trends in children and adolescents, 41:12

Quality of life
- bone and joint complications, 32:1,14
- with diabetes in youth, 33:4
- disability effects on, 34:1–2
- with distal symmetrical polyneuropathy, 23:5
- for ethnic minorities with diabetes, 33:23
- with gastrointestinal disorders, 27:5,9,14
- with geriatric diabetes, 16:11
- oral health-related, 31:34,38,39,41
- with osteoarthritis, 32:14
- psychiatric/psychosocial issues, 33:15,16,18–19
- sexual dysfunction effects, 28:7
- urinary incontinence treatment, 28:14
- visual impairment and blindness, 21:9

Quality-adjusted life year (QALY)
- persistent postpartum diabetes treatment, 1:29
- screening costs and benefits, 1:27

Quantitative glycemic traits
- genetic determinants of, 14:2
- meta-analysis of, 14:3
- TBC1D4 gene, 14:3–4
- in type 2 diabetes, 14:1

Quantitative sensory testing (QST), 23:5–6

Quinoline-3-carboxamide

R

Rabson-Mendenhall syndrome, 7:12

Race/ethnicity. See also specific racial/ethnic groups
- A1c variations independent of glycemia, 1:11–12; 3:13,15
- with dementia, 24:3
- depressive episode likelihood, 33:9
- diabetes by age distribution, 8:7
- diabetes in older adults, 16:3
- differences in stroke in diabetes, 19:7
- ESRD variations, 22:29,58
- high-risk groups for, 15:9–10
- metabolic syndrome stratification by, 13:21
- MODY epidemiology, 7:4
- overweight in diabetes in youth, 15:12
- pediatric screening recommendations, 1:14
- prediabetes prevalence, 3:13
- preexisting diabetes with pregnancy, 5:17–19
- projections for type 1 diabetes, 2:10
- “stroke belt” region, 19:7
- “stroke buckle” region, 19:7
- trends in diabetes in youth, 15:6
- type 1 diabetes prevalence and incidence, 2:5,6
- type 2 diabetes
  - prevalence and incidence, 3:8,12–13
  - risk factors, 13:3–4
  - variants in specific populations, 14:6
- type 2 diabetes prevalence and incidence, 3:5
- types 1 and 2 diabetes in youth, 15:2

Raloxifene, 32:14

Ramipril (ACEI), 19:12; 22:49; 38:9

Rancho Bernardo Study
- A1c levels and FBG comparisons, 1:15
- cognitive decline with diabetes, 24:8
coronary artery calcification and subclinical heart disease, 18:10
stroke risk with diabetes, 19:6
type 2 diabetes/testosterone level association, 13:20
weight loss/mortality association with diabetes, 16:10
Random plasma glucose
confirmation of diagnosis, 1:16
for high risk for diabetes, 1:6
Randomized controlled trials (RCTs). See also specific studies and trials
ACE trial, 38:11
ACT NOV study, 38:10
Canadian Normoglycemia Outcomes Evaluation, 38:9–10
challenges of implementation, 38:1–2
control of risk factors for heart disease, 18:18–19
CPAP treatment for obstructive sleep apnea, 25:18
critique of, 38:13–17
Da Qing Lifestyle Modification, 38:5,17
Diabetes and Atorvastatin (DIATOR) Trial, 37:14
Diabetes Control and Complications Trial (DCCT). See DCCT study,
in diabetes prevention, 38:1–14
diabetic foot ulcer treatment outcomes, 20:22
Diabetic Retinopathy Candesartan Trials, 21:24–25
discussion of prevention trials, 38:13–16
DREAM study, 38:9
extended follow-up beyond hyperglycemia, 38:12–13
Finnish Diabetes Prevention Study, 38:5–6
gestational diabetes treatment effects, 4:10–11
IDPP study, 38:8
intensive glycemic control, 18:13–14
Lifestyle Intervention in Japanese Men with IGT, 38:8,10–11
mild gestational diabetes treatment, 4:10
NAGTATOR trial, 38:9
Orlistat, 38:5
periodontal therapy and glycemic control, 31:12–14
REPAIR T1D, 37:14
SEQUEL/CONQUER studies, 38:10
STOP-NIDDM trial, 38:8
TODAY study, 15:18
Troglitazone Prevention of Diabetes, 4:12
type 2 diabetes prevention, 38:1–11
vagabond trial, 38:9
Zensharen study, 38:10
Rapid-acting insulin, 6:7
Rapid-eye movement sleep. See REM (rapid-eye movement) sleep
Reactive oxygen species (ROS)
formation of, 25:20
in neuropathy pathogenesis, 23:7
with obstructive sleep apnea, 25:19–20
sleep and circadian disturbances, 25:19–20
in stroke etiology and diabetes, 19:3
Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, 19:7–8
Receiver Operator Characteristic (ROC), 1:9; 12:10; 13:24
Receptor for AGEs (RAGE)
diabetes development, 19:10
links to glyceria, 24:4
serum soluble RAGE and heart disease, 19:11
Reduced kidney function, 22:3
Reduction of Endpoints in Non-insulin Dependent diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study, 22:32,49
Relative insulin deficiency
etiology of, 1:3
diabetes type in young, 15:2
REM (rapid-eye movement) sleep
in normal sleep, 25:1
during pregnancy, 25:21
prevalence of sleep apnea with, 25:17
Renal agenesis, 5:60,65
Renal failure. See Kidney failure
Renal insufficiency/dysfunction. See also Diabetic kidney disease
effects on glycerated hemoglobin, 1:12
metformin-associated lactic acidosis, 17:8
peripheral arterial disease association, 20:9
pregnancy effects on, 5:29
type 1 diabetes mortality, 35:11
Renal papillary necrosis
infections with type 1 diabetes, 28:20
prevalence with diabetes, 22:56
Renalase, 12:8
Renin-Angiotensin System Study (RASS), 21:25
Renin-angiotensin-aldosterone system (RAAS)
cardiovascular event reduction with, 38:12
combined hormonal contraception effects, 5:13
early treatment benefits, 22:16
kidney injury with dual therapy, 22:49
renoprotective effect in type 2 diabetes, 22:49
stimulation by oral contraceptives vs. transdermal patch, 5:13
REPAIR T1D, 37:14
Reproductive Risks of Incontinence Study at Kaiser (RRISK)
sexual dysfunction in women, 28:20
urinary incontinence remission, 28:16
urinary tract symptoms in minorities, 28:11
Resistin, 25:20
Respiratory distress, 5:67–68
Respiratory tract infections
influenza and pneumonia, 30:7–8
sinusitis and bronchitis, 30:8
tuberculosis, 30:17–18
Restriction fragment length polymorphisms in type 2 diabetes, 14:2
Retinal arteriole emboli, 21:38
Retinal microaneuerysm, 21:12
Retinal vein occlusion, 21:38
Retinopathy. See also Visual impairment
A1c association with, 1:12
age and duration of diabetes, 21:8–9
APOE epsilon4 allele polymorphism, 21:25
BMI association with, 21:25–26
care of persons with retinopathy, 21:30–92
cataract surgery with, 21:35
comorbidity and mortality, 21:29–30
cost-effectiveness of detection, 21:30–31
diabetic management effects on, 21:12–13
epsilon4 allele polymorphism, 21:25
examinations in high-risk populations, 21:33
glycemic level assessment, 1:16
glycemic measures for, 1:13–14
gender differences in diabetes, 32:6–15
incidence in type 1 vs. type 2 diabetes, 21:16–18
ischemic hypoxic nonproliferative phase, 21:12
Kimmelstiel-Wilson nodules and, 22:7
long-term effects of pregnancy on, 5:27
macular edema with, 21:16–18
medical interventions for, 21:30
microaneurysms in, 1:16
in obesity, 5:29
new interventions for treatment, 21:29–30
pathogenesis, 21:25
photocoagulation treatment of, 21:7
pregestational diabetes, 5:26–28
in presymptomatic diabetes diagnosis, 1:1
prevalence, 1:9; 21:12–16
prevalence in early pregnancy, 5:26
progression risk during pregnancy, 5:26
public health applications of data on, 21:30–33
quality of care with, 41:5
risk factors for, 21:7,19–30
self-reported prevalence of, 41:5
three-step progression of, 15:18; 21:21
RFX5 (regulatory factor X, 6) gene mutations, 7:11
Rheumatoid arthritis
frequency in diabetic persons, 32:1
genetic associations with type 1 diabetes and, 32:15
intestinal microbiota association, 11:8
parvovirus association with, 11:8
prevalence in with diabetes, 32:17
with Turner syndrome, 6:17
Diabetes in America, 3rd Edition

Rhinocerebral mucormycosis, 17:3; 30:16
Rhizopus species, 30:5
Ricin A-chain, 37:11
Rifampicin, 30:17
Risk factor clustering. See Metabolic syndrome
Risk factors for diabetes
bidirectional periodontitis relationship, 31:24
congenital syndromes, 6:16
enteroviral infections and type 1 diabetes, 11:6
glycemic, 1:16
hypoglycemia, 17:10–11
intrauterine growth retardation, 6:18
malnutrition, 6:18
mitochondrial diabetes, 6:18
periodontitis-diabetes common risks, 31:23
for retinopathy (diabetic), 21:19–30
transplant recipients, 6:17–18
type 1 diabetes, 11:1–29
type 2 diabetes, 13:1–37
unique populations at risk, 6:17–18
Risk score for autoantibody-positive relatives, 1:28
Risk scores from clinical factors
for autoantibody-positive relatives of persons with type 1 diabetes, 1:28
predictive value of, 1:23
Rituximab, 37:13
RNLS gene
age at onset of type 1 diabetes, 12:12
type 1 diabetes risk, 12:8
Rochester, Minnesota cohort, 32:2–3
Rogers syndrome, 7:8
Rose questionnaire for peripheral arterial disease, 20:3
Roziglitzazone
bone loss and fractures with, 32:12
Canadian Normoglycemia Outcomes Evaluation, 38:9–10
cancer risk in preclinical studies, 29:11
cognitive decline prevention, 24:13
combination with metformin, 15:18;
38:9,13
for diabetes prevention, 38:9
diabetes risk reduction with, 38:13
myocardial infarction risk with, 24:13
reduction of diabetes risk, 38:9,14
safety update, 38:13
use as insulin sensitizer, 24:4
Rotavirus infections, 11:8
Rotterdam Study, 38:11
R-R interval measures, 23:7
RRISK 2, 28:20–21
Rubella virus
congenital infection and diabetes, 11:8
type 2 diabetes risk factors, 11:15
Russia, mortality in childhood-onset type 1 diabetes, 35:12

S
San Antonio Heart Study (SAHS)
insulinogenic index and type 2 diabetes risk, 13:17–18
metabolic syndrome prevalence, 13:22
metabolic syndrome traits and diabetes risk, 13:24
risk for type 2 diabetes, 13:17
San Luis Valley Study, 23:9–10
Sarcopenia
diabetes-related disability, 34:1:11
in geriatric population, 16:1,5,10
in older adults, 16:1
risk of falls and, 16:15
Sardinia, type 1 diabetes risk in, 12:4
Saudi Arabian screening in dental clinics, 1:24
Scandinavian countries
susceptibility haplotypes in, 12:4
type 1 diabetes incidence in children, 2:10
Schizophrenia
atypical antipsychotic medications in, 6:11
common risk factors for diabetes, 33:24
impaired glucose metabolism with, 33:22
psychiatric/psychosocial issues, 33:22
schizophrenia/autoimmune risks with maternal diabetes, 5:76;
33:21
type 2 diabetes risk factors, 6:11;
33:21–22
Schizophrenia Patient Outcomes Research Team (PORT), 33:22
Scientific Registry of Transplant Recipients (SRTR), 26:2,11
Scotland antenatal centers, long-term effects of intrauterine hyperglycemia, 4:12–13
Scottish Intercollegiate Guidelines Network (SIGN)
prognostic system for foot ulcers, 20:22
risk classification for diabetes, 20:21
Screening for diabetes, 1:6–29
awareness before screening, 1:27
cost-effectiveness of screening, 1:27
cutpoints for, 1:25–26
early screening benefits, 1:24–25
economic analysis of screening, 1:27
etestig for, 1:16
for gestational diabetes, 1:28–29;
4:2
glycated albumin, 1:15
glycated hemoglobin, 1:7
glycemic tests for, 1:15
high risk groups, 1:24
lack of standardized classification, 2:12
microaneurysms at diagnosis, 1:16
patients with neuropathy, 1:16
in patients with serious mental illness, 33:21
in pediatric age group, 1:14
positive A1c vs. oral glucose tolerance test, 1:26
postpartum after gestational diabetes, 13:21
prevalence of screening, 1:25
retinopathy and, 1:16
screening cutpoints for type 2 diabetes, 1:25–26
screening for type 2 diabetes, 1:22–27
screening results with type 1 diabetes, 1:26–28
skin autofluorescence, 1:15–16
type 1 diabetes diagnostic criteria, 1:3,27–28
type 2 diabetes diagnostic criteria, 1:3–4,22–23
type 2 diabetes prevalence in youth, 1:14
venues for, 1:23–24
Screening for Impaired Glucose Tolerance study, 1:11
See also Black/African American
SEARCH for Diabetes in Youth
by age in U.S. populations, 3:4–5
birth-month pattern/seasonal variation, 2:7
cardiac autonomic neuropathy, 15:27;
23:13
carotid intima media thickness, 15:34–37
childhood diabetes and viral infections, 6:4–5
classification with autoantibodies/insulin sensitivity, 2:3–4;
15:3–4
composition of population for, 15:5
depression and quality-of-life measures, 33:4
diabetes autoantibodies, 2:3
diabetes in offspring after gestational diabetes, 4:12
diabetes prevalence/incidence, 15:9
women of childbearing age, 5:4,6
in youth, 15:4
distal symmetric polyneuropathy prevalence, 23:10
DKA prevalence/incidence at onset/diagnosis, 15:17;
17:2
dyslipidemia, 15:33
elevated albumin/creatinine ratio, 15:20
elevated blood pressure, 15:33
etologic classification for, 2:3–4
geographical regions used, 15:4
by glutamic acid decarboxylase autoantibodies, 2:3
glycemic control data, 15:28
lifestyle characteristics
diabetes/prediabetes, 10:2,7,10–11
smoking, 10:16–17
metformin treatment for type 2 diabetes, 15:18
minority/ethnic projections from, 2:10
MODY epidemiology, 7:4
obesity and insulin resistance, 15:34
peripheral neuropathy with type 1 and type 2 diabetes, 15:27
populations monitored, 2:2
race/ethnicity patterns in type 2 diabetes and prediabetes, 3:5
retinopathy prevalence/incidence in minority youth, 15:18
risk for chronic complications, 5:7
type 1 diabetes
complications and insulin use, 15:17
prevalence/incidence age <20 years, 2:5
racial/ethnic variation, 2:6–7; 15:6
risk factors, 15:11
trends in adolescents, 1:14
in youth, 2:9
type 2 diabetes prevalence/incidence
data collection, 3:4
diagnosed diabetes incidence, 3:16–17
ever vs. never breastfeeding, 5:74
pediatric diabetes data, 15:10
sex differences in, 3:5
trends in adolescents, 3:17
in uroto diabetes exposure, 4:12; 13:13
in youth, 3:16
U.S. centers for, 15:4
Seasonality
birth of children with type 1 diabetes, 11:11
diagnosis of type 1 diabetes, 11:3
onset of type 1 diabetes at age <20 years, 2:7–9
Seattle risk score for diabetic foot ulcer, 20:21
Second International Workshop-Conference on Gestational Diabetes Mellitus
glucose measures for screening, 4:2
screening time recommendations, 4:4
Secondary diabetes, 1:4
Second-generation antipsychotics. See Atypical antipsychotic medications
Seipin, 7:15–16
Selective IgA deficiency in celiac disease, 27:9
Self and non-self, 12:2
Semmes-Weinstein monofilament (SWM), 20:18; 23:5
Senile lens changes. See Cataracts
Sepsis. See also Infections associated with diabetes
with chronic kidney disease, 22:22
with diabetes-associated infections, 30:14–15
diagnosis with foot ulcers, 30:13
maternal mortality from, 5:24
precipitation by lactic acidosis, 17:8
SEQUEL secondary analysis on weight loss, 38:10
Sequence tag sites in type 2 diabetes, 14:1
Sercoversion
antibodies in type 1 diabetes progression, 37:2
beta cell injury manifestation, 37:2
Serum soluble RAGE (sRAGE), heart disease association, 19:10–11
Severe albuminuria. See Macroalbuminuria
Severe insulin deficiency
monogenic diabetes, 7:2
type 1 diabetes, 1:3–4
Sex differences
A1c and cancer risk, 29:4
A1c in prediction of incident diabetes, 1:20
in A1c levels, 1:11
adiposity of offspring from gestational diabetes, 4:12
age distribution by sex, 8:7
alcohol consumption, 10:9–10
cardiovascular mortality risk with diabetes, 36:8
with cataracts in type 2 diabetes, 21:33
chronic kidney disease risk factors, 22:12
constipation/laxative used in diabetes, 27:2
coronary artery calcification scores, 15:37–38
depression risks for, 33:9
diagnosed, undiagnosed, and total type 2 diabetes prevalence, 3:10–11
diagnosed diabetes, 3:16
diagnosed diabetes prevalence, 3:5–6; 16:2
in disability with diabetes, 34:11
dysglycemia prevalence in men, 3:14
eating disorders in females age <20 years, 33:19
fractures with type 2 diabetes, 32:4–5
gallstone disease, 26:13–15
hand osteoarthritis, 32:12
in hyperglycemic hyperosmolar state, 17:6
hyperinsulinemia/heart disease association in, 18:11
idiopathic skeletal hyperostosis, 32:17
increased prevalence of diabetes, 3:19
late neonatal deaths, 5:48
lifestyle intervention, 38:17
lung cancer mortality rates, 29:8
macroalbuminuria prevalence, 22:12
metabolic syndrome prevalence, 13:21–23–24
microalbuminuria prevalence, 22:12
mortality in childhood-onset type 1 diabetes, 35:12
mortality rates with hematologic cancers, 29:10
mortality trends in type 2 diabetes, 36:11
musculoskeletal disorder in upper extremity, 32:18
obesity, diabetes, and heart disease, 18:6
peripheral arterial disease prevalence, 20:5
prevalence in type 2 diabetes, 3:13
prevalence in type 2 diabetes, 3:10–12
prevalence of type 2 diabetes, 3:19–20
in retinopathy and visual impairment, 21:9
sex distribution with diabetes, 8:4
sex-specific differences in mortality, 36:5–7
stroke risk with diabetes, 19:5–7
in thyroid cancer occurrence, 29:10
total calories consumed, 10:2
type 1 diabetes mortality by sex, 35:6–7
type 1b diabetes, 6:18
in type 2 diabetes and alcohol consumption, 13:9
type 2 diabetes incidence in girls vs. boys, 3:16
type 2 diabetes/prediabetes prevalence, 3:5
visual impairment, 21:3:9
Sexual dysfunction with diabetes (female)
definition of, 28:20
insulin-treated type 2 diabetes, 28:20–21
mechanisms of, 28:21
symptoms of, 23:4
type 1 diabetes, 28:21
Sexual dysfunction with diabetes (male).
See also Urologic disease in diabetes
data sources and limitations, 28:6
diabetes association in, 28:9–10
erectile dysfunction defined, 28:6
measurement and classification, 28:6
pathophysiology and comorbid conditions, 28:6–7
prevalence, 28:7–8
prevalence and incidence with diabetes, 28:8
treatment recommendations, 28:9–10
SLGT2 (sodium glucose transporter-2) inhibitor, 18:15
SGSM2 gene, 14:6
SH2B3 gene, 12:6
Shift work
sleep and circadian disturbances, 25:24–30
type 2 diabetes risk with, 13:15
SHORT (Short Stature, Hyperextensibility of Joints and/or Inguinal Hernia, Ocular Depression, Reiger Anomaly, and Teething Delay) Syndrome, 9:26
Shortened crown-rump length, 5:67
Shoulder dystocia
cerebral palsy and, 5:49
with gestational diabetes treatment, 4:3,10
macrosomia and, 5:56
reduced risk with gestational diabetes treatment, 4:3
in small-for-gestational age, 5:33
with vaginal delivery, 5:56–59
Sickness Impact Profile, 20:25
Signaling pathways
cascade initiated by insulin receptor, 7:12
hormone-sensitive lipase activation, 25:19
impaired C-peptide-related, 23:7
inflammatory response in kidney disease, 22:8
to melancortin receptors in obesity, 7:11
melatonin, 25:19
nuclear factor (NF)-kappa B, 22:42
placental contribution with cytokines, 5:67
Sildenafil, 28:10
Simultaneous pancreas-kidney transplant, 39:9
Single gene defects. See Monogenic forms of diabetes
Single nucleotide polymorphism genotype, 12:7
Single nucleotide polymorphism (SNP) association with retinopathy, 21:29
diabetic kidney disease association, 22:43
effect of acarbose on prevention, 38:11
GWAS identification correlated, 14:10
importance of, 14:2–3
linkage mapping, 12:6
metformin treatment interaction, 38:11
relation to age at onset, 12:12
in type 1 diabetes, 12:4–5
type 1 diabetes risk association, 12:6
type 2 diabetes, 38:11
in type 2 diabetes mortality, 14:1
Sitagliptin
lansoprazole combination use, 37:14
pancreatic cancer/pancreatitis risks with,
29:12
trends in use of, 39:3–4
Skeletal muscle
AGPAT2 isoform expression in, 7:15
exercise effects on, 13:11; 17:10
impaired insulin signaling in, 6:15
insulin resistance in, 15:2
LMNA gene mutations, 7:19
postprandial hyperglycemia, 14:6
sympathetic activation effects on, 25:19
TBC1D4 level in, 14:6
wasting with neuropathy, 23:5
Skin autofluorescence, 1:15–16
SLC19A2 (thiamine transporter) gene, 7:8
SLC29A2 gene mutation, 7:8–9
SLC30A8 gene
type 2 diabetes association, 14:10
zinc transporter variant, 13:5
SLC47A1 gene, metformin response association, 38:11
Sleep and circadian disturbances
adipocyte function, 25:11
appetite-regulating hormones, 25:10–11
brain glucose utilization, 25:10
circadian system and glucose metabolism,
25:24–30
gestational diabetes risk with, 25:21
growth hormone changes, 25:10
hypothalamic-pituitary-adrenal axis and,
25:10
insomnia and diabetes risk, 25:6–9
insufficient sleep, 25:2–6
long sleep duration impact, 25:11
metabolic pathways involved, 25:10
obstructive sleep apnea, 25:12–20
during pregnancy and gestational diabetes,
25:21–24
sleep fragmentation and shallow sleep,
25:6–9
sympathetic nervous system activity,
25:10
systemic inflammatory response, 25:10
type 2 diabetes risk factors, 13:14–15;
25:1–44
type 2 diabetes sleep breathing disorders,
25:20–21
Sleep Heart Health Study, 25:14,20
Slow wave sleep (SWS), 25:1.21
Small area estimation (SAE) method, 31:6
Small fiber neuropathies (SFN), 23:3
Small-for-gestational age (SGA)
chronic hypertension/gestational diabetes,
5:33
growth restriction definition, 5:49
intellectual performance and, 5:75
with macrosomia trend effects on, 5:55
with maternal diabetes, 5:55
planned preterm delivery with, 5:45
shoulder dystocia risk, 5:33
Smoking
after diagnosis of diabetes, 1:27
diabetic disease and amputation associations,
20:25
association with chronic kidney damage,
22:36–37
cessation and type 2 diabetes risks, 33:22
genetic malformation prediction by,
5:10
covariates for cardiovascular risk,
18:12–13
with diabetes, 10:16–17
dose-response relation to type 2 diabetes risk,
13:15
geriatric diabetic population, 16:6
incidence of intermittent claudication,
20:6
incidence or progression of retinopathy with,
21:27
with mood disorders, 33:23
pregnancy-related myocardial infarction risk,
5:23
risk factor for periodontitis, 31:23
risk factors for diabetic kidney disease,
22:36–37
type 1 diabetes mortality, 35:11
Smooth muscle
in bladder outlet obstruction, 28:6
hyperglycemia effects on, 20:1
proinflammatory process in, 19:3
in prostate, 28:2,4
Social phobia, 33:16
Sociodemographic characteristics, 8.1–67
age distribution with diabetes, 8.4
communication characteristics
household telephone access, 8.14
main interview language, 8.14
data sources and limitations, 8.2–3
demographic characteristics
age distribution, 8.4
age distribution by sex, 8.7
sex distribution, 8.4
diabetes characteristics
age at diagnosis, 8.8
duration, 8.8–9
employment characteristics
current occupations of workers,
8.18–19
hours worked when employed, 8.18
past 12 months, 8.15
prior week, 8.15
reason for not working in prior week,
8.15
type of employer, 8.15–18
veteran status, 8.18
NHANES data, 8.3
NHIS data, 8.3
place of residence
metropolitan/nonmetropolitan county,
8.9
state of U.S., 8.9
time in U.S. for immigrants, 8.10
race/ethnicity distributions, 8.4,6–7
reported health insurance benefits, 8.19
sex distribution, 8.4
social and health benefits, 8.19
socioeconomic characteristics
cohabitation type, 8.11
education, 8.12
family income, 8.12
family size, 8.12
marital status, 8.11
poverty income ratio, 8.12–13
type 2 diabetes risk factors, 13:15
undiagnosed diabetes and prediabetes,
8:20
U.S. region of residence, 8:9–10
world region of residence, 8:10
Socioeconomic status (SES)
association with depression symptoms with diabetes, 33:9
association with retinopathy, 21:29–30
diabetic kidney disease risk factor, 22:30
likelihood of psychiatric disorders with,
33:23
mortality risk for type 1 diabetes, 35:10
risk factors for diabetic kidney disease,
22:30
type 1 diabetes mortality, 35:10
Type 2 diabetes association, 13:14
type 2 diabetes risk factors, 13:13–14
Sodium-lithium countertransport activity, 22:32
Soluble CTLA4Ig. See Abatacept
South Americans. See Central/South Americans
South Carolina
cesarean delivery in diabetic women, 5:46
dyslipidemia and glycemic control in youth,
15:33
oral health with diabetes, 31:21
pediatric diabetes trends, 15:4
pregestational diabetes prevalence during
pregnancy, 5:18
prevalence of diagnosed diabetes, 3:4
racial/ethnic differences in stroke in diabetes, 19:7
U.S. vs. non-U.S. countries diabetes prevalence, 2:2

South Dakota. See also American Indian/Alaska Native
albuminuria with type 2 diabetes, 22:18,30
metabolic syndrome in, 13:23

Spondyloepiphysial dysplasia, 7:11

Spontaneous abortion
early fetal loss rate, 5:35–36
maternal mortality ratio in, 5:22

Stage 1 type 1 diabetes criteria, 37:2
Stage 2 type 1 diabetes criteria, 37:3
Stage 3 type 1 diabetes criteria, 37:3
Staphylococcus aureus, 30:8,12–13,14,16
Staphylococcus epidermidis, 30:16
Staphylococcus pyogenes, 30:14
Staphylococcus saprophyticus, 30:9

State Inpatient Databases, 5:18

Statin therapy. See also Dyslipidemia combined with ezetimibe, 22:52
diabetic patient expenditures for, 40:63
dyslipidemia management, 18:16
expenditures for, 40:66
 genetic association with hard exudates in, 21:25
in geriatric population, 16:14
modification of ESRD risk with, 22:32
preconception use of, 5:36
pregnancy loss with exposure to, 5:36
use in early pregnancy, 5:11

Steno Hospital/Clinic studies
 cardiovascular autonomic neuropathy intervention, 23:13
cause-specific mortality, 35:9
intensive treatment of cardiovascular risk factors, 16:14
 legal blindness with retinopathy, 21:7
life expectancy improvement with type 1 diabetes, 35:5
life expectancy trend, 35:5
multifactorial intervention, 18:18; 22:2,16
multifactorial intervention for kidney disease, 22:54
specific-cause mortality with type 1 diabetes, 35:9
visual impairment incidence, 21:7

Stiff man syndrome, 6:15

Stillbirth (fetal death). See Fetal demise

Stillbirth Collaborative Research Group
 population-based, case-controlled, 5:37
risk of stillbirth with diabetes, 5:43

Stimulated C-peptide response
defining type 1 diabetes, 2:3
evaluation of beta cell function, 37:7
in “remission” in cyclosporine trials, 37:7

STOP-NIDDM (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus), 38:8
acarbose in prevention study, 38:8,12
gene polymorphism evaluation in, 38:11

“Stress” hyperglycemia. 19:9

Stroke and diabetes. 19:1–23
 age and sex difference in stroke risk, 19:5–7
albuminuria risk prediction for, 19:10
antiplatelet use, 19:14
atrial fibrillation, 19:17
autonomic neuropathy risk prediction for, 19:11
blood pressure management, 19:12
carotid and vertebral artery disease treatment, 19:14–17
carotid revascularization in, 19:16–17
classification of, 19:2,3
clinical definition, 19:1
clinical presentation and topography of, 19:3
corony artery disease, 19:17
definition of, 19:1,2
before or during delivery, 5:22
dementia risks with, 24:3
diabetes as independent risk factor, 19:17
disability association with, 34:8
disease course and prognosis, 19:17
dyslipidemia management, 19:12–13
epidemiology in diabetes, 19:4
extracranial carotid and vertebral artery disease treatment, 19:14–16
glycemic control, 19:13–14
hypercoagulability risk prediction for, 19:11
hyperglycemia risk prediction for, 19:9
hypertension/blood pressure control, 19:11–12
hypertension/systolic blood pressure management, 19:11–12
incidence and prevalence in types 1 and 2 diabetes, 19:4–5
inflammation/CRP risk prediction for, 19:10
insulin resistance risk prediction for, 19:9–10
insulin-like growth factor 1 in risk prediction, 19:11
ischemic and hemorrhagic, 19:2
lifestyle interventions, 19:11
lipid assessment for vascular disease, 18:8
magnitudes of diabetes/heart disease risk, 18:7–8
metabolic syndrome, 19:10
metabolic syndrome risk prediction for, 19:10
migraine history and, 5:22
obstructive sleep apnea risk prediction for, 19:10
pathophysiology in diabetes, 19:3
peripheral vascular disease, 19:17
pregestational diabetes and, 5:22–23
race/ethnicity differences in, 19:7–8
receptor for AGEs risk prediction, 19:10–11
risk predictors for, 19:9–11
risk with peripheral arterial disease, 20:14
stroke risk factors in type 2 diabetes, 19:1
stroke subtypes, 19:8–9
transient ischemic attack, 19:2
UKPDS Risk Engine, 19:11
in young persons, 19:8
“Stroke belt” region, 19:7
“Stroke buckle” region, 19:7

Strong Heart Study
albuminuricinratio as cardiovascular disease predictor, 22:19,21
albuminuria with type 2 diabetes, 22:18
lipoprotein concentration and elevated albuminuria risk, 22:32
metabolic syndrome prevalence, 13:23
neuropathy prevalence, 23:10
stroke occurrence in, 19:8

Study of Health in Pomerania (SHIP), 31:21,33,34
Study of Heart and Renal Protection (SHARP), 22:52
Study of Osteoporotic Fractures (SOF), 32:2–3,8,16; 34:11
Study of Thymoglobulin to ARRest Type 1 diabetes (START), 37:13
Study of Women’s Health Across the Nation (SWAN), 28:14,16
Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD), 10:12

Sulfonylurea medications
 acute metabolic complications with, 17:10
CYP2C9, 14:9
fracture rates with, 32:12
glucose intolerance progression to diabetes effects, 1:19
insulin secretagogue action of, 16:16
KCNJ11/ABCC8 target encoding for, 14:11
in MODY, 7:6
in treatment of neonatal diabetes mellitus, 7:10
trends in use of, 39:2
use in geriatric population, 16:14

Sulfonylurea receptor (SUR1)
coding for, 7:5
in K<sub>ATP</sub> channel, 7:5
neonatal diabetes mellitus and, 7:10

Suprachiasmatic nuclei (SCN), 25:24

Surrogate markers
 for Alzheimer’s disease, 24:4
for nonalcoholic fatty liver disease, 26:3

Surveillance, Epidemiology, and End Results Program (SEER), 29:7

Surveillance, HIT-based systems, 2:12

Susceptibility genes and loci
APOE<sup>ε4</sup> for late-onset dementia, 24:3
CTLA4 gene, 11:16; 12:6–7
for ESRD, 22:43
IL2RA/CD25 gene for type 1 diabetes, 12:6
KIAA0350 gene for autoimmune disease, 12:6
SH2B3 (12q24), 12:6
type 1 diabetes, 12:6
type 1 diabetes, 12:6–8
type 1 diabetes, 12:8
type 1 diabetes risk factors, 12:6

Swedish Childhood Diabetes Registry, 2:10
Swedish Medical Birth Registry
brachial plexus palsy, 5:58–59
mothers with type 1 diabetes, 5:70
ponderal index use, 5:56

Swedish National Registry, 22:12–14
Swedish Obese Subjects (SOS), 29:6
Swedish studies
Apgar scores in macrosomia, 5:56
blood pressure and heart disease association, 18:9
cancer risks with glargine insulin, 29:11
cardiovascular risk with metabolic syndrome traits, 18:9
cesarean delivery in diabetic women, 5:46
change in type 1 diabetes genotype, 11:3
diabetes association with prostate size, 28:4–5
diabetes registries, 2:5
fetal sex-associated risk, 5:66
Malmöhus County, Sweden, 38:2–3
mild/severe preeclampsia/eclampsia, 5:34
prevalence of albuminuria, 22:12–14
prevalence of DKA at onset, 15:17
proinsulin prediction of heart disease, 18:11
pulmonary embolism risk factors, 5:23–24
residual brachial plexus palsy effects, 5:59
school performance of offspring of diabetic women, 5:75
sex differences in fetal demise, 5:43
stroke association with maternal diabetes, 5:22
Swedish Childhood Diabetes Registry, 2:10
weight loss and cancer association, 29:6

Sympathetic nervous system activity
autonomic dysfunction with distal symmetrical polyneuropathy, 23:5
effects on skeletal muscle, 25:19
lipolytic effects of, 25:11,19
in obstructive sleep apnea, 25:20
on prostate smooth muscle, 28:4
during REM-related sleep apnea, 25:17
sleep and circadian disturbances, 25:19
with sleep disturbances, 25:10

Sympathomimetic agents, hyperglycemic hyperosmolar state precipitation, 17:6–7
Symptom turnover, 27:5
Systemic inflammatory response. See also Inflammatory response
abdominal obesity enhancement of, 25:20
adipocytokines/adipokines and, 25:10
C-reactive protein association with, 13:18–19
gingivitis effect on, 31:25
glucose metabolism and, 25:10
gut microbiome effects on, 11:8
with obstructive sleep apnea, 25:10,20
periodontal treatment and, 31:14,16
risk factor for stroke, 19:10

T
T lymphocytes/cells. See also Immune Tolerance Network
autoimmune destruction of beta cells, 15:2
autoimmune gastritis, 27:15
in autoimmunity development, 12:11
in diabetes immune response, 37:2
effects of vitamin D on response by, 11:11
foreign peptide recognition, 12:2–3
immune response to gluten, 27:9
immune tolerance intervention studies, 37:13
infiltration of kidney interstitium, 22:9
MHC role in type 1 diabetes risk, 12:2
peptide antigen presentation for activation, 12:3–5
response to infection with diabetes, 30:11
in type 1 diabetes, 12:2–3
in type 1 diabetes immune response, 37:2

TEDDY study
DKA prevalence at onset, 15:17
islet autoimmunity data, 11:2; 12:12
islet autoimmunity triggers, 15:10; 37:2
longitudinal studies, 15:10
viruses in causation of type 1 diabetes, 11:8; 12:12

Temporal trends
American Indian population youth, 3:17
cardiovascular mortality trends, 36:10–11
change in type 1 diabetes genotype, 11:3
changes in age at onset of diabetes, 15:1
childhood diabetes data for type 1 diabetes, 15:6
childhood diabetes data for type 2 diabetes, 15:9–10
chronic hypertension with pregestational diabetes and age, 5:33
diabetes in geriatric population, 16:3
diabetes in U.S. youth, 1:14,54
diabetes medication use, 39:3
diagnosed in diabetes, 3:17–19
diagnosed/undiagnosed diabetes prevalence, 3:19–20
in economic impact of diabetes, 40:69–71
in Framingham Offspring Study, 13:18
functional limitations with diagnosed diabetes, 34:9
geriatric diabetes cost projections, 16:17
gestational diabetes prevalence, 4:7,11
hospitalization/hospital utilization with diabetes, 40:28–32
in hyperinsulinemia prevalence, 13:18
lower extremity amputation frequency, 20:23
maternal death from sepsis, 5:24
medication use and self-care practices, 39:3–4
mortality from hyperglycemic hyperosmolar state, 17:6
national estimates of disability and causes, 34:9
national trends in type 2 diabetes mortality, 36:10
obesity in Pima Indians, 22:37
physical activity levels, 10:12
population factors in increased prevalence, 3:19
prediabetes prevalence, 3:20
pregestational diabetes with pregnancy, 4:7–8
pregestational type 1 diabetes in pregnancy, 5:16
prevalence of low filtration rate with diabetes, 22:12
prevalence of persistent albuminuria with diabetes, 22:12
retinopathy in youth-onset, 15:18
smoking prevalence with diabetes, 10:17–18
total diabetes prevalence, 3:19
type 1 diabetes incidence in youth, 2:9–10; 11:1
mortality, 35:5
prevalence and incidence in adults, 2:11–12
type 2 diabetes mortality, 36:1–14
prevalence/incidence in adolescents, 3:16
types 1 and 2 diabetes in pregnancy trend, 5:14
in visual impairment with diabetes, 21:3

Tennessee
mortality comparison to general population, 35:5
racial/ethnic differences in stroke in diabetes, 19:7

Teplizumab
anti-CD3 intervention studies, 37:11
effects on beta cell function, 37:5,12
in prevention of type 1 diabetes, 37:6–7

Teratogenic effects
first trimester drug use, 5:10
glucose effects on malformations, 5:11
uncontrolled diabetic state, 5:66

Texas. See also San Antonio Heart Study
acute metabolic complications in youth, 15:17

Index—58
gallstone disease in Mexican Americans with diabetes, 26:13
genetics of retinopathy, 21:29
heritability of retinopathy, 21:29
total diabetes percentages, 8:9
Texas University Classification (TUC) risk classification for diabetic foot ulcers, 20:21,22

The Environmental Determinants of Diabetes in the Young (TEDDY) study. See TEDDY study

The Health Improvement Network (THIN)
preexisting diabetes in pregnancy, 5:16
venous thromboembolism risk with pregestational diabetes, 5:23

Thiamine-responsive megaloblastic anemia (TRMA), 7:8

Thiazide diuretics
hyperglycemic hyperosmolar state precipitation by, 17:7
incident diabetes with thiazide, 6:12
micro- and macrovascular event reduction, 19:12

Thiazolidinedione (TZD) medications
bone loss and fractures with, 32:12
cancer risks with, 29:11,13
cautions for use of, 38:16
dementia prevention and treatment, 24:13
glucose intolerance progression to diabetes effects, 1:19
oral glycemic control, 39:2
pioglitazone, 38:10
PPARG gene target coding, 14:11
side effects of, 38:13
steatosis and steatohepatitis effects, 26:4
trends in use of, 39:3–4

“Thriftty” obesity pathway, 15:12

Thymoglobulin (antithymocyte globulin)
ATG, 37:13

Thyroid dysfunction, 6:15
Time-related biases, 29:10

Tinea pedis, 20:18

Tissue plasminogen activator (t-PA), 20:8

Tissue transglutaminase autoantigen (TTG)
in celiac disease detection, 27:9–10
in nondiabetic high-risk children, 27:11

TTN-beta Ncol gene, 21:29

TOAST classification (stroke), 19:2

TODAY (Treatment Options for Type 2
diabetes in Adolescents and Youth) study
albuminuria and renal failure risk, 15:24
exercise recommendations by, 10:12
kidney disease in youth-onset diabetes, 22:2
metformin and lifestyle intervention, 15:18
retinal evaluations in youth, 15:18
sedentary behavior in adolescents, 10:19

Tohono O’odham (Papago) Indian residents, 31:15

Tolbutamide, 38:2,5

Tooth loss/missing teeth
all-cause mortality association, 31:41
diabetes association with, 31:27–32

in well-controlled diabetes, 31:32

Toronto Consensus on Diabetic Neuropathies, 23:5,6

Total cholesterol
diagnosed and undiagnosed diabetes, 9:19
ESRD association with, 22:32
race/ethnicity prevalence, 3:12
retinal hard exudate association with, 21:25
types 1 and 2 diabetes in youth, 15:33

Transcription factor 7-like 2 gene (TCF7L2).
See TCF7L2 gene

Transcription factor NEUROD1, 7:7

Transcutaneous bilirubin estimates
in well-controlled diabetes, 17:25–32

Transplant recipients, diabetes risk with
bone loss and fractures with, 24:13
cancer risks with, 22:2
in nondiabetic high-risk children, 27:1
in celiac disease detection, 25:2
in diabetic nephropathy, 22:31
nicotine effects on, 22:37

Transient ischemic attack (TIA)
carotid artery disease and, 19:17
defined, 19:2–3

Transient neonatal diabetes (TNDM)
chromosome 6q24, 7:9–10
clinical presentation of, 7:10
K<sub>ATP</sub> channel, 7:10

Translating Research into Action for Diabetes (TRIAD)
barriers to self-care, 39:8
death certificate data for mortality, 36:3
death certificate limitations for cause of death, 36:3
diabetes, 1:16–17

Transplant recipients, diabetes risk with,
6:17–18

Trial of Org 10172 in Acute Stroke
Treatment, 19:2

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6), 18:16

TriNet Natural History Study
assays used for screening, 1:27–28
ZnT8 autoantibodies, 1:27–28

TriNet Natural Intervention to Prevent Type 1 Diabetes (NIP)
monoclonal antibody studies, 37:6–7
nutritional supplements on type 1 diabetes, 37:5
prevention of type 1 diabetes, 37:12–13

Trichophyton mentagrophytes, 30:11

Trichophyton rubrum, 30:11

Triglycerides, 9:21–22

with cardiac autonomic neuropathy, 15:27
in diabetes, 1:2,6
enzymes in biosynthesis, 7:15
in familial partial lipodystrophies, 7:17
fenofibrate studies, 18:16
in fetal overweight, 5:73
heart disease association with, 18:8
lower extremity amputation association with, 20:25
metabolic syndrome traits, 13:24

Type 1 diabetes mortality, 35:11

TRIGR (Trial to Reduce IDDM in the Genetically at Risk) study
breastfeeding vs. cow’s milk formula, 15:11
cow’s milk formula exposure and autoimmunity development, 37:3
tropical infections and autoimmunity, 11:4–5

Trisomy 21. See Down syndrome

Troglitazone
diabetes risk reduction with, 38:13
liver failure with, 32:12

Troglitazone in Prevention of Diabetes (TRIPOD) trials, 4:12, 38:8

Tropical diabetes, 6:18

Tuberculosis, 30:17–18

Tumor necrosis factor receptors 1 and 2, 22:2
in diabetic kidney disease, 22:9
in survival models for ESRD, 22:9

Tumor necrosis factor-alpha (TNFa)
adipose tissue inflammatory pathway, 13:19–20
etanercept blocking of, 37:14
in insulin resistance, 13:19
levels with sleep deprivation, 25:10
with obstructive sleep apnea, 25:20
in type 1 diabetes immune response, 37:2
type 2 diabetes risk factors, 13:19

Turner syndrome
diabetes risk with, 6:17
growth hormone in, 6:13

25-hydroxyvitamin D (25(OH)D)
islet autoimmunity and, 11:12
type 1 diabetes risk and levels of, 11:11–12
type 2 diabetes incidence, 13:7

2-hour plasma glucose (PG)
A1c comparisons, 1:14–15
by age stratification, 9:5
association with heart disease risk, 18:7
diagnostic criteria for diabetes, 1:2, 36:1
FPG comparison for prediction, 1:19
glycated albumin correlation, 1:15
in impaired glucose tolerance definition, 1:18
levels in undiagnosed diabetes, 9:5
NHANES methods for, 9:2
nonseparate p.Arg684Ter variant, 14:6
pre-diabetes criteria, 9:5
prediction of cardiovascular disease and mortality, 1:17
race/ethnicity variations in, 1:12
TBCD4 gene, 14:6
undiagnosed diabetes detection by, 3:15
untreated diagnosed diabetes, 9:5

Type 1 diabetes
acute complications in youth, 15:17
albuminuria progression or regression, 22:5–6
autoantibodies in, 1:6
binge eating disorder prevalence in, 33:20

Index–59
bimarkers for initiation phases of, 12:11–12
candidate genes for, 11:16
celiac disease association, 27:11–12
celiac disease in, 27:9–15
chronic kidney disease in, 22:4
clinical stages of, 37:2–3, 5, 6, 7, 11
current surveillance systems, 2:5
data sources and limitations, 2:2–5
defined, 2:3–4
diabetes-periodontitis interactive effects, 31:17–21
etiology of, 1:1
IFIH1 gene representation in, 12:6
incidence in age <20 years, 2:6–7
incidence trends in, 2:9–10
initiation of, 11:13; 12:11–12
international comparisons for, 2:7
onset and progression of, 1:2
polio model for, 11:6
prevalence and incidence, 1:54–70;
2:10–11
public health surveillance/implications, 2:4–5
race/ethnicity projections for, 2:10
seasonality of onset in children, 2:7–9
surveillance for, 2:5, 12–13
treatment during pregnancy, 5:2–3
U.S. adult population, 2:11–12
U.S. age <20 years, 2:6–7
Type 1 Diabetes Genetics Consortium (T1DGC)
affected sibpair families for, 12:6–9
childhood diabetes and viral infections, 6:5
GWAS meta-analysis, 12:6–7
GWAS scans for, 11:3; 12:6–9, 12
ImmunoChip data, 12:9, 11
sample characteristics in, 12:12
type 1 diabetes risk factors, 12:7–8
Type 1 diabetes immune response
etanercept effects in, 37:14
initiation of, 37:2
postprandial hyperglycemia trigger for, 38:8
Type 1 diabetes in youth. See also Diabetes in youth
Cardiac autonomic neuropathy in, 15:27
cardiovascular endpoint predictors, 15:34
complications, 15:13–17
coronary artery calcification in, 15:38
glycemia and cardiovascular disease in, 15:28
incidence, 2:6–7; 15:2, 5–6
microalbuminuria regression in, 15:23–24
mortality in, 15:38–39
prevalence, 2:5; 15:4–5
prevalence trends in, 1:14
projections for, 15:6–8
retinopathy in, 15:18
Type 1 diabetes incidence. See also specific age groups and populations
in adults, 2:3, 11–12
age 15–29 years, 2:11
data for, 2:3
race/ethnicity projections in youth, 2:10
surveillance for, 2:12
trends in youth, 2:9–10
worldwide incidence/prevalence, 2:6–7
in youth, 1:54
Type 1 diabetes mortality
age of onset, 35:6
causes of death, 35:7–8
cause-specific in Norway vs. U.S., 35:10
complication-specific causes of death, 35:6–10
current (post-1980 era) findings, 35:3–4
depth certificate limitations for determining, 35:7–8
dyslipidemia, 35:11
early/premature mortality with, 15:38–39;
35:1, 9
general population comparisons, 35:5
glycemic control as risk factor for, 35:10
historical (pre-1980 era), 35:2–3
hypertension, 35:11
insulin resistance, 35:12
life expectancy improvement in, 35:5
race/ethnicity, 35:7
renal failure, 35:11
risk factors for, 35:11
sex-specific differences in, 35:6–7
smoking, 35:11
socioeconomic factors, 35:10
standardized protocol for classification, 35:8
U.S. active duty military personnel, 2:3
U.S. compared to other countries, 35:12
Type 1 diabetes prevalence. See also specific conditions and populations
adults, 2:10–12
by age, sex, race/ethnicity, 2:5
age <20 years, overall, 2:5
age 0–4 years, 2:5
age 15–19 years, 2:5
European ancestry, 12:1
HLA allele/haplotype population frequencies, 12:4
NHANES 1999–2010 data, 2:2–3
SEARCH study identification of, 2:5
in youth, 2:2; 15:4–5
Type 1 diabetes risk factors. See also Risk scores from clinical factors
diabetic dietary factors, 11:9–14
evironment x environment interactions, 11:17
gene x environment interactions, 11:15–17
genetic factors, 12:1–16
genetic prediction of, 12:10
 genetic study designs for, 12:1–2
HLA genotype, 11:3
infectious agents, 11:3–8
insulin (INS) gene in susceptibility, 12:6
interactive/additive MHC effects, 12:3–5
intestinal microbiota, 11:8
major histocompatibility complex, 12:2–5
metabolic studies, 11:14
MHC loci, 12:2–5
non-MHC risk loci, 12:6
with pediatric-onset inflammatory bowel disease, 27:15
pre- and perinatal factors, 11:15
psychosocial/socioeconomic factors, 11:15
susceptibility genes, 12:6
toxins and chemical compounds, 11:14
vaccines, 11:8
Type 1a diabetes
diagnostic criteria, 1:3
in neonates, 7:9
Type 1b diabetes
characteristics of, 1:3; 6:18
diagnostic criteria for, 15:2
risk factors for, 6:18
single gene defects, 7:8
Type 1.5 diabetes. See Combined types 1 and 2 diabetes
Type 2 diabetes
A1c for screening, 1:26
albuminuria association with, 22:6–7, 12, 15–16
albuminuria with, 22:18
alcohol consumption effects in, 13:9
Asian subgroups, 3:7–8
autoantibody positivity with, 1:5; 11:2
benefits of early screening, 1:24
biases in observational studies for, 29:10
biomarkers for, 13:1
biomarkers in, 13:6
breastfeeding protective effect for, 15:13
chronic hypertension with pregestational, 5:33
chronic kidney disease in, 22:4
chronotype and glycemic control, 25:27–28
common intrinsic rs7903146 polymorphism, 14:2
comparison of A1c and OGTT, 1:26
ccontraceptive use in youth, 5:11
criteria for screening, 1:22–23
data sources and limitations, 3:2–4
definition and diagnostic criteria for, 1:4, 6; 2:3
early-onset types, 15:11
effects of pregnancy on retinopathy, 5:27
epithelial fragility with type 2 diabetes, 21:37
genearchitecture analysis for, 14:2–6
glaucoma risk with, 21:37
glomerular filtration barrier changes in, 22:9
healthcare results of screening, 1:27
hypoglycemia incidence in, 17:10
onset and progression of, 1:2; 13:16; 15:2
periodontal treatment effects on, 31:12–14
post-surgical infections, 30:15
preconceptional care use with, 5:10
pregestational diabetes prevalence during pregnancy, 5:18
Index—60
prevalence and incidence of, 3:1–32
prevalence of screening, 1:25
prostate cancer risk with, 29:9
SGSM2 as causal locus, 14:6
sleep disturbances and, 13:15; 25:20–21
spontaneous abortions with, 5:35–36
sRAGE association, 19:11
visual impairment and blindness, 21:12, 33–34

Type 2 diabetes in youth. See also Diabetes in youth
characteristics of, 15:2
diabetic nephropathy in Pima Indians, 15:24
ESRD incidence in Pima Indian studies, 22:37
fetal overnutrition effects in, 15:12
kidney disease course in, 22:2
microalbuminuria at diagnosis, 15:24
mortality in, 15:39
prevalence and incidence, 15:8–9
projections, 15:10
risk factors, 15:11–13
screening for, 1:14

Type 2 diabetes incidence
C-reactive protein association with, 13:19
diet and activity effects, 28:19
insulin resistance/sensitivity prediction of, 13:17–18
trends in, 15:9–10
in youth, 3:17; 18: 15:9

Type 2 diabetes mortality, 36:1–14
cardiocvascular disease and, 36:8, 10
data sources and limitations, 36:5–7
early/premature mortality with, 15:38–39
epidemiologic surveillance methods, 36:3–5
increased risk of cardiovascular disease, 36:10–12
life expectancy with, 36:8
methodological challenges in assessment, 36:1–3
mortality ascertainment, 36:3
nonvascular disease in, 36:9
vascular disease with, 36:8

Type 2 diabetes prevalence. See also specific populations
Asian subgroups, 3:7
Hispanic ethnicity, 3:7
obstructive sleep apnea association, 25:14
prostate size association with, 28:5
trends in, 3:17
in youth, 3:4, 17; 15:8–9

age and sex demographics, 13:3
atypical antipsychotic medications, 33:21, 24
biomarkers for, 13:19–21
birth weight, 13:13
depression and antidepressant medications, 13:15
dietary factors, 13:5
eye postnatal exposure, 13:13–14
gene-environment interactions, 13:5
impaired glucose metabolism, 13:16–21
insomnia and short sleep, 25:29
insulin resistance in progression, 13:17
intraterine exposure, 13:12–13
KCNJ11 mutations/polymorphisms, 7:11
low acute insulin response, 13:17
metabolic syndrome, 13:21–25
migration and acculturation, 13:14
modifiable risk factors for, 13:1
nocturnal melatonin secretion, 25:28–29
nutrition, 13:6–10
obesity, 13:11–12
physical inactivity, 13:10–12
plasminogen activator inhibitor-1, 13:19
poly cystic ovary syndrome, 13:21
posttraumatic stress disorder, 33:16
previous gestational diabetes, 1:28–29;
4:11; 5:7; 13:21
for progression, 13:16–18
proinsulin:insulin ratios, 13:17
reduction with whole grains, 13:10; 29:6
schizophrenia, 33:22
sleep disturbances and, 13:14–15
smoking and, 13:15–16
socioeconomic status, 13:13–14
sugar-sweetened beverages, 13:9, 14
type 2 diabetes risk, 13:20
in utero exposure to maternal diabetes, 15:13

Types 1 and 2 diabetes combination, 1:4–5

U

U.K. National Institute for Health and Care Excellence (NICE)
A1c for pregestational pregnancy, 5:10
blood glucose recommendations, 5:72

UKPDS Risk Engine, 19:11

Ulcerative colitis. See Inflammatory bowel diseases

Ultralente insulin. See Insulin

Undiagnosed diabetes
with A1c criteria, 36:1
A1c detection of, 3:15
age-specific prevalence, 3:10
blood pressure screening detection of, 1:22; 9:17
criteria for diagnosis, 3:19
disability/impairment status, 34:7–8
gallstone disease with, 26:13, 15, 17
lipid measures in, 9:17–22
lower extremity amputations in, 20:24
methods for diagnosis, 1:15, 26; 3:3
NHANES data on blood pressure for screening, 1:22–23
in nonpregnant women of childbearing age, 5:4–5
physical inactivity in, 10:15
prevalence by measurement/criteria, 3:15–16
prevalence by sex, 3:10–12
prevalence of, 3:9; 16:3
prevalence with age, 3:10
prevalence with Hispanic ethnicity, 3:12
race/ethnicity variation in Alc, 3:13
relation to total diabetes, 3:19
sex differences in, 3:10
2-hour plasma glucose levels in, 9:6–7
waist circumference measures in, 9:14

United Kingdom National Screening committee recommendations, 1:23

United Kingdom Prospective Diabetes Study (UKPDS)
A1c measures by, 1:7
blood pressure control and mortality, 36:10
cardiovascular risk assessment model, 19:11
cholesterol levels and heart disease, 18:8
declines in beta cell function before clinical diagnosis, 1:22
insulin control and neuropathy, 23:11
glycemic control benefits, 16:13
heart disease association blood pressure, 18:9
insulin-cardiovascular disease association, 18:11
intensive glycemic control, 18:13–14
intensive vs. conventional insulin therapy in, 19:13
lower extremity amputation and glycemic control, 20:25
metabolic memory with type 2 diabetes, 21:22
micro- and macrovascular complication reduction, 22:46–47
peripheral arterial disease prevalence, 20:5–6
progression of kidney disease with type 2 diabetes, 22:17
risk estimation model for stroke with type 2 diabetes, 19:11
stroke risk with diabetes and metabolic syndrome, 19:10
visual angle change risk factors, 21:7–8

United Kingdom (U.K.) studies. See also England
corticosteroids, 5:24
chronic hypertension rates >10%, 5:33
diabetes registries, 2:5
gestational age at stillbirth, 5:43
hypertension in pregnancy grading, 5:30
invited vs. random screening, 1:23
major malformations with type 2 diabetes, 5:62
perioperative outcomes with diabetes, 5:46
pregnancy outcomes with diabetes, 5:36
prevalence of pregestational diabetes during pregnancy, 5:16
risk for antenatal stroke, 5:22
risk for venous thromboembolism with pregestational diabetes, 5:23
severe maternal morbidity, 5:25
stillbirths in types 1 vs. 2 diabetes, 5:43
type 2 diabetes prevention studies, 38:2–5
United States Renal Data System (USRDS) registry, 22:25,27
United States (U.S.) population. See also BRFSS data; NHANES data; NHIS data
all-cause mortality with diabetes, 36:1
blood pressure and heart disease association, 18:9
burden of diabetes among youth, 15:4
cardiovascular risk with metabolic syndrome traits, 18:9
cause-specific mortality comparison, 35:10
diabetes burden in youth, 15:8–10
diabetes prediction of cognitive decline, 24:8
diagnosed diabetes prevalence by age, 3:4–5
earby mortality with type 1 diabetes, 35:9
heart disease prevalence in diabetic persons, 18:1–30
lower extremity amputation risk in Medicare population, 20:25
maternal mortality, 5:21
NAION incidence in, 21:37
nephropathy prevalence data, 5:29
PDR and NPDR frequency with pregestational diabetes, 5:27
periodontitis prevalence in, 31:4–7
physical activity and type 2 diabetes risk, 13:11
prevalence of type 1 diabetes in youth, 2:2–3,5,6–7
race/ethnicity projections age in youth, 2:9–10
retrospective insurance claims analysis, 5:14–15
risks with chronic hypertension in pregnancy, 5:33
state ranking with total diabetes percentages, 8:9
stroke association with maternal diabetes, 5:22
type 1 diabetes incidence in youth, 2:6–7
type 1 diabetes mortality comparisons, 35:12–13
type 2 diabetes prevalence trends in youth, 3:17
visual impairment with diabetes, 21:2
University of North Carolina Health Care System, 2:4
Uremia, 22:5
Urinary albumin. See Albuminuria
Urinary incontinence (UI)
prevalence with type 2 diabetes, 28:14
Urine albumin-to-creatinine ratio (UACR)
Urologic disease, congenital anomalies with maternal diabetes, 5:60,65
Urinary tract infections (UTIs)
Urologic disease, congenital anomalies with maternal diabetes, 5:60,65
Venous thromboembolism (VTE)
Veterans Administration Diabetes Trial (VADT)
Veterans Affairs High-density lipoprotein Intervention Trial (VA-HIT), 22:52
Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D), 22:49
Vibratrip, 28:2
Vibrio vulnificus, 30:14
Vietnamese population. See also Asian/Pacific Islander
type 2 diabetes in Asian subgroups, 3.8
Viral etiology of type 1 diabetes (VIGR), 11.5
Viral hepatitis. See Hepatitis
Viral infections. See also Hepatitis
autoimmune trigger for, 11.4
congenital, 6.4–5
Coxsackie virus, 11.4
cytomegalovirus, 6.4–5; 11.8
enterovirus, 11.4–6
HIV, 22.56
IFIH1 gene function, 12.6
immunizations, 15.10
Kilham rat virus, 11.8
measles, mumps, and rubella (MMR) vaccine, 11.9
parvovirus, 11.8
picornaviruses, 12.6
postnatal, 6.5
rotavirus, 11.8
rubella virus, 11.8
seasonal variations in diagnosis, 11.3
viral-mediated mechanisms for diabetes, 6.5
Visceral fat. See also Abdominal obesity accumulation with glucocorticoids, 25.11
gastroesophageal reflux with, 27.8
Vision-threatening retinopathy, 21.12
Visual impairment, 21.1–49. See also Cara安全; Retinopathy
age and duration of diabetes, 21.8–9
age-related macular degeneration, 21.38
age-related macular edema, 21.38
changes in prevalence with type 2 diabetes, 21.3–4
cataracts: Retinopathy
contact lens use with diabetes, 21.37
corneal lesions and dry eye, 21.37
cost in persons with diabetes, 21.11
cranial nerve dysfunction, 21.39
criteria for impairment classification, 21.2
diabetic papillopathy, 21.39
glycemic control and systemic risk factors, 21.7–8
impairment and blindness, 21.2–12
incidence of, 21.4–7
incidence of blindness, 21.5
legal blindness criteria, 21.2
macular edema, 21.16
nonarteritic anterior ischemic optic neuropathy, 21.37–38
ocular findings associated with diabetes, 21.39
open-angle glaucoma, 21.36–37
prevalence by age and diabetes duration, 21.3–4
prevalence of diabetes-related, 21.2–3
prevalence with type 1 diabetes, 21.1
quality of life with, 21.9–10
retinal arterial emboli, 21.38
retinal vein occlusion, 21.38
retinopathy, 21.2
review of data sources, 21.2–3
self-reported diabetes and, 21.3
sex differences, 21.9
sociodemographic/economic relationships to, 21.11
visual acuity after cataract surgery, 21.35–36
visual acuity definition, 21.1
visual acuity prediction of death, 21.11–12
visual angle change risk factors, 21.1.7–8
visual loss/blindness risk factors, 21.7–9
Vitamin B6
levels with peripheral arterial disease, 20.8
malabsorption of, 27.10
Vitamin B12 deficiency
with autoimmune gastritis, 27.15
effects on A1c measurement, 1.12
peripheral neuropathy from, 27.10
Vitamin C
insulin sensitivity effects of, 25.20
intake, 10.10
lower extremity osteoarthritis risks, 32.12
Vitamin D
adult-onset type 1 diabetes, 11.12
deficiency and tuberculosis infection, 30.18
diabetes and periodontitis risk factors, 31.23
dietary intake of, 10.10
genes associated with metabolism of, 11.12
in geriatric population, 16.15
HLA interaction, 11.16
with lower extremity osteoarthritis, 32.12
prevention of type 1 diabetes, 37.5
in prevention trials, 37.3
resistance in congenital generalized lipodystrophy, 7.25
role in glucose metabolism, 13.7
sarcopenia and deficiency of, 34.11
supplementation as prevention, 11.11–12
type 2 diabetes incidence and levels of, 13.7
Vitamin E
effects in cardiovascular autonomic neuropathy, 23.9
insulin sensitivity effects of, 25.20
intake, 10.10
lower extremity osteoarthritis risks, 32.12
malabsorption of, 27.10
protection against diabetes, 11.13
Vitamin K, with celiac disease, 27.10
VLDL (very low-density lipoprotein), 22.32.34
Voglibose study, 38.9
Von Willebrand factor
with peripheral arterial disease, 20.8
type 2 diabetes risk, 13.20
Waist circumference
with abdominal obesity, 13.12
abdominal obesity assessment, 13.1
with BMI for stratification, 13.12
cardiovascular disease association with, 18.11
by diabetes status, treatment, age, 9.11–13
with diagnosed or undiagnosed diabetes, 9.14
measurement of, 9.2
NHANES abdominal criteria, 9.14
risk factors for type 2 diabetes, 13.11
Waist-to-hip ratio. See also BMI (body mass index); Waist circumference
cardiovascular disease risk, 18.10–11
metabolic syndrome characteristics, 18.9
myocardial infarction risk association, 18.10, 11
reproducibility of adiposity measures, 18.11
with type 2 diabetes, 13.11
type 2 diabetes risk factors, 15.12
Wake time after sleep onset (WASO), 25.6
Washington, D.C., periodontitis prevalence, 31.4
Washington state
chronic kidney disease risk, 22.42
dementia and diabetes, 24.8
diagnosed diabetes prevalence, 3.4
major malformations with type 1 diabetes, 5.60
pyelonephritis with diabetes, 30.10
U.S. centers for SEARCH, 2.2; 15.4
Wechsler Adult Intelligence Scale, 24.8
Weight gain
breast cancer chemotherapy, 29.13
with mood stabilizers, 33.22
pioglitazone effects, 38.10
smoking cessation and, 18.12; 33.23
stillbirth risks, 5.43
type 1 diabetes in youth and accelerated, 15.11
Weight loss
adiponectin gene association with, 38.11
in adults, 18.3
and cancer association, 29.6
cardiovascular autonomic neuropathy effects, 23.8, 13
for care of persons with diabetes, 41.13
in celiac disease, 27.12
cognitive effects with, 24.12
distal symmetrical polyneuropathy with, 23.11
in DPP study, 18.18
eating disorders and, 33.19–21
with erectile dysfunction, 28.10
in estimating stillbirth risk, 5.43
evening preference and, 25.27
functional status improvement with, 28.11
in high-risk individuals, 11.9, 22
insulin sensitivity effects of, 38.10
intensive lifestyle intervention and, 34.12
lifestyle modification and, 38:5–6,8–11,13–15,16 with major depressive disorders, 33:2 and mortality in geriatric patients, 16:10 phentermine-topiramate combination, 38:10 postpartum, after gestational diabetes, 5:73 for schizophrenia treatments, 33:22 with serious mental illness, 41:12 small fiber neuropathies with, 23:3 for stroke prevention, 19:11 with type 1 diabetes, 1:3,16; 15:2 type 2 diabetes prevention and, 38:1–2 urinary incontinence prevention, 28:19 vertebral fracture association, 32:1

Wellcome Trust Case-Control Consortium (WTCCC), 12:6–7

WESDR cohort

West Virginia
age-adjusted total preexisting diabetes during pregnancy, 5:13–14 pregestational diabetes prevalence, 5:5

Western Pacific island of Nauru, albuminuria prevalence in, 22:14

White matter hyperintensities (WMH) correlate of cognitive impairment, 24:4 in mild cognitive impairment, 24:2 subclinical brain injury, 19:2–3

White/Caucasian. See also Race/ethnicity ESRD incidence rate in, 22:27–30 estimated chronic kidney disease prevalence by type of diabetes, 22:12 haplotype association in type 1 diabetes, 12:3 knee osteoarthritis prevalence in, 32:16 prevalence of peripheral arterial disease, 20:4 prevalence of persistent albuminuria, 22:12 trend in prevalence of hyperinsulinemia, 13:18 type 1 diabetes in, 1:4 type 1 diabetes risk in siblings, 12:1,3

Whitehall study, 38:2

Williams syndrome, 6:17

Wisconsin. See also specific regional studies A1c and mortality, 35:4,5 albuminuria with insulin treatment, 22:12 diabetes duration and proteinuria incidence, 22:16,30 distal symmetrical polyneuropathy symptoms, 23:9 fatty liver disease and type 2 diabetes mortality, 26:6 retinopathy with type 1 diabetes, 15:17–18 temporal trends in type 1 diabetes incidence, 2:9 visual impairment and diabetes duration, 21:3–4

Wisconsin Diabetes Registry Study (WDRS) diabetic retinopathy, 15:18 retinopathy prevalence in, 21:12

Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR). See WESDR cohort

Wisconsin Sleep Cohort Study leptin/ghrelin levels with sleep, 25:11 obstructive sleep apnea and fasting hyperglycemia, 25:14 prevalence of obstructive sleep apnea, 25:12

Wolcott-Rallison syndrome, 7:11

Wolfram Syndrome, 7:8

Women’s Health and Aging Study (WHAS), 34:11


Women’s Healthy Eating and Living (WHEL) Study, 29:13

Working Group on Outcome Definitions, 5:3

World Health Organization (WHO) A1c diagnostic criteria for, 1:2 A1c endorsement of, 1:13 adiposity measurement recommendations, 18:10 DIAMOND project, 2:5 disability definition and measurement, 34:2 estimates of type 1 diabetes incidence, 2:5 fasting plasma glucose criteria for diagnosis of diabetes, 1:6 gestational diabetes criteria, 4:10 gestational diabetes recommendations, 4:2 glucose cutpoints acceptance by, 1:13 maternal death definition, 5:21 metabolic syndrome criteria, 18:9 mortality in childhood-onset type 1 diabetes, 35:12 osteoporosis definition, 32:2 screening recommendation review, 1:23

World regional characteristics. See specific countries and populations

X

Xerostomia, 31:38

Y

YMCA of the USA Diabetes Prevention Program (Y-USA DPP), 38:15

Youth. See Children and adolescents; Diabetes in youth

Youth-onset diabetes. See Children and adolescents; Diabetes in youth

Z

ZAC (zinc finger) gene apoptosis regulation, 9:16 transient neonatal diabetes, 7:10
Zensharen study of lifestyle intervention, 38:10

Zinc
- dietary intake of, 13:5
- levels in type 1 diabetes, 11:13

Zinc transporter 8 (ZnT8)
- autoantibodies in screening for type 1 diabetes, 1:27,28
- autoantibodies in type 1 diabetes in youth, 15:2
- beta cell destruction, 15:2
- glucose metabolism effects of, 13:5
- identification of type 1 diabetes, 37:2
- in islet autoimmunity, 11:2
- in newly diagnosed type 1 diabetes, 11:13
- in seroconversion, 11:2
- types 1 and 2 diabetes differentiation, 1:3
- variant, 13:5

ZMPSTE24 (zinc metalloproteinase) gene, 7:17